Form 10-Q

0001193125-11-216725.txt : 20110809 0001193125-11-216725.hdr.sgml : 20110809 20110809171155 ACCESSION NUMBER: 0001193125-11-216725 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20110630 FILED AS OF DATE: 20110809 DATE AS OF CHANGE: 20110809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sagent Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001369786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35144 FILM NUMBER: 111021821 BUSINESS ADDRESS: STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700 CITY: SCHAUMBURG STATE: IL ZIP: 60195 BUSINESS PHONE: 847-908-1604 MAIL ADDRESS: STREET 1: 1901 NORTH ROSELLE ROAD, SUITE 700 CITY: SCHAUMBURG STATE: IL ZIP: 60195 FORMER COMPANY: FORMER CONFORMED NAME: Sagent Holding Co. DATE OF NAME CHANGE: 20090529 FORMER COMPANY: FORMER CONFORMED NAME: NHS PHARMACEUTICALS DATE OF NAME CHANGE: 20060720 10-Q 1 d10q.htm FORM 10-Q Form 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2011

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 1-35144

Sagent Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware		98-0536317
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1901 N. Roselle Road, Suite 700 Schaumburg, Illinois		60195
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (847) 908-1600

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ¨ No x

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes ¨ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ¨

Accelerated filer ¨

Non-accelerated filer x

(Do not check if a smaller reporting company)

Smaller reporting company ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

At July 29, 2011, there were 27,871,612 shares of the registrant’s common stock outstanding.

Sagent Pharmaceuticals, Inc.

Table of Contents


		Page No.
PART I –	FINANCIAL INFORMATION

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets at June 30, 2011 and December 31, 2010		1

	Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2011 and 2010		2

	Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2011 and 2010		3

	Notes to Condensed Consolidated Financial Statements		4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		15

Item 3.	Quantitative and Qualitative Disclosures about Market Risk		25

Item 4.	Controls and Procedures		25

PART II –	OTHER INFORMATION

Item 1.	Legal Proceedings		26

Item 1A.	Risk Factors		26

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		26

Item 6.	Exhibits		27

Signature			28

In this report, “Sagent,” “we,” “us” and “our” refers to Sagent Pharmaceuticals, Inc. and subsidiaries, and “Common Stock” refers to Sagent’s common stock.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except share amounts)


	June 30,		December 31,
	2011		2010
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	78,006	$	34,376
Restricted cash and cash equivalents		671		208
Short-term investments		49,235		–
Accounts receivable, net of chargebacks and other deductions		21,600		18,939
Inventories		31,689		30,567
Due from related party		206		868
Prepaid expenses and other current assets		4,739		5,435

Total current assets		186,146		90,393
Restricted cash and cash equivalents		100		100
Property, plant, and equipment, net		788		785
Investment in joint ventures		22,970		24,466
Intangible assets, net		3,031		2,613
Other assets		848		232

Total assets	$	213,883	$	118,589


Liabilities, preferred stock and stockholders’ equity
Current liabilities:
Accounts payable	$	15,110	$	24,449
Due to related party		1,892		2,494
Accrued profit sharing		2,862		3,717
Accrued liabilities		4,764		4,800
Preferred stock warrants		–		1,432
Current portion of long-term debt		6,818		–
Notes payable		20,108		20,726

Total current liabilities		51,554		57,618

Long term liabilities:
Long-term debt		8,182		–
Other long-term liabilities		606		6

Total liabilities		60,342		57,624

Preferred stock
Series A preferred stock—$0.00001 par value; 113,000,000 authorized and outstanding at December 31, 2010 (liquidation preference $113,000)		–		113,000
Series B preferred stock—$0.00001 par value; 39,136,052 authorized and 32,714,284 outstanding at December 31, 2010 (liquidation preference $45,800)		–		44,774

Total preferred stock		–		157,774

Stockholders’ equity (deficit):
Common stock—$0.01 and $0.000008 par value, 100,000,000 and 23,539,769 authorized and 27,855,544 and 2,054,467 outstanding at June 30, 2011 and December 31, 2010, respectively		279		–
Additional paid-in capital		264,485		2,318
Accumulated other comprehensive income		1,755		1,285
Accumulated deficit		(112,978)		(100,412)

Total stockholders’ equity (deficit)		153,541		(96,809)


Total liabilities, preferred stock and stockholders’ equity (deficit)	$	213,883	$	118,589

See accompanying notes to condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

(Unaudited)


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010

Net revenue	$	32,254	$	10,560	$	62,598	$	19,204
Cost of sales		29,505		10,658		55,260		19,009

Gross profit		2,749		(98)		7,338		195
Operating expenses:
Product development		2,374		3,272		4,731		6,066
Selling, general and administrative		6,476		4,355		11,451		8,521
Equity in net loss of joint ventures		524		332		1,197		767

Total operating expenses		9,374		7,959		17,379		15,354


Loss from operations		(6,625)		(8,057)		(10,041)		(15,159)
Interest income and other		56		4		75		8
Interest expense and other		(1,242)		(228)		(1,762)		(467)
Change in fair value of preferred stock warrants		(384)		(408)		(838)		(408)


Loss before income taxes		(8,195)		(8,689)		(12,566)		(16,026)
Provision for income taxes		–		–		–		–


Net loss	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)


Net loss per common share:
Basic	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)
Diluted	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)
Weighted-average of shares used to compute net loss per common share:
Basic		22,196		1,944		12,141		1,916
Diluted		22,196		1,944		12,141		1,916

See accompanying notes to condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)


	Six months ended June 30,
	2011		2010

Cash flows from operating activities
Net loss	$	(12,566)	$	(16,026)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		110		135
Amortization		436		429
Stock-based compensation		1,051		370
Decrease in restricted stock repurchase liability		–		25
Equity in net loss of joint ventures		1,197		767
Change in fair value of preferred stock warrants		838		408
Changes in operating assets and liabilities:
Accounts receivable, net		(2,661)		(579)
Inventories		(1,122)		1,454
Prepaid expenses and other current assets		576		1,000
Due from related party		662		(47)
Accounts payable and other accrued liabilities		(11,052)		(6,403)

Net cash used in operating activities		(22,531)		(18,467)


Cash flows from investing activities
Capital expenditures		(113)		(8)
(Funding) return of principal balance of restricted cash		(463)		226
Investments in unconsolidated joint ventures		(68)		(4,980)
Return of capital from unconsolidated joint venture		924		–
Purchases of investments		(49,391)		–
Purchase of product rights		(603)		(257)

Net cash used in investing activities		(49,714)		(5,019)


Cash flows from financing activities
Reduction in short-term notes payable		(618)		(108)
Proceeds from issuance of long-term debt		15,000		–
Proceeds from issuance of preferred stock, net of issuance costs		–		39,407
Proceeds from issuance of common stock, net of issuance costs		101,573		12
Payment of deferred financing costs		(80)		–

Net cash provided by financing activities		115,875		39,311


Net increase in cash and cash equivalents		43,630		15,825
Cash and cash equivalents, at beginning of period		34,376		7,731

Cash and cash equivalents, at end of period	$	78,006	$	23,556

See accompanying notes to condensed consolidated financial statements

Sagent Pharmaceuticals, Inc.

Notes to Condensed Consolidated Financial Statements

(in thousands, except for share and per share information)

(Unaudited)

Note 1. Summary of significant accounting policies:

Reincorporation:

We completed our initial public offering (“IPO”) on April 26, 2011. In connection with our IPO, we incorporated (the “Reincorporation”) in Delaware as Sagent Pharmaceuticals, Inc., (“Sagent” or the “Company”). Prior to this reincorporation, we were a Cayman Islands company, and our corporate name was Sagent Holding Co. (“Sagent Holding”).

In connection with our IPO and concurrent with our Reincorporation in Delaware, the holders of our preferred stock exchanged each of their outstanding shares of preferred stock for 0.12759 shares of our common stock.

Basis of Presentation:

Our interim condensed consolidated financial statements are unaudited. We prepared the condensed consolidated financial statements following rules for interim reporting as prescribed by the U.S. Securities and Exchange Commission (“SEC”). As permitted under those rules, we have condensed or omitted a number of footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (“U.S. GAAP”). It is management’s opinion that these financial statements include all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of our financial position, operating results and cash flows. Operating results for any interim period are not necessarily indicative of future or annual results.

You should read these statements in conjunction with our consolidated financial statements and related notes for the year ended December 31, 2010, included in our IPO prospectus filed with the SEC on April 21, 2011.

Principles of Consolidation:

The condensed consolidated financial statements include Sagent as well as our wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. We account for our investment in Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited (“KSP”) and Sagent Strides LLC using the equity method of accounting, as our interest in each entity provides for joint financial and operational control. Operating results of our KSP equity method investment are reported on a one-month lag.

Financial Instruments:

We consider all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values. Investments with original maturities of greater than three months and remaining maturities of less than one year are classified as short-term investments. Investments with maturities beyond one year are classified as short-term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. All cash equivalents and short-term investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income (“OCI”).

security or it is more likely than not that we will be required to sell the security before recovery. We also consider specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to other expense and a new cost basis in the investment is established.

New Accounting Pronouncements:

In May 2011, new guidance was issued on the accounting for fair value measurements. The new guidance limits the highest-and-best-use measure to nonfinancial assets, permits certain financial assets and liabilities with offsetting positions in market or counterparty credit risks to be measured at a net basis, and provides guidance on the applicability of premiums and discounts. Additionally, the new guidance expands the disclosures on Level 3 inputs by requiring quantitative disclosure of the unobservable inputs and assumptions, as well as description of the valuation processes and the sensitivity of the fair value to changes in unobservable inputs. We will adopt this guidance on January 1, 2012, and do not believe this guidance will have a significant impact on our financial results.

In June 2011, new guidance was issued regarding the presentation of comprehensive income. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. Instead, an entity will be required to present either a continuous statement of operations and other comprehensive income or separate but consecutive statements of operations and other comprehensive income. We will adopt this guidance on January 1, 2012, and do not believe this guidance will have a significant impact on our financial results.

Note 2. Reverse stock split:

All common share and per share amounts in the condensed consolidated financial statements and notes thereto have been restated to reflect a reverse stock split effective on April 26, 2011, whereby every 7.8378 shares of common stock, including the shares of preferred stock that were converted to common stock on April 26, 2011, were combined into one share of common stock. Immediately prior to the consummation of our IPO, but following the reverse stock split, the number of authorized shares was increased to 105 million, consisting of 100 million shares of common stock and 5 million shares of undesignated preferred stock, each with a par value of $0.01 per share.

Note 3. Investments:

Our investments at June 30, 2011 were comprised of the following:


	Cost basis		Unrealized gains		Unrealized losses		Recorded basis		Cash and cash equivalents		Short term investments
Assets
Cash	$	47,352	$	-	$	-	$	47,352	$	47,352	$	-
Money market funds		30,654		-		-		30,654		30,654		-
Commercial paper		4,998		-		(1)		4,997		-		4,997
Corporate bonds and notes		39,391		1		(84)		39,239		-		39,239
US government securities		5,002		-		(2)		4,999		-		4,999

	$	127,397	$	1	$	(87)	$	127,241	$	78,006	$	49,235

Investments with continuous unrealized losses for less than twelve months and their related fair values were as follows:


	Fair value		Unrealized losses
Commercial paper	$	4,997	$	(1)
Corporate bonds and notes		39,239		(84)
US government securities		4,999		(2)

	$	49,235	$	(87)

Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. We do not believe that any remaining unrealized losses represent an other-than-temporary impairment based on our evaluation of available evidence as of June 30, 2011.

The original cost and estimated current fair value of our fixed-income securities are set forth below.


	Cost basis		Estimated fair value
Due in one year or less	$	18,219	$	18,171
Due between one and five years		31,172		31,064

	$	49,391	$	49,235

Note 4. Inventories:

Inventories at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011						December 31, 2010
	Approved		Pending regulatory approval		Inventory		Approved		Pending regulatory approval		Inventory
Finished goods	$	31,320	$	1,640	$	32,960	$	31,151	$	-	$	31,151
Raw materials		-		262		262		-		262		262
Inventory reserve		(1,533)		-		(1,533)		(846)		-		(846)

	$	29,787	$	1,902	$	31,689	$	30,305	$	262	$	30,567

Our finished goods inventory pending regulatory approval at June 30, 2011, included $1,640 related to our levofloxacin and gemcitabine products, which were approved and launched during July 2011.

Note 5. Intangible assets, net:

Intangible assets at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011						December 31, 2010
	Gross carrying amount		Accumulated amortization		Intangible assets, net		Gross carrying amount		Accumulated amortization		Intangible assets, net
Product licensing rights	$	1,688	$	(853)	$	835	$	1,618	$	(668)	$	950
Product development rights		2,196		-		2,196		1,663		-		1,663

	$	3,884	$	(853)	$	3,031	$	3,281	$	(668)	$	2,613

Movements in intangible assets were due to the following:


	Product licensing rights		Product development rights
December 31, 2010	$	950	$	1,663

Acquisition of product rights		70		533

Amortization of product rights		(185)		-


June 30, 2011	$	835	$	2,196

Amortization expense related to our product licensing rights was $81 for the three months ended June 30, 2011, and $185 for the six months ended June 30, 2011. The weighted-average period prior to the next extension or renewal for the five products comprising our product licensing rights intangible asset was 38 months at June 30, 2011.

We currently estimate amortization expense over each of the next five years as follows:


For the year ending:	Amortization expense
June 30, 2012	$	2,521

June 30, 2013		250

June 30, 2014		122

June 30, 2015		93

June 30, 2016		44

Note 6. Investment in KSP:

Changes in our investment in KSP during the six months ended June 30, 2011 were as follows:


Investment in KSP at January 1, 2011	$	23,663
Equity in net loss of KSP		(1,952)
Currency translation adjustment		557

Investment in KSP at June 30, 2011	$	22,268

Condensed statement of operations information of KSP is presented below.


	Three months ended June 30,				Six months ended June 30,
Condensed statement of operations information	2011		2010		2011		2010

Net revenues	$	-	$	-	$	-	$	-

Gross profit		-		-		-		-

Net loss		(1,369)		(549)		(3,057)		(1,097)

During the three and six months ended June 30, 2011, KSP’s development activities increased, as initial batch validation activities were initiated at its manufacturing facility.

Note 7. Accrued liabilities:

Accrued liabilities at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011		December 31, 2010
Payroll and employee benefits	$	1,871	$	1,736
Sales and marketing		2,182		2,338
Other accrued liabilities		711		726

	$	4,764	$	4,800

Note 8. Debt:

In March 2011, our principal operating subsidiary amended its $25,000 senior secured revolving credit facility (the “Revolver”) to permit, among other things, the entry into a new $15,000 term loan credit facility (the “Term Note”) and the incurrence of debt and granting of liens thereunder. The amendment also requires that we become a borrower under the Revolver. The interest rate on the Revolver, which bears interest at a rate equal to either an adjusted London Interbank Offered Rate (“LIBOR”), plus a margin of 5.50%, or an alternate base rate plus a margin of 4.50%, was 8.50% at June 30, 2011 and December 31, 2010.

In March 2011, our principal operating subsidiary entered into a $15,000 Term Note, which expires June 16, 2013. Borrowings under the Term Note will be used for general corporate purposes, including funding of our working capital. The interest rate on the Term Note, which bears interest at LIBOR plus a margin of 9.0%, subject to a 3.0% LIBOR floor, was 12.0% at March 31, 2011. Equal monthly amortization payments in respect to the Term Note are payable beginning September 1, 2011. Under the agreement, we are required to maintain the lesser of $15,000 or 65% of our consolidated cash balances with a single financial institution and are also required to pay a financing fee of $600 when the Term Note has been repaid. The financing fee will be amortized to interest expense over the life of the loan, and the related obligation is included in other long-term liabilities on our balance sheet. The Term Note is secured by a second lien on substantially all of the assets of our principal operating subsidiary.

The Term Note contains various covenants substantially similar to the senior secured revolving credit facility, including a covenant to maintain minimum net invoiced revenues, restrictions on our ability to incur additional indebtedness, create liens, make certain investments, pay dividends, sell assets, or enter into a merger or acquisition. With respect to dividends, our principal operating subsidiary, as the borrower under the term loan credit facility, was prohibited, subject to certain limited exceptions, from declaring dividends or otherwise making any distributions, loans or advances to us as the parent company. This restriction will continue until we become a borrower under the Term Note.

Aggregate maturities of our long-term debt for the years ended June 30, were as follows:


For the year ending:

June 30, 2012	$	6,818
June 30, 2013	$	8,182

Note 9. Fair value measurements:

Assets and liabilities measured at fair value on a recurring basis as of June 30, 2011 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Commerical paper	$	4,997	$	-	$	4,997	$	-
Corporate bonds and notes		39,239		-		39,239		-
US government securities		4,999		-		4,999		-

Total assets	$	49,235	$	-	$	49,235	$	-

Liabilities
Preferred stock warrants	$	-	$	-	$	-	$	-

	$	-	$	-	$	-	$	-

The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity.

Liabilities measured at fair value on a recurring basis as of December 31, 2010 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Liabilities
Preferred stock warrants	$	1,432	$	-	$	-	$	1,432

	$	1,432	$	-	$	-	$	1,432

On April 26, 2011, the holder of our preferred stock warrants exercised all of the warrants concurrent with our IPO, acquiring 454,500 shares of our common stock having a fair value at the IPO of $7,272, for $5,002 of cash. We recorded $384 and $838 of expense related to the preferred stock warrants during the three and six months ended June 30, 2011, respectively, and $408 of expense related to the preferred stock warrants during the three and six months ended June 30, 2010.

During the three and six months ended June 30, 2011 and 2010, changes in the fair value of our preferred stock warrants measured using significant unobservable inputs (Level 3), were comprised of the following:


	Three months ended June 30, 2011		Six months ended June 30, 2011
Balance at beginning of period	$	1,886	$	1,432
Change in fair value of warrants		384		838
Exercise of warrants		(2,270)		(2,270)

Balance at end of period	$	-	$	-


	Three months ended June 30, 2010		Six months ended June 30, 2010
Balance at beginning of period	$	-	$	-
Issuance of warrants		619		619
Change in fair value of warrants		408		408

Balance at end of period	$	1,027	$	1,027

Note 10. Comprehensive income (loss):

Comprehensive income (loss) for the three and six months ended June 30, 2011 and 2010 is comprised of the following:


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Net loss, as reported	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)
Comprehensive income (loss)
Unrealized loss on available for sale securities, net of tax		(87)		-		(87)		-
Currency translation adjustment, net of tax		313		-		557		-

Total comprehensive loss	$	(7,969)	$	(8,689)	$	(12,096)	$	(16,026)

Note 11. Earnings per share:

Basic earnings per share is calculated by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Because of their anti-dilutive effect, 1,730,364 and 19,821,420 common share equivalents, comprised of preferred shares, restricted stock, preferred stock warrants and unexercised stock options, have been excluded from the calculation of diluted earnings per share for the periods ended June 30, 2011 and 2010, respectively. The table below presents the computation of basic and diluted earnings per share for the three and six month periods ended June 30, 2011 and 2010:


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Basic and dilutive numerator:
Net loss, as reported	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)


Denominator:
Weighted-average common shares outstanding—basic (in thousands)		22,196		1,944		12,141		1,916
Net effect of dilutive securities:
Weighted-average conversion of Class A and Class B preferred stock		-		-		-		-
Stock options and restricted stock		-		-		-		-

Weighted-average common shares outstanding—diluted (in thousands)		22,196		1,944		12,141		1,916


Net loss per common share (basic)	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)

Net loss per common share (diluted)	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)

On April 19, 2011, we completed our IPO, issuing 5,750,000 shares of our common stock in exchange for consideration of $92 million. The underwriters exercised their overallotment option on April 21, 2011, resulting in the issuance of an additional 862,500 shares of our common stock for consideration of $13.8 million. The offering closed on April 26, 2011; we received net proceeds from the offering of $95.8 million.

Note 12. Stock-based compensation:

We granted 74,170 stock options during the three and six months ended June 30, 2011. There were 44,194 and 190,290 stock options exercised during the three and six months ended June 30, 2011, with an aggregate intrinsic value of $385 and $1,744, respectively.

Note 13. Revenue and revenue deductions:

Net revenue by product line is as follows:


	Three months ended June 30,				Six months ended June 30,
Therapeutic class:	2011		2010		2011		2010
Anti-infective	$	9,848	$	8,037	$	22,441	$	14,808

Critical care		17,469		1,437		30,163		2,784

Oncology		4,937		1,086		10,045		1,612

	$	32,254	$	10,560	$	62,598	$	19,204

Accrued chargebacks are shown as a reduction in accounts receivable. Changes in accrued chargebacks during the three and six month periods ended June 30, 2011 resulted from the following:


	Three months ended June 30, 2011		Six months ended June 30, 2011
Accrued chargebacks at beginning of period	$	13,110	$	13,507

Provision for chargebacks		40,732		70,114

Credits or checks issued		(35,253)		(65,032)

Accrued chargebacks at end of period	$	18,589	$	18,589

Note 14. Related party transactions:

As of June 30, 2011 and December 31, 2010, respectively, we had a receivable of $206 and $868 from Sagent Strides LLC, which is expected to offset future profit-sharing payments. As of June 30, 2011, and December 31, 2010, respectively, we had a payable of $1,892 and $2,494 to Sagent Strides LLC, principally for the acquisition of inventory and amounts due under profit-sharing arrangements. During the six months ended June 30, 2011, Sagent Strides LLC distributed $1,848 of profit sharing receipts to its joint venture partners. As the Sagent Strides joint venture is in a cumulative loss position, our share of this distribution has been treated as a return of capital in the condensed consolidated statement of cash flows.

Note 15. Commitments and contingencies:

From time to time, we are subject to claims and litigation arising in the normal course of business. At this time, there are no proceedings of which we are aware that we expect will have a material adverse effect on our consolidated financial position or results of operations.

In January 2011, Infusive Technologies, LLC (“Infusive”) filed a complaint against us in the United States District Court of Utah, Central Division, alleging that we had breached the terms of an acquisition agreement entered into in September 2008 for failing to use reasonable commercial efforts to develop and commercialize certain products based on patents and other intellectual property assigned to us by Infusive, thereby avoiding a $1,250 contingent payment under the agreement. The complaint seeks compensatory damages of at least $15,000, plus interest, and punitive damages of at least $50,000. We intend to vigorously defend ourselves in this litigation, including bringing a number of counterclaims against Infusive in such litigation. In March 2011, we filed motions for change in venue and to dismiss the complaint and Infusive filed its first amended complaint, which, among other things, alleged additional facts to support its allegations and eliminated the claim for punitive damages. In May 2011, we responded to Infusive’s first amended complaint and filed further counterclaims in the matter. We do not expect that this lawsuit will have a material adverse effect on our consolidated financial position or results of operations.

Note 16. Condensed parent company only financial statements:

The following condensed financial statements present the Company’s financial position as of June 30, 2011 and December 31, 2010, and its results of operations and cash flows for the three and six month periods ended June 30, 2011 and 2010 on a parent-company only basis. In the parent company only financial statements, the Company’s investment in subsidiaries is stated at cost plus the equity in undistributed earnings of subsidiaries since the date of formation. The Company’s share of loss is recorded as equity in net loss of unconsolidated subsidiaries. The parent company only financial statements should be read in conjunction with the Company’s condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Balance Sheets

(in thousands)


	June 30, 2011		December 31, 2010
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	40,676	$	7,110
Short term investments		49,235		–
Prepaid expenses and other current assets		436		1,285

Total current assets		90,347		8,395
Investment in unconsolidated subsidiaries		41,278		30,602
Investment in unconsolidated joint ventures		22,268		23,663

Total assets	$	153,893	$	62,660


Liabilities, preferred stock and stockholders’ equity
Current liabilities:
Accounts payable	$	119	$	248
Accrued liabilities		233		15
Preferred stock warrants		–		1,432

Total current liabilities		352		1,695

Total liabilities		352		1,695

Preferred stock
Series A preferred stock		–		113,000
Series B preferred stock		–		44,774


Total preferred stock		–		157,774

Stockholders’ equity:
Common stock		279		–
Additional paid-in capital		264,485		2,318
Accumulated other comprehensive income		1,755		1,285
Accumulated deficit		(112,978)		(100,412)

Total stockholders’ equity (deficit)		153,541		(96,809)


Total liabilities, preferred stock and stockholders’ equity (deficit)	$	153,893	$	62,660

Sagent Pharmaceuticals, Inc.

Condensed Statements of Operations

(in thousands, unaudited)


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Net revenue	$	–	$	–	$	–	$	–
Cost of sales		–		–		–		–

Gross profit		–		–		–		–
Operating expenses:
Selling, general and administrative		707		212		1,204		405
Equity in net loss of joint venture		919		255		1,952		642
Equity in net loss of unconsolidated subsidiaries		6,224		7,818		8,611		14,575

Total operating expenses		7,850		8,285		11,767		15,622


Loss from operations		(7,850)		(8,285)		(11,767)		(15,622)

Interest income and other		39		4		39		4
Change in value of preferred stock warrants		(384)		(408)		(838)		(408)


Loss before income taxes		(8,195)		(8,689)		(12,566)		(16,026)
Provision for income taxes		–		–		–		–


Net loss	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)

Sagent Pharmaceuticals, Inc.

Condensed Statement of Cash Flows

(in thousands, unaudited)


	Six months ended June 30,
	2011		2010
Cash flows from operating activities
Net loss	$	(12,566)	$	(16,026)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation		1,051		370
Decrease in restricted stock repurchase liability		–		25
Equity in net loss of joint venture		1,952		642
Equity in net loss of unconsolidated subsidiaries		8,611		14,575
Change in fair value of preferred stock warrants		838		408
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		849		–
Accounts payable and accrued liabilities		(66)		(24)

Net cash provided by (used in) operating activities		669		(30)


Cash flows from investing activities
Investments in unconsolidated subsidiaries		(19,285)		(33,615)
Purchase of investments		(49,391)		–
Investments in joint venture		–		(4,664)

Net cash used in investing activities		(68,676)		(38,279)


Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs		–		39,407
Proceeds from issuance of common stock, net of issuance costs		101,573		12

Net cash provided by financing activities		101,573		39,419


Net increase in cash and cash equivalents		33,566		1,110
Cash and cash equivalents, at beginning of period		7,110		–

Cash and cash equivalents, at end of period	$	40,676	$	1,110

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion should be read in conjunction with our condensed consolidated financial statements included elsewhere in this report and with our audited financial statements and the notes found in our IPO prospectus filed with the SEC on April 21, 2011. Unless otherwise noted, all dollar amounts are in thousands.

Disclosure Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact including, but not limited to, our expected gross margin percentage, included in this report are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “plan,” “intend,” “believe,” “may,” “will,” “should,” “can have,” “likely” and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. For example, all statements we make relating to our estimated and projected costs, expenditures, cash flows, growth rates and financial results, our plans and objectives for future operations, growth or initiatives, strategies or the expected outcome or impact of pending or threatened litigation are forward-looking statements. In addition, this report contains forward-looking statements regarding our ability to generate operating profit in the near term; the adequacy of our current cash balances, including cash received from our IPO, to fund our ongoing operations; our utilization of our net operating loss carryforwards; our expected gross margin percentage for 2011; and our ability to meet our obligations under the Senior Secured Revolving Credit Agreement and Term Loan Credit Agreement.

These forward-looking statements involve risks and uncertainties, and the cautionary statements set forth below, as well as elsewhere in this Report on Form 10-Q, and those contained in the “Risk Factors” found in our IPO prospectus filed with the SEC on April 21, 2011, identify important factors that could cause actual results to differ materially from those predicted in our forward-looking statements. Such factors, include, but are not limited to:

•

we rely on our business partners for the manufacture of our products, and if our business partners fail to supply us with high-quality API or finished products in the quantities we require on a timely basis, sales of our products could be delayed or prevented, our revenues would decline and we may not achieve profitability;

•

if we or any of our business partners are unable to comply with the regulatory standards applicable to pharmaceutical drug manufacturers, we may be unable to meet the demand for our products, may lose potential revenues and may not achieve profitability;

•

any change in the regulations, enforcement procedures or regulatory policies established by the FDA and other regulatory agencies could increase the costs or time of development of our products and delay or prevent sales of our products and our revenues would decline and we may not achieve profitability;

•

two of our products, heparin and cefepime, each of which is supplied to us by a single vendor, represent a significant portion of our net revenues and, if the volume or pricing of either of these products declines, or we are unable to satisfy market demand for either of these products, it could have a material adverse effect on our business, financial position and results of operations;

•

if we are unable to continue to develop and commercialize new products in a timely and cost-effective manner, we may not achieve our expected revenue growth or profitability or such revenue growth and profitability, if any, could be delayed;

•

if we are unable to maintain our GPO relationships, our revenues would decline and future profitability would be jeopardized;

•

we rely on a limited number of pharmaceutical wholesalers to distribute our products;

•

we may be exposed to product liability claims that could cause us to incur significant costs or cease selling some of our products;

•

if reimbursement for our current or future products is reduced or modified, our business could suffer;

•

current economic conditions could adversely affect our operations;

•

we are subject to a number of risks associated with managing our international network of collaborations;

•

we may never realize the expected benefits from our investment in our KSP joint venture; and

•

we may seek to engage in strategic transactions that could have a variety of negative consequences, and we may not realize the benefits of such transactions.

We derive many of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, or cautionary statements, are disclosed under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this report. All written and oral forward-looking statements attributable to us, or persons acting on our behalf, are expressly qualified in their entirety by the cautionary statements as well as other cautionary statements that are made from time to time in our SEC filings and public communications. You should evaluate all forward-looking statements made in this report in the context of these risks and uncertainties.

We cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this report are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Introduction

We are an injectable pharmaceutical company that develops and sources products that we sell primarily in the U.S. through our highly experienced sales and marketing team. With a primary focus on generic injectable pharmaceuticals, we currently offer our customers a broad range of products across anti-infective, oncolytic and critical care indications in a variety of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags. We generally seek to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience. We have rapidly established a large and diverse product portfolio and pipeline as a result of our innovative business model, which combines an extensive network of collaborations with API suppliers and finished product developers and manufacturers in Asia, Europe, the Middle East and the Americas with our proven and experienced U.S.-based regulatory, quality assurance, business development, project management, and sales and marketing teams.

On April 26, 2011, we completed our initial public offering (“IPO”), issuing 6,612,500 shares of our common stock at an initial price of $16.00 per share. We received net proceeds from the IPO, after deducting underwriting discounts and commissions and estimated offering expenses of approximately $95.8 million. We plan to use the proceeds from this offering for general corporate purposes.

Discussion and Analysis

Consolidated results of operations

The following compares our consolidated results of operations for the three months ended June 30, 2011 with those of the three months ended June 30, 2010:


	Three months ended June 30,
	2011		2010		$ change		% change

Net revenue	$	32,254	$	10,560	$	21,694		205	%
Cost of sales		29,505		10,658		18,847		177	%

Gross profit		2,749		(98)		2,847		N/M
Gross profit as % of net revenues		8.5%		-0.9%		9.4%

Operating expenses:
Product development		2,374		3,272		(898)		-27	%
Selling, general and administrative		6,476		4,355		2,121		49	%
Equity in net loss of joint ventures		524		332		192		58	%

Total operating expenses		9,374		7,959		1,415		18	%


Loss from operations		(6,625)		(8,057)		1,432		18	%
Interest income and other		56		4		52		1300	%
Interest expense		(1,242)		(228)		(1,014)		-445	%
Change in fair value of preferred stock warrants		(384)		(408)		24		6	%


Loss before income taxes		(8,195)		(8,689)		494		6	%
Provision for income taxes		—		—		–		0	%


Net loss	$	(8,195)	$	(8,689)	$	494		6	%

Net loss per common share:
Basic	$	(0.37)	$	(4.47)	$	4.10		92	%
Diluted	$	(0.37)	$	(4.47)	$	4.10		92	%

Net revenue: Net revenue for the three months ended June 30, 2011 totaled $32.3 million, an increase of $21.7 million, or 205%, as compared to $10.6 million for the three months ended June 30, 2010. The launch of 31 new codes or presentations of 10 products since June 30, 2010 contributed $20.2 million, or 93%, of the net revenue increase in the second quarter. Net revenue for products launched prior to June 30, 2010 increased $1.5 million, or 14%, to $12.1 million in the second quarter of 2011 due to increased unit volume, partially offset by lower pricing.

Cost of sales: Cost of goods sold for the three months ended June 30, 2011 totaled $29.5 million, an increase of $18.8 million, or 177%, as compared to $10.7 million for the three months ended June 30, 2010. Gross profit as a percentage of net revenue was 8.5% for the three months ended June 30, 2011, and (0.9)% for the three months ended June 30, 2010. The increase in gross profit as a percentage of net revenue was driven primarily by our introduction of new, higher margin products in the latter half of 2010, principally heparin and topotecan.

Product development: Product development expense for the three months ended June 30, 2011 totaled $2.4 million, a decrease of $0.9 million, or 27%, as compared to $3.3 million for the three months ended June 30, 2010. The decrease in product development expense was primarily due to the timing of activities under our development programs, as the number of products under development has not changed significantly as compared with the first quarter of 2010.

As of June 30, 2011, our new product pipeline included 35 products represented by 66 ANDAs which we had filed, or licensed rights to, that were under review by the US Food and Drug Administration (“FDA”) and ten products represented by 12 ANDAs that have been recently approved and were pending commercial launch, including our levofloxacin, gemcitabine and piperacillin and tazobactam products, which were launched in July 2011. We expect to launch most of these remaining new products by the end of 2012. We also had an additional 25 products represented by 26 ANDAs under initial development at June 30, 2011.

Selling, general and administrative: Selling, general and administrative expenses for the three months ended June 30, 2011, totaled $6.5 million, an increase of $2.1 million, or 49%, as compared to $4.4 million for the three months ended June 30, 2010. The increase in selling, general and administrative expense was primarily due to increases in headcount and corporate infrastructure to support our initial public offering and anticipated revenue growth. Selling, general and administrative expense as a percentage of net revenue was 20% and 41% for the three months ended June 30, 2011 and 2010, respectively; the reduction reflects the benefit of increased net sales across our established sales and administrative organization, which were established in anticipation of new product launches.

Equity in net loss of joint ventures: Equity in net loss of joint ventures for the three months ended June 30, 2011 totaled $0.5 million, an increase of $0.2 million, or 58%, as compared to $0.3 million for the three months ended June 30, 2010. The increase was primarily due to additional development activities of our KSP joint venture, as the manufacturing facility commenced validation and development activities, partially offset by increased income generated by the Sagent Strides joint venture.

Interest expense: Interest expense for the three months ended June 30, 2011 totaled $1.2 million, an increase of $1.0 million, or 445%, as compared to $0.2 million for the three months ended June 30, 2010. The increase was principally due to higher average borrowings under our expanded senior secured revolving credit facility and borrowings under our new term loan credit facility during the three months ended June 30, 2011 as compared to the three months ended June 30, 2010.

Provision for income taxes: We have generated tax losses since inception and do not believe that it is more likely than not that our net operating loss carryforwards and other deferred tax assets will be utilized. As a result, we have decided that a full valuation allowance is needed against our deferred tax assets. The exercise of the overallotment option as part of our initial public offering in April 2011 has triggered an ownership change as defined by Section 382 of the US Internal Revenue Code. This change will limit the amount of our net operating loss carryforwards which we could utilize to offset future taxable income. Because none of our current net operating loss carryforwards expire before 2027, we expect that despite the use limitations triggered by our IPO, we will have a reasonable opportunity to utilize all of these loss carryforwards before they expire, but such loss carryforwards will be usable only to the extent that we generate sufficient taxable income.

Net loss and net loss per common share: The net loss for the three months ended June 30, 2011 of $8.2 million decreased by $0.5 million, or 6%, from the $8.7 million net loss for the three months ended June 30, 2010. Net loss per common share decreased by $4.10, or 92%. The decrease in net loss per common share is due to the following factors:


Basic and diluted EPS for the three months ended June 30, 2010	$	(4.47)

Increases in operations		0.25

Increase in common shares outstanding		3.85

Basic and diluted EPS for the three months ended June 30, 2011	$	(0.37)

The following compares our consolidated results of operations for the six months ended June 30, 2011 with those of the six months ended June 30, 2010:


	Six months ended June 30,
	2011		2010		$ change		% change

Net revenue	$	62,598	$	19,204	$	43,394		226	%
Cost of sales		55,260		19,009		36,251		191	%

Gross profit		7,338		195		7,143		3663	%
Gross profit as % of net revenues		11.7%		1.0%		10.7%

Operating expenses:
Product development		4,731		6,066		(1,335)		-22	%
Selling, general and administrative		11,451		8,521		2,930		34	%
Equity in net loss of joint ventures		1,197		767		430		56	%

Total operating expenses		17,379		15,354		2,025		13	%


Loss from operations		(10,041)		(15,159)		5,118		34	%
Interest income and other		75		8		67		838	%
Interest expense		(1,762)		(467)		(1,295)		-277	%
Change in fair value of preferred stock warrants		(838)		(408)		(430)		-105	%


Loss before income taxes		(12,566)		(16,026)		3,460		22	%
Provision for income taxes		—		—		–		0	%


Net loss	$	(12,566)	$	(16,026)	$	3,460		22	%

Net loss per common share:
Basic	$	(1.04)	$	(8.36)	$	7.32		88	%
Diluted	$	(1.04)	$	(8.36)	$	7.32		88	%

Net revenue: Net revenue for the six months ended June 30, 2011 totaled $62.6 million, an increase of $43.4 million, or 226%, as compared to $19.2 million for the six months ended June 30, 2010. The launch of 31 codes or presentations of 10 products since June 30, 2010 contributed $34.3 million, or 79%, of the net revenue increase in the first half of the current year. Net revenue for products launched prior to June 30, 2010 increased $9.1 million, or 47%, to $28.3 million in the first half of 2011, due primarily to increased unit volumes.

Cost of sales: Cost of goods sold for the six months ended June 30, 2011 totaled $55.3 million, an increase of $36.3 million, or 191%, as compared to $19.0 million for the six months ended June 30, 2010. Gross profit as a percentage of net revenue was 11.7% for the six months ended June 30, 2011, and 1.0% for the six months ended June 30, 2010. The increase in gross profit as a percentage of net revenue was primarily driven by our introduction of new, higher margin products in the latter half of 2010, principally heparin and topotecan. We currently expect that gross profit as a percentage of net revenues will be in the mid-teens for the full year.

Product development: Product development expense for the six months ended June 30, 2011 totaled $4.7 million, a decrease of $1.3 million, or 22%, as compared to $6.1 million for the six months ended June 30, 2010. The decrease in product development expense was primarily due to the timing of activities under our development programs, as the number of products under development has not changed significantly as compared with the first half of 2010.

Selling, general and administrative: Selling, general and administrative expenses for the six months ended June 30, 2011, totaled $11.5 million, an increase of $2.9 million, or 34%, as compared to $8.5 million for the six months ended June 30, 2010. The increase in selling, general and administrative expense was primarily due to increases in headcount and corporate infrastructure to support our initial public offering and anticipated revenue growth. Selling, general and administrative expense as a percentage of net revenue was 18% and 44% for the six months ended June 30, 2011 and 2010, respectively; the reduction reflects the benefit of increased net sales across our established sales and administrative organization, which were established in anticipation of new product launches.

Equity in net loss of joint ventures: Equity in net loss of joint ventures for the six months ended June 30, 2011 totaled $1.2 million, an increase of $0.4 million, or 56%, as compared to $0.8 million for the six months ended June 30, 2010. The increase was primarily due to additional development activities of our KSP joint venture, as the manufacturing facility commenced validation and development activities, partially offset by increased income generated by the Sagent Strides joint venture.

Interest expense: Interest expense for the six months ended June 30, 2011 totaled $1.8 million, an increase of $1.3 million, or 277%, as compared to $0.5 million for the six months ended June 30, 2010. The increase was principally due to higher average borrowings under our expanded senior secured revolving credit facility and borrowings under our new term loan credit facility during the six months ended June 30, 2011 as compared to the six months ended June 30, 2010.

Net loss and net loss per common share: The net loss for the six months ended June 30, 2011 of $12.6 million decreased by $3.4 million, or 21%, from the $16.0 million net loss for the six months ended June 30, 2010. Net loss per common share decreased by $7.32, or 88%. The decrease in net loss per common share is due to the following factors:


Basic and diluted EPS for the six months ended June 30, 2010	$	(8.36)

Increases in operations		1.80

Increase in common shares outstanding		5.52

Basic and diluted EPS for the six months ended June 30, 2011	$	(1.04)

Liquidity and Capital Resources

Funding Requirements

As of June 30, 2011, we have not generated any operating profit and may not in the near term. We expect our continuing operating losses to result in the continued use of cash for operations. Our future capital requirements will depend on a number of factors, including the continued commercial success of our existing products, launching the 45 products that are represented by our 78 ANDAs that have been recently approved and are pending commercial launch or are pending approval by the FDA as of June 30, 2011, including our levofloxacin, piperacillin and tazobactam and gemcitabine products, which were launched in July 2011, and successfully identifying and sourcing other new product opportunities.

Based on our existing business plan, we expect the net proceeds of our April 2011 initial public offering, approximately $95.8 million, after deducting underwriters discounts and commissions and offering expenses, together with our other existing sources of liquidity, will be sufficient to fund our planned operations, including the continued development of our product pipeline, for at least the next 12 months. However, we may require additional funds in the event we change our business plan or encounter unexpected developments, including unforeseen competitive conditions within our product markets, changes in the regulatory environment or the loss of key relationships with suppliers, group purchasing organizations or end-user customers.

If required, additional funding may not be available to us on acceptable terms or at all. In addition, the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities or by selling convertible debt securities, further dilution to our existing stockholders may result. To the extent our capital resources are insufficient to meet our future capital requirements, we will need to finance our future cash needs through public or private equity offerings or debt financings, which may not be available to us on terms we consider acceptable or at all.

If adequate funds are not available, we may be required to terminate, significantly modify or delay the development or commercialization of new products. We may elect to raise additional funds even before we need them if we believe that the conditions for raising capital are favorable.

Cash Flows

Overview

On June 30, 2011, cash and cash equivalents on hand totaled $78.0 million, working capital totaled $134.5 million and our current ratio (current assets to current liabilities) was approximately 3.6 to 1.0. We have invested $49.3 million of the proceeds from our IPO in other short-term investments, generally U.S. government or high quality investment grade corporate debt securities with a remaining term of two years or less.

Sources and Uses of Cash

Operating activities: Net cash used in operating activities was $22.5 million for the six months ended June 30, 2011, compared with $18.5 million during the six months ended June 30, 2010. The increase in the use of cash was primarily due to an $8.9 million increase in our operating assets and liabilities, principally from reductions in our outstanding payable balances, partially offset by a decrease in our net loss of $3.4 million.

Investing activities: Net cash used in investing activities was $49.7 million for the six months ended June 30, 2011, compared with $5.0 million during the six months ended June 30, 2010. The change in cash flows from investing activities relates primarily to the investment of $49.4 million of the proceeds from our April 2011 IPO in short-term available-for-sale securities.

Financing activities: Net cash provided by financing activities was $115.9 million for the six months ended June 30, 2011, including $101.6 million from the issuance of common shares, which includes net proceeds of $95.8 million from our initial public offering, and $15.0 million from our term loan credit facility, compared with $39.3 million for the six months ended June 30, 2010, which included $39.4 million in proceeds from the issuance of Class B preferred stock.

Senior Secured Revolving Credit Facility

On June 16, 2009, our principal operating subsidiary entered into a senior secured revolving credit facility with Midcap Financial, LLC. In December 2010, our principal operating subsidiary entered into an amendment to the senior secured revolving credit facility pursuant to which it is able to borrow up to $25.0 million in revolving loans, subject to borrowing availability. The borrowing availability is calculated based on eligible accounts receivable and inventory. On March 8, 2011, our principal operating subsidiary further amended the senior secured revolving credit facility to, among other things, permit the entry into our new $15.0 million term loan credit facility, which we describe below, and the incurrence of debt and granting of liens thereunder.

The senior secured revolving credit facility expires June 16, 2013. Borrowings under the senior secured revolving credit facility may be used for general corporate purposes, including funding working capital. Amounts drawn bear an interest rate equal to either an adjusted London Interbank Offered Rate (“LIBOR”), plus a margin of 5.50%, or an alternate base rate plus a margin of 4.50%. Loans under the senior secured revolving credit facility are secured by substantially all of our assets.

The senior secured revolving credit facility contains various covenants, including net sales performance, ability to incur additional indebtedness, create liens, make certain investments, pay dividends, sell assets, or enter into a merger or acquisition. With respect to dividends, our principal operating subsidiary, as the borrower under the senior secured credit facility, was prohibited, subject to certain limited exceptions, from declaring dividends or otherwise making any distributions, loans or advances to Sagent until Sagent becomes a borrower under the senior secured revolving credit facility. We expect Sagent to become a borrower under this agreement during the third quarter.

As of June 30, 2011, we had $20.1 million of outstanding borrowings under our senior secured revolving credit facility, which represented our maximum borrowing availability as of that date based on our borrowing base calculation. The interest rate on the senior secured revolving credit facility was 8.50% at June 30, 2011 and December 31, 2010. As of June 30, 2011, we were in compliance with all the covenants under the senior secured revolving credit facility.

Term Loan Credit Facility

On March 8, 2011, our principal operating subsidiary entered into a $15.0 million term loan credit facility with Midcap Funding III, LLC, as agent and a lender, and the other financial institutions party thereto, as lenders. The term loan credit facility is coterminous with the senior secured revolving credit facility and expires June 16, 2013. Borrowings under the term loan facility may be used for general corporate purposes, including funding working capital. Loans outstanding under the term loan credit facility bear interest at LIBOR, plus a margin of 9.0%, subject to a 3.0% LIBOR floor. Equal monthly amortization payments in respect of the term loan will be payable beginning September 1, 2011. The term loan credit facility is secured by a second lien on substantially all of our assets.

The term loan credit facility contains various covenants substantially similar to the senior secured revolving credit facility, including a covenant to maintain minimum net invoiced revenue, restriction on the borrower’s ability to incur additional indebtedness, create liens, make certain investments, pay dividends, sell assets, or enter into a merger or acquisition. With respect to dividends, our principal operating subsidiary, as the borrower under the term loan credit facility, was prohibited, subject to certain limited exceptions, including an exception to distribute $1.5 million to us to cover fees and expenses related to the IPO, from declaring dividends or otherwise making any distributions, loans or advances to us, until Sagent becomes a borrower under the term loan credit facility. We expect Sagent to become a borrower under this agreement during the third quarter.

Off-Balance Sheet Arrangements and Aggregate Contractual Obligations

We have no off-balance sheet arrangements other than the contractual obligations that are discussed below and in our Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2010, included in our IPO prospectus, filed with the SEC on April 21, 2011.

Aggregate Contractual Obligations:

The following table summarizes our long-term contractual obligations and commitments as of June 30, 2011. The actual amount that may be required in the future to repay our senior secured revolving credit facility may be different, including as a result of additional borrowings under our senior secured revolving credit facility.


	Payments due by period
Contractual obligations (1)	Total		Less than one year		1-3 years		3-5 years		More than five years
Long-term debt obligations (2)	$	35,269	$	27,087	$	8,182	$	–	$	–

Operating lease obligations (3)		1,382		235		491		521		135

Contingent milestone payments (4)		14,002		10,385		2,616		936		65

Joint venture funding requirements (5)		513		340		148		–		25

	$	51,166	$	38,047	$	11,437	$	1,457	$	225

⁽¹⁾

We had no material purchase commitments, individually or in the aggregate, under our manufacturing and supply agreements.

⁽²⁾

Includes amounts payable under our senior secured revolving credit facility based on interest rates calculated at the applicable borrowing rate as of June 30, 2011. As of June 30, 2011, we had approximately $20.1 million of outstanding borrowings under our senior secured revolving credit facility. Also includes amounts payable under our term loan credit facility of $15.0 million as of June 30, 2011.

⁽³⁾

Includes annual minimum lease payments related to noncancelable operating leases.

⁽⁴⁾

Includes management’s estimate for contingent potential milestone payments and fees pursuant to strategic business agreements for the development and marketing of finished dosage form pharmaceutical products assuming all contingent milestone payments occur. Does not include contingent royalty payments, which are dependent on the introduction of new products.

⁽⁵⁾

Includes minimum funding requirements in connection with our existing joint ventures.

Critical Accounting Policies

We prepare our condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Actual results could differ from those estimates and assumptions. Our significant accounting policies are described in Note 2 to our consolidated financial statements for the year ended December 31, 2010, or in Note 1 to this Form 10-Q. Our significant accounting estimates are described in our Management’s Discussion and Analysis of Financial Condition and Results of Operations for the year ended December 31, 2010. We have identified the following critical accounting policies:

•

Revenue Recognition;

•

Revenue Deductions;

•

Inventories;

•

Accounting Estimates and Judgments;

•

Income Taxes:

•

Stock-Based Compensation;

•

Product Development; and

•

Intangible Assets.

For a discussion of critical accounting policies affecting us, see the discussion under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies” in our IPO prospectus filed with the SEC on April 21, 2011. During the second quarter, we invested $49.4 million in available-for-sale marketable securities. We have identified our policy with respect to the valuation and impairment of marketable securities as a new critical accounting policy, as further described below.

Valuation and Impairment of Marketable Securities

Our investments in available-for-sale securities are reported at fair value. Unrealized gains and losses related to changes in the fair value of investments are included in accumulated other comprehensive income, net of tax, as reported in our balance sheets. Changes in the fair value of investments impact our net income (loss) only when such investments are sold or an other-than-temporary impairment is recognized. Realized gains and losses on the sale of securities are determined by specific identification of each security’s cost basis. We regularly review our investment portfolio to determine if any investment is other-than-temporarily impaired due to changes in credit risk or other potential valuation concerns, which would require us to record an impairment charge in the period any such determination is made. In making this judgment, we evaluate, among other things, the duration and extent to which the fair value of an investment is less than its cost, the financial condition of the issuer and any changes thereto, and our intent to sell, or whether it is more likely than not it will be required to sell, the investment before recovery of the investment’s amortized cost basis. Our assessment on whether an investment is other-than-temporarily impaired or not, could change in the future due to new developments or changes in assumptions related to any particular investment.

There have been no other material changes to the Company’s critical accounting policies and estimates since December 31, 2010.

New Accounting Guidance

See Note 1. Summary of Significant Accounting Policies, for a discussion of new accounting guidance.

Contingencies

See Note 15. Commitments and Contingencies, and Part II, Item 1. Legal Proceedings for a discussion of contingencies.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Our market risks relate primarily to changes in interest rates. Our senior secured revolving credit facility bears floating interest rates that are tied to LIBOR and an alternate base rate and our new term loan credit facility bears floating rate interest rates that are tied to LIBOR and, therefore our statements of operations and our cash flows will be exposed to changes in interest rates. A one percentage point increase in LIBOR would cause an increase to the interest expense on our borrowings under our senior secured revolving credit facility and new term loan credit facility of approximately $0.2 million and $0.2 million, respectively. We historically have not engaged in interest rate hedging activities related to our interest rate risk.

At June 30, 2011, we had cash and cash equivalents and short-term investments of $78.0 million and $49.2 million, respectively. Our cash and cash equivalents are held primarily in cash and money market funds, and our short-term investments are held primarily in corporate and U.S. government debt securities. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of these investments, we believe that we do not have any material exposure to changes in the fair value of our investment portfolio as a result of changes in interest rates.

While we operate primarily in the U.S., we do have foreign currency considerations. We generally incur sales and pay our expenses in U.S. dollars. Our KSP joint venture and substantially all of our business partners that supply us with API, product development services and finished product manufacturing are located in a number of foreign jurisdictions, and we believe they generally incur their respective operating expenses in local currencies. As a result, these business partners may be exposed to currency rate fluctuations and experience an effective increase in their operating expenses in the event their local currency appreciates against the U.S. dollar. In this event, such business partners may elect to stop providing us with these services or attempt to pass these increased costs back to us through increased prices for product development services, API sourcing or finished products that they supply to us. Historically we have not used derivatives to protect against adverse movements in currency rates.

We do not have any foreign currency or any other material derivative financial instruments.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Disclosure controls and procedures are controls and other procedures designed to ensure that information required to be disclosed by us in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that the information is accumulated and communicated to our management, including our certifying officers, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

Except as described above in Note 15 to our Condensed Consolidated Financial Statements, there have been no material developments in our legal proceedings since those reported in our IPO prospectus filed with the SEC on April 21, 2011. From time to time we are subject to claims and litigation arising in the ordinary course of business. At this time, there are no proceedings of which management is aware that are expected to have a material adverse effect on the consolidated financial position or results of operations.

Item 1A. Risk Factors.

There are no material changes from the risk factors previously disclosed in our IPO prospectus filed April 21, 2011.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Unregistered Sales of Equity Securities

None.

Use of Proceeds

On April 26, 2011, we completed our offering of 5,750,000 shares of common stock in an initial public offering. In the offering, 5,750,000 shares of common stock were sold at a per share price of $16.00 and an additional 862,500 shares of common stock were sold directly to our underwriters when they exercised their option to purchase additional shares at a per share price of $16.00, resulting in net proceeds of approximately $95.8 million, after deducting underwriting discounts and commissions of approximately $7.4 million and expenses of approximately $2.6 million. None of these payments were direct or indirect payments to any of the Company’s directors or officers or their associates or to persons owning 10 percent or more of the Company’s common stock.

The shares were registered under the Securities Act on a registration statement on Form S-1 (Registration Nos. 333-170179 and 333-173597). The Securities and Exchange Commission declared the registration statement effective on April 19, 2011. The managing underwriters for the offering were Morgan Stanley, Bank of America Merrill Lynch and Jefferies & Company.

We plan to use the net proceeds of the offering for general corporate purposes, which we expect to include funding working capital, operating expenses, the continued development of our product pipeline and portfolio, the maintenance and expansion of our current collaboration arrangements, the strengthening of our existing commercial organization and the selective pursuit of business development opportunities in our focus segment areas. We do not, however, have agreements or commitments for any specific investments or acquisitions at this time.

There has been no material change in the planned use of proceeds from our initial public offering as described in our IPO prospectus filed with the SEC on April 21, 2011.

Item 6. Exhibits.


Exhibit Number		Description

3.1		Certificate of Incorporation of Sagent Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.3 in the Company’s Registration Statement on Form S-1, as amended (File Nos. 333-170979 and 333-173597)).

3.2		Bylaws of Sagent Pharmaceuticals, Inc. (Incorporated by reference to Exhibit 3.4 in the Company’s Registration Statement on Form S-1, as amended (File Nos. 333-170979 and 333-173597)).

31.1		Certification of Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.

32.1		Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1		The following materials from Sagent’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011 are formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Cash Flows, (iv) Notes to the Condensed Consolidated Financial Statements, tagged as blocks of text, and (v) document and entity information.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


		SAGENT PHARMACEUTICALS INC.

		/s/ Ronald Pauli

		Ronald Pauli Chief Financial Officer August 9, 2011

EX-31.1 2 dex311.htm SECTION 302 CEO CERTIFICATION Section 302 CEO Certification

EXHIBIT 31.1

Certifications

I, Jeffrey M. Yordon, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Sagent Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Paragraph omitted in accordance with SEC Release No. 34-47986;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2011

/s/ Jeffrey M. Yordon

Jeffrey M. Yordon

President and Chief Executive Officer

EX-31.2 3 dex312.htm SECTION 302 CFO CERTIFICATION Section 302 CFO Certification

EXHIBIT 31.2

Certifications

I, Ronald Pauli, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Sagent Pharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

(a)

(b)

Paragraph omitted in accordance with SEC Release No. 34-47986;

(c)

(d)

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2011

/s/ Ronald Pauli

Ronald Pauli

Chief Financial Officer

EX-32.1 4 dex321.htm SECTION 906 CEO AND CFO CERTIFICATION Section 906 CEO and CFO Certification

EXHIBIT 32.1

CERTIFICATIONS OF

CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey M. Yordon, President and Chief Executive Officer of Sagent Pharmaceuticals, Inc. (“Sagent”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that Sagent’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in Sagent’s Quarterly Report on Form 10-Q fairly presents in all material respects Sagent’s financial condition and results of operations.

/s/ Jeffrey M. Yordon

Jeffrey M. Yordon

President and Chief Executive Officer

August 9, 2011

I, Ronald Pauli, Chief Financial Officer of Sagent Pharmaceuticals, Inc. (“Sagent”), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that Sagent’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2011, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in Sagent’s Quarterly Report on Form 10-Q fairly presents in all material respects Sagent’s financial condition and results of operations.

/s/ Ronald Pauli

Ronald Pauli

Chief Financial Officer

August 9, 2011

A signed original of these written statements required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Sagent Pharmaceuticals, Inc. and will be retained by Sagent Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 sgnt-20110630.xml XBRL INSTANCE DOCUMENT 0001369786 us-gaap:SeriesBPreferredStockMember 2011-06-30 0001369786 us-gaap:SeriesAPreferredStockMember 2011-06-30 0001369786 us-gaap:SeriesBPreferredStockMember 2010-12-31 0001369786 us-gaap:SeriesAPreferredStockMember 2010-12-31 0001369786 2010-06-30 0001369786 2009-12-31 0001369786 2011-04-01 2011-06-30 0001369786 2010-04-01 2010-06-30 0001369786 2010-01-01 2010-06-30 0001369786 2011-06-30 0001369786 2010-12-31 0001369786 2011-07-29 0001369786 2011-01-01 2011-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares false --12-31 Q2 2011 2011-06-30 10-Q 0001369786 27871612 Non-accelerated Filer Sagent Pharmaceuticals, Inc. 3717000 2862000 408000 408000 838000 384000 1432000 Note 13. Revenue and revenue deductions: Net revenue by product line is as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="68%"> <tr><td width="48%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three months ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom">Therapeutic class:</td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Anti-infective</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9,848</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,037</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,441</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14,808</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> Critical care</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17,469</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,437</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,163</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,784</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Oncology</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,937</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,086</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10,045</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,612</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  32,254</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  10,560</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  62,598</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">  19,204</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> Accrued chargebacks are shown as a reduction in accounts receivable. Changes in accrued chargebacks during the three and six month periods ended June 30, 2011 resulted from the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="68%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Three months ended June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Six months ended June 30, 2011</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Accrued chargebacks at beginning of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,110  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">13,507  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> Provision for chargebacks</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">40,732  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70,114  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Credits or checks issued</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(35,253) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(65,032) </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Accrued chargebacks at end of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,589  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,589  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td></tr></table> Note 2. Reverse stock split: All common share and per share amounts in the condensed consolidated financial statements and notes thereto have been restated to reflect a reverse stock split effective on April 26, 2011, whereby every 7.8378 shares of common stock, including the shares of preferred stock that were converted to common stock on April 26, 2011, were combined into one share of common stock. Immediately prior to the consummation of our IPO, but following the reverse stock split, the number of authorized shares was increased to 105 million, consisting of 100 million shares of common stock and 5 million shares of undesignated preferred stock, each with a par value of $0.01 per share.

Note 7. Accrued liabilities: Accrued liabilities at June 30, 2011 and December 31, 2010 were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr><td width="70%"> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="10%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">December 31, 2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Payroll and employee benefits</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,871</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,736</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Sales and marketing</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,182</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,338</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Other accrued liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">711</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">726</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,764</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,800</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>

24449000

15110000

18939000

21600000

4800000

4764000

1285000

1755000

2318000

264485000

429000

436000

118589000

213883000

90393000

186146000

7731000

23556000

34376000

78006000

15825000

43630000

Note 15. Commitments and contingencies: From time to time, we are subject to claims and litigation arising in the normal course of business. At this time, there are no proceedings of which we are aware that we expect will have a material adverse effect on our consolidated financial position or results of operations. In January 2011, Infusive Technologies, LLC ("Infusive") filed a complaint against us in the United States District Court of Utah, Central Division, alleging that we had breached the terms of an acquisition agreement entered into in September 2008 for failing to use reasonable commercial efforts to develop and commercialize certain products based on patents and other intellectual property assigned to us by Infusive, thereby avoiding a $1,250 contingent payment under the agreement. The complaint seeks compensatory damages of at least $15,000, plus interest, and punitive damages of at least $50,000. We intend to vigorously defend ourselves in this litigation, including bringing a number of counterclaims against Infusive in such litigation. In March 2011, we filed motions for change in venue and to dismiss the complaint and Infusive filed its first amended complaint, which, among other things, alleged additional facts to support its allegations and eliminated the claim for punitive damages. In May 2011, we responded to Infusive's first amended complaint and filed further counterclaims in the matter. We do not expect that this lawsuit will have a material adverse effect on our consolidated financial position or results of operations.

0.000008

0.01

23539769

100000000

2054467

27855544

279000

Note 10. Comprehensive income (loss): Comprehensive income (loss) for the three and six months ended June 30, 2011 and 2010 is comprised of the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="70%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center">Three months ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net loss, as reported</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,195)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,689)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12,566)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,026)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Comprehensive income (loss)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Unrealized loss on available for sale securities, net of tax</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(87)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(87)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Currency translation adjustment, net of tax</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">313</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">557</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total comprehensive loss</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(7,969)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,689)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12,096)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,026)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>

Note 16. Condensed parent company only financial statements: The following condensed financial statements present the Company's financial position as of June 30, 2011 and December 31, 2010, and its results of operations and cash flows for the three and six month periods ended June 30, 2011 and 2010 on a parent-company only basis. In the parent company only financial statements, the Company's investment in subsidiaries is stated at cost plus the equity in undistributed earnings of subsidiaries since the date of formation. The Company's share of loss is recorded as equity in net loss of unconsolidated subsidiaries. The parent company only financial statements should be read in conjunction with the Company's condensed consolidated financial statements. Sagent Pharmaceuticals, Inc. Condensed Balance Sheets (in thousands)   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="77%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">December 31, 2010</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center">(Unaudited)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" colspan="5"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Current assets:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Cash and cash equivalents</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,676  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7,110  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Short term investments</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">49,235  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Prepaid expenses and other current assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">436  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,285  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Total current assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">90,347  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,395  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Investment in unconsolidated subsidiaries</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41,278  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,602  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Investment in unconsolidated joint ventures</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,268  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23,663  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total assets</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,893  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,660  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Liabilities, preferred stock and stockholders' equity</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Current liabilities:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Accounts payable</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">119  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">248  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Accrued liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">233  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Preferred stock warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,432  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total current liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">352  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,695  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Total liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">352  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,695  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Preferred stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Series A preferred stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">113,000  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Series B preferred stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44,774  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Total preferred stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">157,774  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Stockholders' equity:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Common stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">279  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Additional paid-in capital</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">264,485  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,318  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Accumulated other comprehensive income</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,755  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,285  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Accumulated deficit</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(112,978)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(100,412)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Total stockholders' equity (deficit)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">153,541  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(96,809)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total liabilities, preferred stock and stockholders' equity (deficit)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">153,893  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">62,660  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>   Sagent Pharmaceuticals, Inc. Condensed Statements of Operations (in thousands, unaudited)   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="66%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three months ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">    2011    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">    2010    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">    2011    </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">    2010    </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net revenue</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Cost of sales</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Gross profit</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Operating expenses:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Selling, general and administrative</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">707  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">212  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,204  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">405  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Equity in net loss of joint venture</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">919  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">255  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,952  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">642  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Equity in net loss of unconsolidated subsidiaries</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6,224  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,818  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,611  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,575  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Total operating expenses</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,850  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,285  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">11,767  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">15,622  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Loss from operations</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(7,850)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,285)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(11,767)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(15,622)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> Interest income and other</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Change in value of preferred stock warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(384)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(408)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(838)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(408)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Loss before income taxes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,195)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(8,689)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(12,566)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(16,026)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Provision for income taxes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Net loss</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,195)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,689)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12,566)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,026)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>   Sagent Pharmaceuticals, Inc. Condensed Statement of Cash Flows (in thousands, unaudited)   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="82%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Cash flows from operating activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Net loss</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12,566)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,026)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Stock-based compensation</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,051  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">370  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Decrease in restricted stock repurchase liability</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">25  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Equity in net loss of joint venture</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,952  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">642  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Equity in net loss of unconsolidated subsidiaries</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8,611  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14,575  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Change in fair value of preferred stock warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">838  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">408  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Changes in operating assets and liabilities:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Prepaid expenses and other current assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">849  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Accounts payable and accrued liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(66)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(24)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Net cash provided by (used in) operating activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">669  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(30)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Cash flows from investing activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Investments in unconsolidated subsidiaries</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19,285)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(33,615)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Purchase of investments</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(49,391)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Investments in joint venture</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4,664)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net cash used in investing activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(68,676)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(38,279)  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Cash flows from financing activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Proceeds from issuance of preferred stock, net of issuance costs</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,407  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Proceeds from issuance of common stock, net of issuance costs</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101,573  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net cash provided by financing activities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101,573  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,419  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> Net increase in cash and cash equivalents</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">33,566  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,110  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Cash and cash equivalents, at beginning of period</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7,110  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">–  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Cash and cash equivalents, at end of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40,676  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,110  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td></tr></table>

19009000

10658000

55260000

29505000

Note 8. Debt: In March 2011, our principal operating subsidiary amended its $25,000 senior secured revolving credit facility (the "Revolver") to permit, among other things, the entry into a new $15,000 term loan credit facility (the "Term Note") and the incurrence of debt and granting of liens thereunder. The amendment also requires that we become a borrower under the Revolver. The interest rate on the Revolver, which bears interest at a rate equal to either an adjusted London Interbank Offered Rate ("LIBOR"), plus a margin of 5.50%, or an alternate base rate plus a margin of 4.50%, was 8.50% at June 30, 2011 and December 31, 2010. In March 2011, our principal operating subsidiary entered into a $15,000 Term Note, which expires June 16, 2013. Borrowings under the Term Note will be used for general corporate purposes, including funding of our working capital. The interest rate on the Term Note, which bears interest at LIBOR plus a margin of 9.0%, subject to a 3.0% LIBOR floor, was 12.0% at March 31, 2011. Equal monthly amortization payments in respect to the Term Note are payable beginning September 1, 2011. Under the agreement, we are required to maintain the lesser of $15,000 or 65% of our consolidated cash balances with a single financial institution and are also required to pay a financing fee of $600 when the Term Note has been repaid. The financing fee will be amortized to interest expense over the life of the loan, and the related obligation is included in other long-term liabilities on our balance sheet. The Term Note is secured by a second lien on substantially all of the assets of our principal operating subsidiary. The Term Note contains various covenants substantially similar to the senior secured revolving credit facility, including a covenant to maintain minimum net invoiced revenues, restrictions on our ability to incur additional indebtedness, create liens, make certain investments, pay dividends, sell assets, or enter into a merger or acquisition. With respect to dividends, our principal operating subsidiary, as the borrower under the term loan credit facility, was prohibited, subject to certain limited exceptions, from declaring dividends or otherwise making any distributions, loans or advances to us as the parent company. This restriction will continue until we become a borrower under the Term Note. Aggregate maturities of our long-term debt for the years ended June 30, were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr><td width="87%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> For the year ending:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="top"> June 30, 2012</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">    6,818</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> June 30, 2013</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">8,182</td> <td valign="bottom" nowrap="nowrap">  </td></tr></table>

135000

110000

Note 12. Stock-based compensation: We granted 74,170 stock options during the three and six months ended June 30, 2011. There were 44,194 and 190,290 stock options exercised during the three and six months ended June 30, 2011, with an aggregate intrinsic value of $385 and $1,744, respectively.

868000

206000

2494000

1892000

-8.36

-4.47

-1.04

-0.37

-8.36

-4.47

-1.04

-0.37

Note 11. Earnings per share: Basic earnings per share is calculated by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding for the period. Because of their anti-dilutive effect, 1,730,364 and 19,821,420 common share equivalents, comprised of preferred shares, restricted stock, preferred stock warrants and unexercised stock options, have been excluded from the calculation of diluted earnings per share for the periods ended June 30, 2011 and 2010, respectively. The table below presents the computation of basic and diluted earnings per share for the three and six month periods ended June 30, 2011 and 2010:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="70%"> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="2%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center">Three months ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Basic and dilutive numerator:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Net loss, as reported</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,195)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8,689)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(12,566)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16,026)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Denominator:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Weighted-average common shares outstanding—basic (in thousands)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,196</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,944</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,141</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,916</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net effect of dilutive securities:</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Weighted-average conversion of Class A and Class B preferred stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Stock options and restricted stock</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Weighted-average common shares outstanding—diluted (in thousands)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">22,196</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,944</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12,141</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,916</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net loss per common share (basic)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.37)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.47)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.04)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.36)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Net loss per common share (diluted)</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.37)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(4.47)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1.04)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(8.36)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> On April 19, 2011, we completed our IPO, issuing 5,750,000 shares of our common stock in exchange for consideration of $92 million. The underwriters exercised their overallotment option on April 21, 2011, resulting in the issuance of an additional 862,500 shares of our common stock for consideration of $13.8 million. The offering closed on April 26, 2011; we received net proceeds from the offering of $95.8 million.

24466000

22970000

Note 6. Investment in KSP: Changes in our investment in KSP during the six months ended June 30, 2011 were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="50%"> <tr><td width="84%"> </td> <td valign="bottom" width="5%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Investment in KSP at January 1, 2011</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">    23,663  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Equity in net loss of KSP</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,952) </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Currency translation adjustment</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">557  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Investment in KSP at June 30, 2011</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22,268  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> Condensed statement of operations information of KSP is presented below.   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="92%"> <tr><td width="64%"> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Three months ended June 30,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center">Six months ended June 30,</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom" nowrap="nowrap">Condensed statement of operations information</td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">2010</td> <td valign="bottom"> </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net revenues</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> Gross profit</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Net loss</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,369) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(549) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3,057) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,097) </td> <td valign="bottom" nowrap="nowrap">  </td></tr></table> During the three and six months ended June 30, 2011, KSP's development activities increased, as initial batch validation activities were initiated at its manufacturing facility.

Note 9. Fair value measurements: Assets and liabilities measured at fair value on a recurring basis as of June 30, 2011 consisted of the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="52%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Total fair value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Quoted prices in active markets for identical assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Significant other observable inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Significant unobservable inputs (Level 3)</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Commerical paper</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,997 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,997 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Corporate bonds and notes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,239 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,239 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> US government securities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,999 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,999 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Total assets</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,235 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,235 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Preferred stock warrants</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>   The fair value of our Level 2 investments is based on a combination of quoted market prices of similar securities and matrix pricing provided by third-party pricing services utilizing securities of similar quality and maturity. Liabilities measured at fair value on a recurring basis as of December 31, 2010 consisted of the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="54%"> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="9%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Total fair value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Quoted prices in active markets for identical assets (Level 1)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Significant other observable inputs (Level 2)</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Significant unobservable inputs (Level 3)</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Liabilities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Preferred stock warrants</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,432</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,432</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,432</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,432</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> On April 26, 2011, the holder of our preferred stock warrants exercised all of the warrants concurrent with our IPO, acquiring 454,500 shares of our common stock having a fair value at the IPO of $7,272, for $5,002 of cash. We recorded $384 and $838 of expense related to the preferred stock warrants during the three and six months ended June 30, 2011, respectively, and $408 of expense related to the preferred stock warrants during the three and six months ended June 30, 2010. During the three and six months ended June 30, 2011 and 2010, changes in the fair value of our preferred stock warrants measured using significant unobservable inputs (Level 3), were comprised of the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="68%"> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="12%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Three months ended June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Six months ended June 30, 2011</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top" nowrap="nowrap"> Balance at beginning of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,886 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,432 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Change in fair value of warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">384 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">838 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Exercise of warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,270) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2,270) </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Balance at end of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="16"> </td> <td height="16" colspan="4"> </td> <td height="16" colspan="4"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Three months ended June 30, 2010</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Six months ended June 30, 2010</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Balance at beginning of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Issuance of warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">619 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">619 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Change in fair value of warrants</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">408 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">408 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> Balance at end of period</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,027 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,027 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>

195000

-98000

7338000

2749000

-16026000

-8689000

-12566000

-8195000

-767000

-332000

-1197000

-524000

-6403000

-11052000

579000

2661000

47000

-662000

-1454000

1122000

25000

-1000000

-576000

-226000

463000

Note 5. Intangible assets, net: Intangible assets at June 30, 2011 and December 31, 2010 were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="46%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="10" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="10" align="center">December 31, 2010</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Gross carrying amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Accumulated amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Intangible assets, net</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Gross carrying amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Accumulated amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Intangible assets, net</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Product licensing rights</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,688 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(853) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">835 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,618</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(668) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">950 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Product development rights</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,196 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2,196 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,663</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1,663 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,884 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(853) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,031 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3,281</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(668) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,613 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> Movements in intangible assets were due to the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr><td width="62%"> </td> <td valign="bottom" width="13%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="13%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Product licensing rights</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Product development rights</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> December 31, 2010</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">950  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,663  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top" nowrap="nowrap"> Acquisition of product rights</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">533  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top" nowrap="nowrap"> Amortization of product rights</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(185)  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">-  </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td height="5"> </td> <td height="5" colspan="4"> </td> <td height="5" colspan="4"> </td></tr> <tr><td valign="top"> June 30, 2011</td> <td valign="bottom">  </td> <td valign="top">$</td> <td valign="top" align="right">835  </td> <td valign="top" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="top">$</td> <td valign="top" align="right">2,196  </td> <td valign="top" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>   Amortization expense related to our product licensing rights was $81 for the three months ended June 30, 2011, and $185 for the six months ended June 30, 2011. The weighted-average period prior to the next extension or renewal for the five products comprising our product licensing rights intangible asset was 38 months at June 30, 2011. We currently estimate amortization expense over each of the next five years as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="35%"> <tr><td width="81%"> </td> <td valign="bottom" width="14%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom" nowrap="nowrap">For the year ending:</td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Amortization expense</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> June 30, 2012</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2,521</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> June 30, 2013</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">250</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> June 30, 2014</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">122</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr><td valign="top"> June 30, 2015</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">93</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td height="8"> </td> <td height="8" colspan="4"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> June 30, 2016</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44</td></tr></table>

2613000

3031000

467000

228000

1762000

1242000

Note 4. Inventories: Inventories at June 30, 2011 and December 31, 2010 were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="50%"> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="3%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="10" align="center">June 30, 2011</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="10" align="center">December 31, 2010</td> <td valign="bottom"> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Approved</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Pending regulatory approval</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Inventory</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Approved</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Pending regulatory approval</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Inventory</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Finished goods</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,320</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,640</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">32,960</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,151</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,151</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Raw materials</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">262</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Inventory reserve</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,533)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1,533)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(846)</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(846)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">29,787</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1,902</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">31,689</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,305</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">262</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30,567</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> Our finished goods inventory pending regulatory approval at June 30, 2011, included $1,640 related to our levofloxacin and gemcitabine products, which were approved and launched during July 2011.

30567000

31689000

8000

4000

75000

56000

Note 3. Investments: Our investments at June 30, 2011 were comprised of the following:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="100%" align="center"> <tr><td width="44%"> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="4%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Cost basis</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Unrealized gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Unrealized losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Recorded basis</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Cash and cash equivalents</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Short term investments</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Assets</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom"> </td> <td valign="bottom"> </td></tr> <tr><td valign="top"> Cash</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,352 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,352 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">47,352 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Money market funds</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,654 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,654 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">30,654 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Commercial paper</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,998 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,997 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,997 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Corporate bonds and notes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,391 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(84) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,239 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,239 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> US government securities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5,002 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,999 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">- </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,999 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">127,397 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(87) </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">127,241 </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">78,006</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,235 </td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table> Investments with continuous unrealized losses for less than twelve months and their related fair values were as follows:   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr><td width="71%"> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="8%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Fair value</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Unrealized losses</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Commercial paper</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">4,997</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(1)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Corporate bonds and notes</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">39,239</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(84)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr bgcolor="#cceeff"><td valign="top"> US government securities</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4,999</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">    49,235</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(87)</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr></table>   Unrealized losses from fixed-income securities are primarily attributable to changes in interest rates. We do not believe that any remaining unrealized losses represent an other-than-temporary impairment based on our evaluation of available evidence as of June 30, 2011. The original cost and estimated current fair value of our fixed-income securities are set forth below.   <table style="border-collapse: collapse;" border="0" cellspacing="0" cellpadding="0" width="60%"> <tr><td width="71%"> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td> <td valign="bottom" width="7%"> </td> <td> </td> <td> </td> <td> </td></tr> <tr><td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Cost basis</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="border-bottom: #000000 1px solid;" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> Due in one year or less</td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,219</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">18,171</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr><td valign="top"> Due between one and five years</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,172</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31,064</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td></tr> <tr bgcolor="#cceeff"><td valign="top"> </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">    49,391</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">49,235</td> <td valign="bottom" nowrap="nowrap">  </td></tr> <tr style="font-size: 1px;"><td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">  </td></tr></table>

57624000

60342000

118589000

213883000

57618000

51554000

6818000

8182000

39311000

115875000

-5019000

-49714000

-18467000

-22531000

-16026000

-8689000

-12566000

-8195000

20726000

20108000

15354000

7959000

17379000

9374000

-15159000

-8057000

-10041000

-6625000

232000

848000

6000

606000

80000

49391000

257000

603000

4980000

68000

8000

113000

5435000

4739000

924000

12000

101573000

15000000

39407000

-108000

-618000

785000

788000

Note 14. Related party transactions: As of June 30, 2011 and December 31, 2010, respectively, we had a receivable of $206 and $868 from Sagent Strides LLC, which is expected to offset future profit-sharing payments. As of June 30, 2011, and December 31, 2010, respectively, we had a payable of $1,892 and $2,494 to Sagent Strides LLC, principally for the acquisition of inventory and amounts due under profit-sharing arrangements. During the six months ended June 30, 2011, Sagent Strides LLC distributed $1,848 of profit sharing receipts to its joint venture partners. As the Sagent Strides joint venture is in a cumulative loss position, our share of this distribution has been treated as a return of capital in the condensed consolidated statement of cash flows.

6066000

3272000

4731000

2374000

208000

671000

100000

-100412000

-112978000

19204000

10560000

62598000

32254000

8521000

4355000

11451000

6476000

370000

1051000

49235000

Note 1. Summary of significant accounting policies: Reincorporation: We completed our initial public offering ("IPO") on April 26, 2011. In connection with our IPO, we incorporated (the "Reincorporation") in Delaware as Sagent Pharmaceuticals, Inc., ("Sagent" or the "Company"). Prior to this reincorporation, we were a Cayman Islands company, and our corporate name was Sagent Holding Co. ("Sagent Holding"). In connection with our IPO and concurrent with our Reincorporation in Delaware, the holders of our preferred stock exchanged each of their outstanding shares of preferred stock for 0.12759 shares of our common stock. Basis of Presentation: Our interim condensed consolidated financial statements are unaudited. We prepared the condensed consolidated financial statements following rules for interim reporting as prescribed by the U.S. Securities and Exchange Commission ("SEC"). As permitted under those rules, we have condensed or omitted a number of footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). It is management's opinion that these financial statements include all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of our financial position, operating results and cash flows. Operating results for any interim period are not necessarily indicative of future or annual results. You should read these statements in conjunction with our consolidated financial statements and related notes for the year ended December 31, 2010, included in our IPO prospectus filed with the SEC on April 21, 2011. Principles of Consolidation: The condensed consolidated financial statements include Sagent as well as our wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. We account for our investment in Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited ("KSP") and Sagent Strides LLC using the equity method of accounting, as our interest in each entity provides for joint financial and operational control. Operating results of our KSP equity method investment are reported on a one-month lag. Financial Instruments: We consider all highly liquid interest-earning investments with a maturity of three months or less at the date of purchase to be cash equivalents. The fair values of these investments approximate their carrying values. Investments with original maturities of greater than three months and remaining maturities of less than one year are classified as short-term investments. Investments with maturities beyond one year are classified as short-term based on their highly liquid nature and because such marketable securities represent the investment of cash that is available for current operations. All cash equivalents and short-term investments are classified as available-for-sale and realized gains and losses are recorded using the specific identification method. Changes in market value, excluding other-than-temporary impairments, are reflected in other comprehensive income ("OCI"). Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. We employ a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, we evaluate, among other factors, general market conditions, credit quality of debt instrument issuers, the duration and extent to which the fair value is less than cost, and for equity securities, our intent and ability to hold, or plans to sell, the investment. For fixed income securities, we also evaluate whether we have plans to sell the security or it is more likely than not that we will be required to sell the security before recovery. We also consider specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to other expense and a new cost basis in the investment is established. New Accounting Pronouncements: In May 2011, new guidance was issued on the accounting for fair value measurements. The new guidance limits the highest-and-best-use measure to nonfinancial assets, permits certain financial assets and liabilities with offsetting positions in market or counterparty credit risks to be measured at a net basis, and provides guidance on the applicability of premiums and discounts. Additionally, the new guidance expands the disclosures on Level 3 inputs by requiring quantitative disclosure of the unobservable inputs and assumptions, as well as description of the valuation processes and the sensitivity of the fair value to changes in unobservable inputs. We will adopt this guidance on January 1, 2012, and do not believe this guidance will have a significant impact on our financial results. In June 2011, new guidance was issued regarding the presentation of comprehensive income. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. Instead, an entity will be required to present either a continuous statement of operations and other comprehensive income or separate but consecutive statements of operations and other comprehensive income. We will adopt this guidance on January 1, 2012, and do not believe this guidance will have a significant impact on our financial results.

-96809000

153541000

157774000

113000000

44774000

113000000

45800000

0.00001

113000000

39136052

113000000

32714284

1916000

1944000

12141000

22196000

1916000

1944000

12141000

22196000

EX-101.SCH 6 sgnt-20110630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statements Of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Statements Of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Summary Of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Reverse Stock Split link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Investment In KSP link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Revenue And Revenue Deductions link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 11501 - Disclosure - Commitments And Contingencies link:presentationLink link:calculationLink link:definitionLink 11601 - Disclosure - Condensed Parent Company Only Financial Statements link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 sgnt-20110630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 sgnt-20110630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 sgnt-20110630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and entity information [Abstract]. Document And Entity Information Statement [Table] Statement [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Condensed Consolidated Balance Sheets Class of Stock [Axis] Class of Stock [Domain] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Assets Abstract Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, at end of period Cash and cash equivalents, at beginning of period Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Restricted Cash and Cash Equivalents, Current Restricted cash and cash equivalents Short-term Investments Short-term investments Short-term Investments, Total Accounts Receivable, Net, Current Accounts receivable, net of chargebacks and other deductions Accounts Receivable, Net, Current, Total Inventory, Net Inventories Inventory, Net, Total Due from Related Parties, Current Due from related party Due from Related Parties, Current, Total Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current, Total Assets, Current Total current assets Total current assets Restricted Cash and Cash Equivalents, Noncurrent Restricted cash and cash equivalents Property, Plant and Equipment, Net Property, Plant and Equipment, Net, Ending Balance Property, Plant and Equipment, Net, Beginning Balance Property, plant, and equipment, net Property, Plant and Equipment, Net, Total Equity Method Investments Investment in joint ventures Intangible Assets, Net (Excluding Goodwill) Intangible assets, net 0 2,613 Other Assets, Noncurrent Other Assets, Noncurrent, Total Other assets Assets Total assets Liabilities, preferred stock and stockholders' equity Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Due to Related Parties, Current Due to related party Due to Related Parties, Current, Total Carrying value as of the balance sheet date of obligations incurred and payable to partners for profit sharing on sales made to third parties. This reflects the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Profit Sharing Current Accrued profit sharing Accrued Liabilities, Current Accrued liabilities Accrued Liabilities, Current, Total Carrying value as of the balance sheet date of preferred stock warrant obligations measured at fair value on a recurring basis. Preferred Stock Warrants Preferred stock warrants Long-term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Current Maturities, Total Notes Payable, Current Notes payable Notes Payable, Current, Total Liabilities, Current Total current liabilities Long term liabilities: Long-term Debt, Excluding Current Maturities Long-term debt Long-term Debt, Excluding Current Maturities, Total Other Liabilities, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent, Total Liabilities Total liabilities Total liabilities Preferred stock Temporary Equity, Carrying Amount Temporary Equity, Carrying Amount, Ending Balance Temporary Equity, Carrying Amount, Beginning Balance Total preferred stock Temporary Equity, Carrying Amount, Total Stockholders' equity (deficit): Common Stock, Value, Issued Common Stock, Value, Issued, Ending Balance Common Stock, Value, Issued, Beginning Balance Common stock-$0.01 and $0.000008 par value, 100,000,000 and 23,539,769 authorized and 27,855,544 and 2,054,467 outstanding at June 30, 2011 and December 31, 2010, respectively Common Stock, Value, Issued, Total Additional Paid in Capital, Common Stock Additional Paid in Capital, Common Stock, Ending Balance Additional Paid in Capital, Common Stock, Beginning Balance Additional paid-in capital Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Retained Earnings (Accumulated Deficit) Retained Earnings (Accumulated Deficit), Ending Balance Retained Earnings (Accumulated Deficit), Beginning Balance Accumulated deficit Retained Earnings (Accumulated Deficit), Total Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Parent, Ending Balance Stockholders' Equity Attributable to Parent, Beginning Balance Total stockholders' equity (deficit) Total stockholders' equity (deficit) Liabilities And Stockholders Equity Total liabilities, preferred stock and stockholders' equity (deficit) Temporary Equity, Par or Stated Value Per Share Preferred stock, par value Temporary Equity, Shares Authorized Preferred stock, authorized shares Temporary Equity, Shares Outstanding Preferred stock, outstanding shares Temporary Equity, Liquidation Preference Preferred stock, liquidation preference Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, authorized shares Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding, Ending Balance Common Stock, Shares, Outstanding, Beginning Balance Common stock, outstanding shares Condensed Consolidated Statements Of Operations Sales Revenue, Goods, Net Net revenue Sales Revenue, Goods, Net, Total Cost of Goods Sold Cost of sales Cost of Goods Sold, Total Cost of sales Gross Profit Gross profit Gross profit Operating expenses: Research and Development Expense Product development Research and Development Expense, Total Selling, General and Administrative Expense Selling, general and administrative Selling, General and Administrative Expense, Total Income (Loss) from Equity Method Investments Equity in net loss of joint ventures Equity in net loss of joint ventures Income (Loss) from Equity Method Investments, Total Equity in net loss of joint ventures Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Loss from operations Investment Income, Net Interest income and other Investment Income, Net, Total Interest Expense Interest expense and other Interest expense and other Interest Expense, Total Reflects the change in value of preferred stock warrant obligations measured at fair value on a recurring basis during the period. Change in Fair Value of Preferred Stock Warrants Change in fair value of preferred stock warrants Change in fair value of preferred stock warrants Change in fair value of preferred stock warrants Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before income taxes Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit), Total Net Income (Loss) Attributable to Parent Net loss Net loss Net loss Earnings Per Share Net loss per common share: Earnings Per Share, Basic Basic Earnings Per Share, Basic, Total Earnings Per Share, Diluted Diluted Earnings Per Share, Diluted, Total Weighted-average of shares used to compute net loss per common share: Weighted Average Number of Shares Outstanding, Basic Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted Average Number of Shares Outstanding, Diluted Diluted Weighted Average Number of Shares Outstanding, Diluted, Total Condensed Consolidated Statements Of Cash Flows Cash flows from operating activities Cash flows from operating activities Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Depreciation, Total Amortization Amortization, Total Share-based Compensation Stock-based compensation Share-based Compensation, Total Increase (Decrease) in Payables under Repurchase Agreements Decrease in restricted stock repurchase liability Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable, net Accounts receivable, net Increase (Decrease) in Inventories Inventories Inventories Increase (Decrease) in Inventories, Total Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other current assets Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Increase (Decrease) in Due from Related Parties, Current Due from related party Due from related party Due from related party Increase (Decrease) in Due from Related Parties, Current, Total Increase (Decrease) in Accounts Payable and Accrued Liabilities Accounts payable and other accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash flows from investing activities Payments to Acquire Productive Assets Capital expenditures Capital expenditures Payments to Acquire Productive Assets, Total Increase (Decrease) in Restricted Cash (Funding) return of principal balance of restricted cash (Funding) return of principal balance of restricted cash Increase (Decrease) in Restricted Cash, Total Payments to Acquire Interest in Joint Venture Investments in unconsolidated joint ventures Investments in unconsolidated joint ventures Proceeds from Divestiture of Interest in Joint Venture Return of capital from unconsolidated joint venture Payments to Acquire Available-for-sale Securities Purchases of investments Payments to Acquire Available-for-sale Securities, Total Purchases of investments Payments to Acquire Intangible Assets Purchase of product rights Purchase of product rights Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash flows from financing activities Proceeds from (Repayments of) Short-term Debt Reduction in short-term notes payable Proceeds from (Repayments of) Short-term Debt, Total Proceeds from Issuance of Long-term Debt Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt, Total Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Payment of Financing and Stock Issuance Costs Payment of deferred financing costs Payment of deferred financing costs Payment of Financing and Stock Issuance Costs, Total Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) Net increase in cash and cash equivalents Summary Of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary Of Significant Accounting Policies Reverse stock split [Abstract]. Reverse Stock Split Reverse stock split disclosure [Text Block]. Reverse Stock Split Disclosure [Text Block] Reverse Stock Split Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Investments Inventories Inventory Disclosure [Text Block] Inventories Intangible Assets, Net Intangible Assets Disclosure [Text Block] Intangible Assets, Net Investment In KSP Equity Method Investments Disclosure [Text Block] Investment In KSP Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Debt Debt Disclosure [Text Block] Debt Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Comprehensive Income (Loss) Comprehensive Income Note Text Block Comprehensive Income (Loss) Earnings Per Share [Text Block] Earnings Per Share Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Revenue and revenue deductions [Abstract]. Revenue And Revenue Deductions Revenue and revenue deductions disclosure [Text Block]. Revenue And Revenue Deductions Disclosure [Text Block] Revenue And Revenue Deductions Related Party Transactions Related Party Transactions Disclosure [Text Block] Related Party Transactions Commitments And Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments And Contingencies Condensed Parent Company Only Financial Statements Condensed Financial Information of Parent Company Only Disclosure [Text Block] Condensed Parent Company Only Financial Statements EX-101.PRE 10 sgnt-20110630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) (USD $) In Thousands, except Share data	Jun. 30, 2011	Dec. 31, 2010
Common stock, par value	$ 0.01	$ 0.000008
Common stock, authorized shares	100,000,000	23,539,769
Common stock, outstanding shares	27,855,544	2,054,467
Series A Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, authorized shares	0	113,000,000
Preferred stock, outstanding shares	0	113,000,000
Preferred stock, liquidation preference	$ 0	$ 113,000
Series B Preferred Stock [Member]
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, authorized shares	0	39,136,052
Preferred stock, outstanding shares	0	32,714,284
Preferred stock, liquidation preference	$ 0	$ 45,800

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References+ Details

- Definition

The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References+ Details

XML 12 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Operations (USD $) In Thousands, except Per Share data	3 Months Ended		6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010	Jun. 30, 2011	Jun. 30, 2010
Condensed Consolidated Statements Of Operations
Net revenue	$ 32,254	$ 10,560	$ 62,598	$ 19,204
Cost of sales	29,505	10,658	55,260	19,009
Gross profit	2,749	(98)	7,338	195
Operating expenses:
Product development	2,374	3,272	4,731	6,066
Selling, general and administrative	6,476	4,355	11,451	8,521
Equity in net loss of joint ventures	524	332	1,197	767
Total operating expenses	9,374	7,959	17,379	15,354
Loss from operations	(6,625)	(8,057)	(10,041)	(15,159)
Interest income and other	56	4	75	8
Interest expense and other	(1,242)	(228)	(1,762)	(467)
Change in fair value of preferred stock warrants	(384)	(408)	(838)	(408)
Loss before income taxes	(8,195)	(8,689)	(12,566)	(16,026)
Provision for income taxes
Net loss	$ (8,195)	$ (8,689)	$ (12,566)	$ (16,026)
Net loss per common share:
Basic	$ (0.37)	$ (4.47)	$ (1.04)	$ (8.36)
Diluted	$ (0.37)	$ (4.47)	$ (1.04)	$ (8.36)
Weighted-average of shares used to compute net loss per common share:
Basic	22,196	1,944	12,141	1,916
Diluted	22,196	1,944	12,141	1,916

XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2011	Jul. 29, 2011
Document And Entity Information
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2011
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2011
Entity Registrant Name	Sagent Pharmaceuticals, Inc.
Entity Central Index Key	0001369786
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		27,871,612

XML 14 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 15 R12.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Jun. 30, 2011

Accrued Liabilities

Accrued Liabilities

Note 7. Accrued liabilities:

Accrued liabilities at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011		December 31, 2010
Payroll and employee benefits	$	1,871	$	1,736
Sales and marketing		2,182		2,338
Other accrued liabilities		711		726

	$	4,764	$	4,800

XML 16 R17.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

6 Months Ended

Jun. 30, 2011

Stock-Based Compensation

Stock-Based Compensation

Note 12. Stock-based compensation:

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

XML 17 R8.htm IDEA: XBRL DOCUMENT

Investments

6 Months Ended

Jun. 30, 2011

Investments

Investments

Note 3. Investments:

Our investments at June 30, 2011 were comprised of the following:


	Cost basis		Unrealized gains		Unrealized losses		Recorded basis		Cash and cash equivalents		Short term investments
Assets
Cash	$	47,352	$	-	$	-	$	47,352	$	47,352	$	-
Money market funds		30,654		-		-		30,654		30,654		-
Commercial paper		4,998		-		(1)		4,997		-		4,997
Corporate bonds and notes		39,391		1		(84)		39,239		-		39,239
US government securities		5,002		-		(2)		4,999		-		4,999

	$	127,397	$	1	$	(87)	$	127,241	$	78,006	$	49,235

Investments with continuous unrealized losses for less than twelve months and their related fair values were as follows:


	Fair value		Unrealized losses
Commercial paper	$	4,997	$	(1)
Corporate bonds and notes		39,239		(84)
US government securities		4,999		(2)

	$	49,235	$	(87)

The original cost and estimated current fair value of our fixed-income securities are set forth below.


	Cost basis		Estimated fair value
Due in one year or less	$	18,219	$	18,171
Due between one and five years		31,172		31,064

	$	49,391	$	49,235

- Definition

Tabular disclosure of investments in certain debt and equity securities (and certain other trading assets) which include all debt and equity securities (other than those equity securities accounted for under the equity or cost methods of accounting) with readily determinable fair values. Other trading assets include assets that are carried on the balance sheet at fair value and held for trading purposes. A debt security represents a creditor relationship with an enterprise that is in the form of a security. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities (and other trading assets).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694
-Topic 320

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901
-Topic 320

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

+ Details

XML 18 R14.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Jun. 30, 2011

Fair Value Measurements

Fair Value Measurements

Note 9. Fair value measurements:

Assets and liabilities measured at fair value on a recurring basis as of June 30, 2011 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Assets
Commerical paper	$	4,997	$	-	$	4,997	$	-
Corporate bonds and notes		39,239		-		39,239		-
US government securities		4,999		-		4,999		-

Total assets	$	49,235	$	-	$	49,235	$	-

Liabilities
Preferred stock warrants	$	-	$	-	$	-	$	-

	$	-	$	-	$	-	$	-

Liabilities measured at fair value on a recurring basis as of December 31, 2010 consisted of the following:


	Total fair value		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Liabilities
Preferred stock warrants	$	1,432	$	-	$	-	$	1,432

	$	1,432	$	-	$	-	$	1,432


	Three months ended June 30, 2011		Six months ended June 30, 2011
Balance at beginning of period	$	1,886	$	1,432
Change in fair value of warrants		384		838
Exercise of warrants		(2,270)		(2,270)

Balance at end of period	$	-	$	-


	Three months ended June 30, 2010		Six months ended June 30, 2010
Balance at beginning of period	$	-	$	-
Issuance of warrants		619		619
Change in fair value of warrants		408		408

Balance at end of period	$	1,027	$	1,027

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

XML 19 R19.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2011

Related Party Transactions

Related Party Transactions

Note 14. Related party transactions:

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 04
-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 20 R15.htm IDEA: XBRL DOCUMENT

Comprehensive Income (Loss)

6 Months Ended

Jun. 30, 2011

Comprehensive Income (Loss)

Comprehensive Income (Loss)

Note 10. Comprehensive income (loss):

Comprehensive income (loss) for the three and six months ended June 30, 2011 and 2010 is comprised of the following:


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Net loss, as reported	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)
Comprehensive income (loss)
Unrealized loss on available for sale securities, net of tax		(87)		-		(87)		-
Currency translation adjustment, net of tax		313		-		557		-

Total comprehensive loss	$	(7,969)	$	(8,689)	$	(12,096)	$	(16,026)

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 55
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 14-26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

+ Details

XML 21 R13.htm IDEA: XBRL DOCUMENT

Debt

6 Months Ended

Jun. 30, 2011

Debt

Debt

Note 8. Debt:

In March 2011, our principal operating subsidiary amended its $25,000 senior secured revolving credit facility (the "Revolver") to permit, among other things, the entry into a new $15,000 term loan credit facility (the "Term Note") and the incurrence of debt and granting of liens thereunder. The amendment also requires that we become a borrower under the Revolver. The interest rate on the Revolver, which bears interest at a rate equal to either an adjusted London Interbank Offered Rate ("LIBOR"), plus a margin of 5.50%, or an alternate base rate plus a margin of 4.50%, was 8.50% at June 30, 2011 and December 31, 2010.

Aggregate maturities of our long-term debt for the years ended June 30, were as follows:


For the year ending:

June 30, 2012	$	6,818
June 30, 2013	$	8,182

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

XML 22 R6.htm IDEA: XBRL DOCUMENT

Summary Of Significant Accounting Policies

6 Months Ended

Jun. 30, 2011

Summary Of Significant Accounting Policies

Summary Of Significant Accounting Policies

Note 1. Summary of significant accounting policies:

Reincorporation:

We completed our initial public offering ("IPO") on April 26, 2011. In connection with our IPO, we incorporated (the "Reincorporation") in Delaware as Sagent Pharmaceuticals, Inc., ("Sagent" or the "Company"). Prior to this reincorporation, we were a Cayman Islands company, and our corporate name was Sagent Holding Co. ("Sagent Holding").

Basis of Presentation:

Our interim condensed consolidated financial statements are unaudited. We prepared the condensed consolidated financial statements following rules for interim reporting as prescribed by the U.S. Securities and Exchange Commission ("SEC"). As permitted under those rules, we have condensed or omitted a number of footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America ("U.S. GAAP"). It is management's opinion that these financial statements include all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of our financial position, operating results and cash flows. Operating results for any interim period are not necessarily indicative of future or annual results.

Principles of Consolidation:

The condensed consolidated financial statements include Sagent as well as our wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. We account for our investment in Kanghong Sagent (Chengdu) Pharmaceutical Corporation Limited ("KSP") and Sagent Strides LLC using the equity method of accounting, as our interest in each entity provides for joint financial and operational control. Operating results of our KSP equity method investment are reported on a one-month lag.

Financial Instruments:

Investments are considered to be impaired when a decline in fair value is judged to be other-than-temporary. Fair value is calculated based on publicly available market information or other estimates determined by management. We employ a systematic methodology on a quarterly basis that considers available quantitative and qualitative evidence in evaluating potential impairment of our investments. If the cost of an investment exceeds its fair value, we evaluate, among other factors, general market conditions, credit quality of debt instrument issuers, the duration and extent to which the fair value is less than cost, and for equity securities, our intent and ability to hold, or plans to sell, the investment. For fixed income securities, we also evaluate whether we have plans to sell the security or it is more likely than not that we will be required to sell the security before recovery. We also consider specific adverse conditions related to the financial health of and business outlook for the investee, including industry and sector performance, changes in technology, and operational and financing cash flow factors. Once a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded to other expense and a new cost basis in the investment is established.

New Accounting Pronouncements:

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

XML 23 R9.htm IDEA: XBRL DOCUMENT

Inventories

6 Months Ended

Jun. 30, 2011

Inventories

Inventories

Note 4. Inventories:

Inventories at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011						December 31, 2010
	Approved		Pending regulatory approval		Inventory		Approved		Pending regulatory approval		Inventory
Finished goods	$	31,320	$	1,640	$	32,960	$	31,151	$	-	$	31,151
Raw materials		-		262		262		-		262		262
Inventory reserve		(1,533)		-		(1,533)		(846)		-		(846)

	$	29,787	$	1,902	$	31,689	$	30,305	$	262	$	30,567

Our finished goods inventory pending regulatory approval at June 30, 2011, included $1,640 related to our levofloxacin and gemcitabine products, which were approved and launched during July 2011.

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

XML 24 R10.htm IDEA: XBRL DOCUMENT

Intangible Assets, Net

6 Months Ended

Jun. 30, 2011

Intangible Assets, Net

Intangible Assets, Net

Note 5. Intangible assets, net:

Intangible assets at June 30, 2011 and December 31, 2010 were as follows:


	June 30, 2011						December 31, 2010
	Gross carrying amount		Accumulated amortization		Intangible assets, net		Gross carrying amount		Accumulated amortization		Intangible assets, net
Product licensing rights	$	1,688	$	(853)	$	835	$	1,618	$	(668)	$	950
Product development rights		2,196		-		2,196		1,663		-		1,663

	$	3,884	$	(853)	$	3,031	$	3,281	$	(668)	$	2,613

Movements in intangible assets were due to the following:


	Product licensing rights		Product development rights
December 31, 2010	$	950	$	1,663

Acquisition of product rights		70		533

Amortization of product rights		(185)		-


June 30, 2011	$	835	$	2,196

We currently estimate amortization expense over each of the next five years as follows:


For the year ending:	Amortization expense
June 30, 2012	$	2,521

June 30, 2013		250

June 30, 2014		122

June 30, 2015		93

June 30, 2016		44

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References+ Details

XML 25 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 26 R18.htm IDEA: XBRL DOCUMENT

Revenue And Revenue Deductions

6 Months Ended

Jun. 30, 2011

Revenue And Revenue Deductions

Revenue And Revenue Deductions

Note 13. Revenue and revenue deductions:

Net revenue by product line is as follows:


	Three months ended June 30,				Six months ended June 30,
Therapeutic class:	2011		2010		2011		2010
Anti-infective	$	9,848	$	8,037	$	22,441	$	14,808

Critical care		17,469		1,437		30,163		2,784

Oncology		4,937		1,086		10,045		1,612

	$	32,254	$	10,560	$	62,598	$	19,204

Accrued chargebacks are shown as a reduction in accounts receivable. Changes in accrued chargebacks during the three and six month periods ended June 30, 2011 resulted from the following:


	Three months ended June 30, 2011		Six months ended June 30, 2011
Accrued chargebacks at beginning of period	$	13,110	$	13,507

Provision for chargebacks		40,732		70,114

Credits or checks issued		(35,253)		(65,032)

Accrued chargebacks at end of period	$	18,589	$	18,589

XML 27 R11.htm IDEA: XBRL DOCUMENT

Investment In KSP

6 Months Ended

Jun. 30, 2011

Investment In KSP

Investment In KSP

Note 6. Investment in KSP:

Changes in our investment in KSP during the six months ended June 30, 2011 were as follows:


Investment in KSP at January 1, 2011	$	23,663
Equity in net loss of KSP		(1,952)
Currency translation adjustment		557

Investment in KSP at June 30, 2011	$	22,268

Condensed statement of operations information of KSP is presented below.


	Three months ended June 30,				Six months ended June 30,
Condensed statement of operations information	2011		2010		2011		2010

Net revenues	$	-	$	-	$	-	$	-

Gross profit		-		-		-		-

Net loss		(1,369)		(549)		(3,057)		(1,097)

During the three and six months ended June 30, 2011, KSP's development activities increased, as initial batch validation activities were initiated at its manufacturing facility.

- Definition

The entire disclosure for equity investment, or group of investments, for which combined disclosure is appropriate, including: (a) the name of each investee and percentage of ownership of common stock, (b) accounting policies for investments in common stock, (c) difference between the amount at which the investment is carried and the amount of underlying equity in net assets and the accounting treatment of the difference, (d) the total fair value of each identified investment for which a market value is available, (e) summarized information as to assets, liabilities, and results of operations of the investees (for investments in unconsolidated subsidiaries, common stock of joint ventures, or other investments using the equity method), and (f) material effects of possible conversions, exercises, or contingent issuances of the investee. Other disclosures include (a) the names of any investee in which the investor owns 20 percent or more of the voting stock and investment is not accounted for using the equity method, and the reasons why not, and (b) the names of any investee in which the investor owns less than 20 percent of the voting stock and the investment is accounted for using the equity method, and the reasons why it is.

+ References+ Details

XML 28 R21.htm IDEA: XBRL DOCUMENT

Condensed Parent Company Only Financial Statements

6 Months Ended

Jun. 30, 2011

Condensed Parent Company Only Financial Statements

Condensed Parent Company Only Financial Statements

Note 16. Condensed parent company only financial statements:

The following condensed financial statements present the Company's financial position as of June 30, 2011 and December 31, 2010, and its results of operations and cash flows for the three and six month periods ended June 30, 2011 and 2010 on a parent-company only basis. In the parent company only financial statements, the Company's investment in subsidiaries is stated at cost plus the equity in undistributed earnings of subsidiaries since the date of formation. The Company's share of loss is recorded as equity in net loss of unconsolidated subsidiaries. The parent company only financial statements should be read in conjunction with the Company's condensed consolidated financial statements.

Sagent Pharmaceuticals, Inc.

Condensed Balance Sheets

(in thousands)


	June 30, 2011		December 31, 2010
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	40,676	$	7,110
Short term investments		49,235		–
Prepaid expenses and other current assets		436		1,285

Total current assets		90,347		8,395
Investment in unconsolidated subsidiaries		41,278		30,602
Investment in unconsolidated joint ventures		22,268		23,663

Total assets	$	153,893	$	62,660


Liabilities, preferred stock and stockholders' equity
Current liabilities:
Accounts payable	$	119	$	248
Accrued liabilities		233		15
Preferred stock warrants		–		1,432

Total current liabilities		352		1,695

Total liabilities		352		1,695

Preferred stock
Series A preferred stock		–		113,000
Series B preferred stock		–		44,774


Total preferred stock		–		157,774

Stockholders' equity:
Common stock		279		–
Additional paid-in capital		264,485		2,318
Accumulated other comprehensive income		1,755		1,285
Accumulated deficit		(112,978)		(100,412)

Total stockholders' equity (deficit)		153,541		(96,809)


Total liabilities, preferred stock and stockholders' equity (deficit)	$	153,893	$	62,660

Sagent Pharmaceuticals, Inc.

Condensed Statements of Operations

(in thousands, unaudited)


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Net revenue	$	–	$	–	$	–	$	–
Cost of sales		–		–		–		–

Gross profit		–		–		–		–
Operating expenses:
Selling, general and administrative		707		212		1,204		405
Equity in net loss of joint venture		919		255		1,952		642
Equity in net loss of unconsolidated subsidiaries		6,224		7,818		8,611		14,575

Total operating expenses		7,850		8,285		11,767		15,622


Loss from operations		(7,850)		(8,285)		(11,767)		(15,622)

Interest income and other		39		4		39		4
Change in value of preferred stock warrants		(384)		(408)		(838)		(408)


Loss before income taxes		(8,195)		(8,689)		(12,566)		(16,026)
Provision for income taxes		–		–		–		–


Net loss	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)

Sagent Pharmaceuticals, Inc.

Condensed Statement of Cash Flows

(in thousands, unaudited)


	Six months ended June 30,
	2011		2010
Cash flows from operating activities
Net loss	$	(12,566)	$	(16,026)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation		1,051		370
Decrease in restricted stock repurchase liability		–		25
Equity in net loss of joint venture		1,952		642
Equity in net loss of unconsolidated subsidiaries		8,611		14,575
Change in fair value of preferred stock warrants		838		408
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		849		–
Accounts payable and accrued liabilities		(66)		(24)

Net cash provided by (used in) operating activities		669		(30)


Cash flows from investing activities
Investments in unconsolidated subsidiaries		(19,285)		(33,615)
Purchase of investments		(49,391)		–
Investments in joint venture		–		(4,664)

Net cash used in investing activities		(68,676)		(38,279)


Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs		–		39,407
Proceeds from issuance of common stock, net of issuance costs		101,573		12

Net cash provided by financing activities		101,573		39,419


Net increase in cash and cash equivalents		33,566		1,110
Cash and cash equivalents, at beginning of period		7,110		–

Cash and cash equivalents, at end of period	$	40,676	$	1,110

- Definition

The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.

+ References+ Details

XML 29 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements Of Cash Flows (USD $) In Thousands	6 Months Ended
	Jun. 30, 2011	Jun. 30, 2010
Cash flows from operating activities
Net loss	$ (12,566)	$ (16,026)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	110	135
Amortization	436	429
Stock-based compensation	1,051	370
Decrease in restricted stock repurchase liability		25
Equity in net loss of joint ventures	1,197	767
Change in fair value of preferred stock warrants	838	408
Changes in operating assets and liabilities:
Accounts receivable, net	(2,661)	(579)
Inventories	(1,122)	1,454
Prepaid expenses and other current assets	576	1,000
Due from related party	662	(47)
Accounts payable and other accrued liabilities	(11,052)	(6,403)
Net cash used in operating activities	(22,531)	(18,467)
Cash flows from investing activities
Capital expenditures	(113)	(8)
(Funding) return of principal balance of restricted cash	(463)	226
Investments in unconsolidated joint ventures	(68)	(4,980)
Return of capital from unconsolidated joint venture	924
Purchases of investments	(49,391)
Purchase of product rights	(603)	(257)
Net cash used in investing activities	(49,714)	(5,019)
Cash flows from financing activities
Reduction in short-term notes payable	(618)	(108)
Proceeds from issuance of long-term debt	15,000
Proceeds from issuance of preferred stock, net of issuance costs		39,407
Proceeds from issuance of common stock, net of issuance costs	101,573	12
Payment of deferred financing costs	(80)
Net cash provided by financing activities	115,875	39,311
Net increase in cash and cash equivalents	43,630	15,825
Cash and cash equivalents, at beginning of period	34,376	7,731
Cash and cash equivalents, at end of period	$ 78,006	$ 23,556

XML 30 R7.htm IDEA: XBRL DOCUMENT

Reverse Stock Split

6 Months Ended

Jun. 30, 2011

Reverse Stock Split

Reverse Stock Split

Note 2. Reverse stock split:

XML 31 R16.htm IDEA: XBRL DOCUMENT

Earnings Per Share

6 Months Ended

Jun. 30, 2011

Earnings Per Share

Earnings Per Share

Note 11. Earnings per share:


	Three months ended June 30,				Six months ended June 30,
	2011		2010		2011		2010
Basic and dilutive numerator:
Net loss, as reported	$	(8,195)	$	(8,689)	$	(12,566)	$	(16,026)


Denominator:
Weighted-average common shares outstanding—basic (in thousands)		22,196		1,944		12,141		1,916
Net effect of dilutive securities:
Weighted-average conversion of Class A and Class B preferred stock		-		-		-		-
Stock options and restricted stock		-		-		-		-

Weighted-average common shares outstanding—diluted (in thousands)		22,196		1,944		12,141		1,916


Net loss per common share (basic)	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)

Net loss per common share (diluted)	$	(0.37)	$	(4.47)	$	(1.04)	$	(8.36)

- Definition

The entire disclosure for earnings per share.

+ References+ Details

XML 32 R20.htm IDEA: XBRL DOCUMENT

Commitments And Contingencies

6 Months Ended

Jun. 30, 2011

Commitments And Contingencies

Commitments And Contingencies

Note 15. Commitments and contingencies:

In January 2011, Infusive Technologies, LLC ("Infusive") filed a complaint against us in the United States District Court of Utah, Central Division, alleging that we had breached the terms of an acquisition agreement entered into in September 2008 for failing to use reasonable commercial efforts to develop and commercialize certain products based on patents and other intellectual property assigned to us by Infusive, thereby avoiding a $1,250 contingent payment under the agreement. The complaint seeks compensatory damages of at least $15,000, plus interest, and punitive damages of at least $50,000. We intend to vigorously defend ourselves in this litigation, including bringing a number of counterclaims against Infusive in such litigation. In March 2011, we filed motions for change in venue and to dismiss the complaint and Infusive filed its first amended complaint, which, among other things, alleged additional facts to support its allegations and eliminated the claim for punitive damages. In May 2011, we responded to Infusive's first amended complaint and filed further counterclaims in the matter. We do not expect that this lawsuit will have a material adverse effect on our consolidated financial position or results of operations.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 33 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (USD $) In Thousands	Jun. 30, 2011	Dec. 31, 2010
Assets
Cash and cash equivalents	$ 78,006	$ 34,376
Restricted cash and cash equivalents	671	208
Short-term investments	49,235
Accounts receivable, net of chargebacks and other deductions	21,600	18,939
Inventories	31,689	30,567
Due from related party	206	868
Prepaid expenses and other current assets	4,739	5,435
Total current assets	186,146	90,393
Restricted cash and cash equivalents	100	100
Property, plant, and equipment, net	788	785
Investment in joint ventures	22,970	24,466
Intangible assets, net	3,031	2,613
Other assets	848	232
Total assets	213,883	118,589
Liabilities, preferred stock and stockholders' equity
Accounts payable	15,110	24,449
Due to related party	1,892	2,494
Accrued profit sharing	2,862	3,717
Accrued liabilities	4,764	4,800
Preferred stock warrants		1,432
Current portion of long-term debt	6,818
Notes payable	20,108	20,726
Total current liabilities	51,554	57,618
Long term liabilities:
Long-term debt	8,182
Other long-term liabilities	606	6
Total liabilities	60,342	57,624
Preferred stock
Total preferred stock		157,774
Stockholders' equity (deficit):
Common stock-$0.01 and $0.000008 par value, 100,000,000 and 23,539,769 authorized and 27,855,544 and 2,054,467 outstanding at June 30, 2011 and December 31, 2010, respectively	279
Additional paid-in capital	264,485	2,318
Accumulated other comprehensive income	1,755	1,285
Accumulated deficit	(112,978)	(100,412)
Total stockholders' equity (deficit)	153,541	(96,809)
Total liabilities, preferred stock and stockholders' equity (deficit)	213,883	118,589
Series A Preferred Stock [Member]
Preferred stock
Total preferred stock		113,000
Series B Preferred Stock [Member]
Preferred stock
Total preferred stock		$ 44,774

XML 34 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.11 Html 13 107 1 false 2 0 false 3 true false R1.htm 00090 - Document - Document And Entity Information Sheet http://www.SagentPharma.com/role/DocumentDocumentAndEntityInformation Document And Entity Information false false R2.htm 00100 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.SagentPharma.com/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R3.htm 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.SagentPharma.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 00200 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.SagentPharma.com/role/StatementCondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements Of Operations false false R5.htm 00300 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.SagentPharma.com/role/StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements Of Cash Flows false false R6.htm 10101 - Disclosure - Summary Of Significant Accounting Policies Sheet http://www.SagentPharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary Of Significant Accounting Policies false false R7.htm 10201 - Disclosure - Reverse Stock Split Sheet http://www.SagentPharma.com/role/DisclosureReverseStockSplit Reverse Stock Split false false R8.htm 10301 - Disclosure - Investments Sheet http://www.SagentPharma.com/role/DisclosureInvestments Investments false false R9.htm 10401 - Disclosure - Inventories Sheet http://www.SagentPharma.com/role/DisclosureInventories Inventories false false R10.htm 10501 - Disclosure - Intangible Assets, Net Sheet http://www.SagentPharma.com/role/DisclosureIntangibleAssetsNet Intangible Assets, Net false false R11.htm 10601 - Disclosure - Investment In KSP Sheet http://www.SagentPharma.com/role/DisclosureInvestmentInKsp Investment In KSP false false R12.htm 10701 - Disclosure - Accrued Liabilities Sheet http://www.SagentPharma.com/role/DisclosureAccruedLiabilities Accrued Liabilities false false R13.htm 10801 - Disclosure - Debt Sheet http://www.SagentPharma.com/role/DisclosureDebt Debt false false R14.htm 10901 - Disclosure - Fair Value Measurements Sheet http://www.SagentPharma.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R15.htm 11001 - Disclosure - Comprehensive Income (Loss) Sheet http://www.SagentPharma.com/role/DisclosureComprehensiveIncomeLoss Comprehensive Income (Loss) false false R16.htm 11101 - Disclosure - Earnings Per Share Sheet http://www.SagentPharma.com/role/DisclosureEarningsPerShare Earnings Per Share false false R17.htm 11201 - Disclosure - Stock-Based Compensation Sheet http://www.SagentPharma.com/role/DisclosureStockBasedCompensation Stock-Based Compensation false false R18.htm 11301 - Disclosure - Revenue And Revenue Deductions Sheet http://www.SagentPharma.com/role/DisclosureRevenueAndRevenueDeductions Revenue And Revenue Deductions false false R19.htm 11401 - Disclosure - Related Party Transactions Sheet http://www.SagentPharma.com/role/DisclosureRelatedPartyTransactions Related Party Transactions false false R20.htm 11501 - Disclosure - Commitments And Contingencies Sheet http://www.SagentPharma.com/role/DisclosureCommitmentsAndContingencies Commitments And Contingencies false false R21.htm 11601 - Disclosure - Condensed Parent Company Only Financial Statements Sheet http://www.SagentPharma.com/role/DisclosureCondensedParentCompanyOnlyFinancialStatements Condensed Parent Company Only Financial Statements false false All Reports Book All Reports Process Flow-Through: 00100 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Jun. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00200 - Statement - Condensed Consolidated Statements Of Operations Process Flow-Through: 00300 - Statement - Condensed Consolidated Statements Of Cash Flows sgnt-20110630.xml sgnt-20110630.xsd sgnt-20110630_cal.xml sgnt-20110630_def.xml sgnt-20110630_lab.xml sgnt-20110630_pre.xml true true EXCEL 35 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]E-F$T-34T95\S.&(V7S0P-35?.&(S-E\X,F4T M.#@Q.3EB-38B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7 M;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN M=&%N9VEB;&5?07-S971S7TYE=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5S=&UE;G1?26Y?2U-0/"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!R96AE;G-I=F5?26YC;VUE7TQO#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E=F5N=65?06YD7U)E=F5N=65?1&5D=6-T:6]N#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5\\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I3='EL97-H965T($A2968],T0B5V]R:W-H965T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-F$T-34T M95\S.&(V7S0P-35?.&(S-E\X,F4T.#@Q.3EB-38-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO939A-#4U-&5?,SAB-E\T,#4U7SAB,S9?.#)E-#@X M,3DY8C4V+U=O'0O:'1M;#L@8VAA2!) M;F9O2!);F9O'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^9F%L'0^2G5N(#,P+`T*"0DR,#$Q/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!296=I2!#96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3,V.3'0^+2TQ,BTS,3QS<&%N/CPO2!#;VUM;VX@4W1O8VLL(%-H87)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2P@<&QA;G0L(&%N M9"!E<75I<&UE;G0L(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2`H9&5F M:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\2`H9&5F:6-I="D\+W1D/@T* M("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D M('-H87)E'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'!E;G-E2!I M;B!N970@;&]S'0^)FYB'0^ M)FYB'0^)FYB'0^)FYB3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]E-F$T-34T95\S M.&(V7S0P-35?.&(S-E\X,F4T.#@Q.3EB-38-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO939A-#4U-&5?,SAB-E\T,#4U7SAB,S9?.#)E-#@X,3DY M8C4V+U=O'0O:'1M;#L@8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!I;B!N970@;&]S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S6UE;G0@;V8@9&5F97)R960@9FEN86YC M:6YG(&-O2!F:6YA;F-I;F<@86-T:79I M=&EE3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E-F$T-34T95\S.&(V7S0P-35?.&(S-E\X,F4T M.#@Q.3EB-38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO939A-#4U M-&5?,SAB-E\T,#4U7SAB,S9?.#)E-#@X,3DY8C4V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)VUA#LG/CQF;VYT('-T>6QE/3-$ M)V9O;G0M9F%M:6QY.B!!F4],T0R/CQB M/DYO=&4@,2XF;F)S<#M3=6UM87)Y(&]F('-I9VYI9FEC86YT(&%C8V]U;G1I M;F<@<&]L:6-I97,Z(#PO8CX\+V9O;G0^/"]P/@T*#0H\<"!S='EL93TS1"=M M87)G:6XM=&]P.B`Q,G!X.R!M87)G:6XM8F]T=&]M.B`P<'@[)SX\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/E=E(&-O;7!L971E9"!O=7(@:6YI=&EA;"!P=6)L M:6,@;V9F97)I;F<@*"))4$\B*2!O;B!!<')I;"9N8G-P.S(V+"`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`Q,2P@;F5W(&=U:61A;F-E('=A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$)VUA#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M M:6QY.B!!F4],T0R/D%L;"!C;VUM;VX@ M2!E=F5R>2`W+C@S-S@@2!P'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`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`\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%SF4],T0Q/B9N8G-P M.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X@/"]T M9#X-"CQT9"!V86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$ M8F]T=&]M/B`\+W1D/CPO='(^#0H\='(^/'1D('9A;&EG;CTS1'1O<#X-"@T* M/'`@3H@07)I86P[)R!C;&%S M6QE/3-$)V9O;G0M9F%M:6QY M.B!!F4],T0R/C0W+#,U,B9N8G-P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R M87`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`],T1N;W=R M87`^/&9O;G0@F4],T0Q/B9N M8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S6QE/3-$)V9O M;G0M9F%M:6QY.B!!F4],T0R/D-O;6UE MF4],T0Q/B9N8G-P.R9N8G-P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C M;&%SF4],T0Q/B9N8G-P.R9N8G-P.SPO M9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C M;&%S3H@07)I86P[)R!C;&%S6QE/3-$)V9O M;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I M9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B@Q*29N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!! MF4],T0R/C,Y+#,Y,29N8G-P.SPO9F]N M=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`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`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`C,#`P,#`P(#%P M>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X-"@T*/'`@6QE/3-$)V)O6QE/3-$)V)O"!S M;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@ M=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N M/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P M(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X-"@T*/'`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`Q,G!X.R<^)FYBF4],T0Q/B9N M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C M;&%S3H@07)I86P[)R!C;&%SF4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!C;&%S3H@07)I86P[ M)R!C;&%SF5D/&)R("\^;&]S M6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@ M,65M.R<^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%SF4] M,T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S M3H@07)I86P[)R!C;&%S6QE/3-$)W1E>'0M:6YD M96YT.B`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY M.B!!F4],T0R/C,Y+#(S.3PO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^/&9O M;G0@F4],T0Q/B9N8G-P.R9N M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I M86P[)R!C;&%S3H@07)I86P[)R!C;&%S6QE/3-$)W1E M>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S6QE M/3-$)V9O;G0M6QE/3-$)V)O"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D/B9N8G-P.SPO M=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N8G-P.R9N8G-P.SPO=&0^#0H\ M=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S='EL93TS1"=B;W)D97(M=&]P M.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P.SPO<#X\+W1D/@T*/'1D('9A M;&EG;CTS1&)O='1O;3X-"@T*/'`@6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT9"!V86QI9VX],T1B M;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3H@07)I86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M M:6QY.B!!F4],T0R/B9N8G-P.R9N8G-P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S M6QE/3-$)V9O;G0M9F%M:6QY.B!! MF4],T0R/B9N8G-P.R9N8G-P.SPO9F]N M=#X\+W1D/CPO='(^#0H\='(@#L@;6%R9VEN+6)O='1O M;3H@,'!X.R!F;VYT+7-I>F4Z(#%P>#LG/B9N8G-P.SPO<#X-"@T*/'`@3H@07)I86P[)R!C;&%SF5D(&QO3H@07)I86P[)R!C;&%S#LG/B9N8G-P.SPO<#X-"@T*/'1A8FQE('-T>6QE/3-$)V)O6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/D1U92!I;B!O;F4@>65A6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/C$X+#(Q.3PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O M='1O;2!N;W=R87`],T1N;W=R87`^/&9O;G0@F4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@ M07)I86P[)R!C;&%S3H@ M07)I86P[)R!C;&%S6QE/3-$)W1E>'0M:6YD96YT.B`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^ M/&9O;G0@3H@ M07)I86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T>6QE M/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R M/C,Q+#`V-#PO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R M87`],T1N;W=R87`^/&9O;G0@F4Z(#%P>#LG/CQT9"!V M86QI9VX],T1B;W1T;VT^(#PO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/B9N M8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\<"!S M='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N8G-P M.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@6QE M/3-$)V)OF4],T0Q/B9N8G-P.R9N8G-P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL M93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I M86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R0\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\9F]N="!S='EL93TS M1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D M/CPO='(^#0H\='(@"!D;W5B;&4[)SXF;F)S<#L\+W`^ M/"]T9#X-"CQT9#XF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3XF M;F)S<#LF;F)S<#L\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@ M"!D;W5B;&4[)SXF;F)S<#L\ M+W`^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%]E-F$T-34T95\S.&(V7S0P-35?.&(S-E\X,F4T M.#@Q.3EB-38-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO939A-#4U M-&5?,SAB-E\T,#4U7SAB,S9?.#)E-#@X,3DY8C4V+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)VUA#LG/CQF;VYT('-T>6QE/3-$)V9O M;G0M9F%M:6QY.B!!F4],T0R/CQB/DYO M=&4@-"XF;F)S<#M);G9E;G1O6QE/3-$)VUA#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/DEN=F5N=&]R:65S(&%T($IU;F4F;F)S<#LS,"P@ M,C`Q,2!A;F0@1&5C96UB97(F;F)S<#LS,2P@,C`Q,"!W97)E(&%S(&9O;&QO M=W,Z(#PO9F]N=#X\+W`^#0H-"CQP('-T>6QE/3-$)VUA#L@;6%R9VEN+6)O='1O;3H@,'!X.R!F;VYT+7-I>F4Z(#$X<'@[)SXF;F)S M<#L\+W`^#0H-"CQT86)L92!S='EL93TS1"=B;W)D97(M8V]L;&%PF4],T0Q/B9N8G-P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/CQB/D1E8V5M8F5R)FYBF4],T0Q/B9N8G-P.SPO9F]N=#X\+W1D/CPO='(^#0H\='(^ M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%SF4] M,T0Q/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\ M9F]N="!C;&%S3H@07)I86P[)R!C M;&%S3QBF4],T0Q/B9N8G-P M.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!C;&%S M3H@07)I86P[)R!C;&%S3QB6QE/3-$)W1E>'0M:6YD96YT.B`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`],T1N;W=R87`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`M,65M.R!M87)G:6XM;&5F=#H@,65M.R<^/&9O;G0@F4],T0Q/B9N8G-P.R9N M8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S M='EL93TS1"=F;VYT+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I M86P[)R!C;&%S6QE M/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R M/B9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG M;CTS1')I9VAT/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R/BTF;F)S<#L\+V9O;G0^/"]T9#X-"CQT M9"!V86QI9VX],T1B;W1T;VT@;F]W6QE M/3-$)V9O;G0M9F%M:6QY.B!!F4],T0R M/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O M;3X\9F]N="!C;&%SF4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\ M+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT M+69A;6EL>3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C;&%SF4],T0Q/B9N8G-P.R9N8G-P.SPO9F]N=#X\+W1D/@T* M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL M>3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C;&%S3H@07)I86P[)R!C;&%S6QE/3-$)V9O;G0M9F%M:6QY.B!! MF4],T0R/B9N8G-P.SPO9F]N=#X\+W1D M/@T*/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQF;VYT('-T M>6QE/3-$)V9O;G0M9F%M:6QY.B!!F4] M,T0R/B@X-#8I/"]F;VYT/CPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M(&YO M=W)A<#TS1&YO=W)A<#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@07)I M86P[)R!C;&%S6QE/3-$)V9O;G0M6QE/3-$)V)O"!S;VQI9#LG/B9N8G-P.SPO M<#X\+W1D/@T*/'1D/B9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M M/B9N8G-P.R9N8G-P.SPO=&0^#0H\=&0@=F%L:6=N/3-$8F]T=&]M/@T*#0H\ M<"!S='EL93TS1"=B;W)D97(M=&]P.B`C,#`P,#`P(#%P>"!S;VQI9#LG/B9N M8G-P.SPO<#X\+W1D/@T*/'1D('9A;&EG;CTS1&)O='1O;3X-"@T*/'`@ ZIP 36 0001193125-11-216725-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-11-216725-xbrl.zip M4$L#!!0````(`)6)"3]V`\UEI%<``,6I!@`1`!P`'2<=Q[G,N,W%;IRT?3YY(!*2<$>1*D#:5G_]LPM2$B51LF11EFCA M9MK()(A]Q6(!["[.__8X\,D]$Y*'P;N*=6)6"`OG9X^/#R<"&PKTZ8G;CBH5E-H'ZB$WN$[!=8^ ML29O+E/(87!&6J?M4]NT+-(^LYRS>I-<_):T>^P(GP!Y@7Q7R<##QR>AZ,%' MIG/*`QG1P&65I.69SX,_5C3'UQU`:]S\<:']@Z-:6^UV^U2]G32%CCP^:9OM MMW&:O!PW]=A<.\G=.G8D!1 M`BF,1M4QQ]]P&=9LJ[D*2M)B_`'H3H_2X>2#+I4=U3A]D4>'Y'FLA-ZMT__\ M]OG6[;,!K4ZH`1D3L+UH5G0'L5 M09L-QSQYE%Z%G"8=H5J%0<0>07&9&X&^*C6"-V[ZF'OO*A?R[KI[U[ASS#OL MY2ZEYNXV`H7$47'I4RFON[=1Z/YQ\+RZA^5]R9PR6FTFZW&^>GTLVE7DO40 MO)0HW1E['/KG M,VPX'T+7H9=ABE*`Z/U42<]/Q\_&/62^.3]-Y5>\,"]>M3!SJ3MT85KVG6.A M-$T]-/)EFB;#'S[;CB)GE MR/ZU>H8CYGH<,0OBB%4*CEB[Y\B<3[EW%NS.P3HDT@J9GYIW=OL0A=:LVNVM MC;A5"B.^S@!]AA&'M?WW@"\L[&-\AES"EY8SX8;'[X&2*7!L]R4>,&!E.'6G MX,6`41D+]C[=^SC[?OOQ_'3\<.IVY7^ONOW(@G#`@V4=JZV=,]FG@LEE/2]V M<7Z:H2!IE$>P/2'X23J6=[+0QW*4LYV`1+[%0Y_-BP2>_^HK%WC^C=ZDOV?GI0B?3OB]C<*?A(9E@%$G#8'A_^?!W#2VR*X!)?G M,#0[WI?VN`CPVVBX&1R80?XY"P&[F';\JS)CE_!<4/\J\-CC/]AH(PA9.[FT MQP6`X6`0!FJ-=ZM&U'45:Z^?`*^ M-EM-JV'9,[BL`#:/V"?N,W$)O.^%8C,^?($A35V7^6@.F4=43UDT9KJ>A_N5 M];@$C@71%SK83,3)+C=)MKE=%D<3CG$*V9K2F>:V-0'-;Y:\!# MQSI_;#R%=!E_[ZR+Q8 M^47R(\RZ?HC>U3?`YH,/'6QD#W_VH[=#(J.1#][]@(H>#ZI1.#PCYO#Q+4D? M=,(H"@?)L\K/O>@M?M4%*.,/\7>U2P?<'YV1"\&I_[9"7-R^?%>Y&T05(OG_ MH)D]^;B#/[Z$X`=8SLG/=#!\&W3D\&U*'H'IAHCTMS>A]8S@IZ>=<2>G"';R MQQ!__?C#CS\L):FQ,Y*^L&B";V=$AB)$G(G/`T:X)%22;NC[X<.8A`T17R8+ MHI!$1,Z(94\HF;!SL?N(=L#=3D%T0N$Q474!-3J4T,?X%U":O'M7`5V&6=J7 M0^JJ:(#T[R'UO/'?#]R+^N\JC=9?*@DH!4B,Z8N\<8M:VB+A0>1E6GODGOJ\ M%R!22-^DU_KR3XIZKD&_$.CDIUBB)'/XS(S)Q7%GY:GZS+!:3>ZFW3\;$`XJ M&#WPH%$AZ2L7/"]27!!:VS%.O!#G%MW^/`S8EP#&-56:T M6+8=M51N^6.)9/+\T;FEZL(2<*@68DGCLY?CQ/KJ,SMCCN?@GTSU'[&&CT2& M/O>`X*6*9N].T="5V[O^:*$L",740CD\H>B1P"OK) M=1GK=B>P,EC``BU=]LPMX'`)7N4!'H:=D:K%!I,EG,^Z\`B?;,_$BR#B`*6+ MQR3W;)&XX=YUKVC/X<\;^WKIGX+W^M'V\-M&J];:&(<@?!`8")W\6\#@*5H4 M6N8KX+<,TVEJF1^5S&W;J-4L+?2C$KI5,UIFN:Q[CN.2<5/Z#!GSKM):OO,Z M;3+U]FJ'W7PUS0?BFET*KDZ7B4O%47AF6VS'%3R*FT:MT2[5*-;2+T[Z1DT[ M:\-9JM6*N%K[\TORU;;=8`H]D;:E7O!$5TSVGHR/U;A M6X;9:FCA'ZGP3<.LU;7TCU3Z1L.R2R7\/*\F"S,-T\S&F^8+<)UHO97(/?WI M@@>5G@RK:-.<8^$):`]^6%<<=G+^/M/1/>03K*FG>:=YIW6RW1DI^82IR+339U6:4E[R;I.BU+ M0=P^],XZU/U#$BPT+OOA0X`YUY2(<>XXX?#$=<,84_<%/J)+D@LG8QR(G71$.5%=) M,CAT_(K3P2W3_$M>RDC.\GXN@7R3;&7+W%^F]"YAYW@LJSV33?S9@W&7#SLM M22553ZE),GFG?S^=TDMTMMD!BO66/Y9?J'DKFA*$T.1.V1'I,``4X$0;=M,Y M=]?FVK>\LQ+,LL@A5ZFZ?LBE`WFZ57A-5.T[YB*==SY?9LF&]$>,_5 M]4S=4&3-\S'8X8,)>JF91M.Q2S\.M484IA%-$Z;H6NDUHC26N0Q.]*5@'H\D M48::H0O-I8S94;C,!S,P?W'JAEUWWI1T0&I-*$X3&G7#=.RR:D*>$2SUV6BY M`^$TYUXFA/"P-L!8X.FMKQ?=\6@9]5:[]'ZU5@2M"*]S%B][M(3FW5)X&5U- M?HX#2=+K$#:[[6#NF@0A67)WS=#GTT(]MSE"$`>](IT M2"1PVQL1=AF=X_O`:[Q+B*AKP%3DS!"ODDO^&B2Q.#Q0$3$@%?"\)'I&(&9T M"M6U0%T>T,`%0(!">BFN5!T%P!R)7PH6A:1/[QGI,!9@K$VDOH2G@G5]YD8J M#&B!&/*'RB*UQ6,RH1`RZQG3MZY[P-@0Z'!992>_EJF MN=!F"<.5(BSVF&D=@U)),&E*(^:D8!!&W3YYX%$?-&1(!9J_6/'OS^:):4UU M]63)R,J8JZ>L3GIG7GI[\T4:B'9#1VCZP-"ERX+/G'8X],#9[NYUL5HO9+J: M&=,U7O;X4P(/]S*7'&1QC;8DN@^5\"-SU27;F=>6>FTF8_4X[G\QG[K_I;DB M8$X'^.D`OY>.!,N]@V,<^'4085Y:8K,2RS6T2?&P-"1P(F`#6CL<'0 M#T<,O>J`=7ET%'$@>]^+,EI-77#ZV&3>=,I5XFH]SV7/MNR6^BS9*8#._V"X MNCP&"W8PA^*V8;7*5;Y)"[]`X3M.N2H%E-1CN\8-T$G>8F:_0MNZ%U3WIJ6= MMF,5O5UZWZW8U86,,?X]EA)&7GT)Q,0A%Q/^7A`RN"D\X0 M+@-:!&YSH7)/XN8TGH6;E"R26PYCJU5OS7%&=;LFJ$W,OM-J.6M"*L2JMTVG MG0R#)X7__/K?&&8_'R.0+Z)+*L2(![U_J9#1 MY7PPVT\BU&PZU@PZ:\$L!LWU!ZCMU.N-?:&Y@58Y-:>Y-SS7U\(FS!H[0O-& MY1!>I7'7'UGR;Y'&VJJW[/H:R.=CLB,:-C?JCED4#3!U@^Y.JN\H'3&4^P+^80I&4BHT[OV.*"&9?^)0/ M$K+0B^\E?@057&)F0IJF$H1B@!=ZAS%F0X1=THGA-9/RA%Q`+WTNT_Y59HH" M$81D*$*7,8R75ED)#WV.B0?):_J`_Y]FA!#V.$1T'KCO)TDM%#@2,:2/4"_) MP4@25S!!!!,VEJ3+#$/)D[P.D=:?5:##(4L4#A!^CHQVF"]T%9"_TR"F8I1F MN5P%W1A]?/*-N?T`;]X$)3/(Y\^7Y)?*^&7E#1#M`^D44T.&($,`3WOPCXQ( M/$DO0B,`C6XQ-T@2&)61X,##2^!@A'SY'M&^02Y!L04P[R-/:F$9A/H^EB;L M3034IQ[I",PNV=^.$S'X+@% M,).X3$1`/*H5=S06 ME&3L#ZG^AN4!$!##J!MAJ@PQ])5+DIXR,)*,,#3UJ M2>Z'=1,_/"'_9NJS0%%USWNA"&/I`S365:GW.)S]>Y;J"XSBJ0G(IG5UL!AT M0OZ%'&<-XG_9X`B_);U3`PW$^5ZK$@U"-S7$--N`G M?JYR(!6Q*'HN!US*-(%KHO'P<@(QZ0LK!'6Y`%3H("E//6EN)";(P"0\S+I2 MV@!D@WU*51X'U&2=".KI)GHGX^$0=%#UK=HEMB2)&/;Y@">95@HW9(56# M.1$S?9`Q?QF#N\3>9CR0C?R(11\D7;[?4'$ME*7SE-,(+LRMR@SUFHYV+ MVSRH;7!:RJL%E"PS_:\(G*[C2$8P*M$T;LGO3TB-]_PK;.HC], MH>P_25X+18^4,@AE_R,E9QXK0W+B%Q817.<:6/Y(,-PX/HX:]?N.U?^E95CM M^IN-L=`9&B67>J/5UE(_,JE;ME%O-+38CTWL#<.T2R;V'#^F2*_%+N9RG>7[ M]27Q7=;-5RNZG290$W@`!+[X:JD8N_,]$$R%<'EJT831)O2>%!H:1X MEL;<6*@<(X,$3(6N1?2Q)(:IJ(EFWWYVLUS3KI9]8;*O;H&)5H%7H0)Z^!^O M[,LZ_,NQ\%+Y=^Z(1((&TD_3+R:YEMK?V9/2.Y93*F77HC]Z>Z=5H#`5J->; M6O3'*?JRCOX<;Z?P M4MS[6733:#=TX,FQ25V'&QVCU"W;,-LEBSO18M]>[*\CW*C)- M[*NJ;Y"A*ONX;A$.1#L5:'5&H!TJ>5+O"@&M*W)CCDL\N&?)(7A23*PCN<>I MP&OIN4R^\[#FF1O**"F1AM^S_\8\&N$7<>"I@G>=&!LR*H)Q)<*9OB0/7*8^ MQ=I6^'HR+I.Z;5.,I"K5!"U4J")'AKMHC#P4WQ1PD&:`8Z:@Z>5A6#W7O=^A?Z<\#!_'-\F^JFDMJ=TT[?UY51+NV;)`5EYCH MS)J66ZIJ[=V`(`;497'$7>I++)KHGFQI,98:QIT1,[6*'ZA/40MO^PPK6A\\ M(7,&'W]PM6!2)>C"6(*-D&\2.O@$]<(I*GMIGN;FI7GJ^RM2LT/0.6O6U6O3 M3?8O#F9[Y+!SOG,+F8RKG.@L_0.46*Y+.">U@TSC?X5C>Q_R_^5[0&,/*SR_ MV;N4#XKC!T;3^@.C#&?.$_5+[@]YTK,[)"59V^69*%-]HZWPS7V:/0MS?+4, M5;(\>T4BW$6[5T'@BYN=@O(D<`=KLI7%IE>5E$1GMR)^WP>A-=-H-!N%3-/Z M1+S,BM`T+%A2E%T/=CPU%V/P;OMXY03>LY+9"3\*:[>%5A5L]MJ&[=1+K^Y: M(PK3"(7(3RW;LHI9M!Z8%2R#(W@CV)!R3UUJ$TB6O=G)G5G-:%/YDJ;2T>ZA M5H<)(I9AM\H_<>99R%*'4I8[24=SKL#TIB(G]D*3F?0W@9"VT57W0,V+9A-[15U!HQU0C':#2?PIQJNDSJ.@,`= MV]]B(O,5544.E+U=,JAF*7VXBVK77H77FO!MO#M6OGWYE]\1B[,Z(D8 M;S>&TKAZ]W,K:H?J!!4YZ_I;"5M`_>N%I91 M4)_/NXH:CGN)?T)8[]?);9L)&Q?_J8 M6YWK"0&6I_0O_83^ENFKL2XF`^**HF" MOHXI0^_::K7(C>1P#--\G0'9)3C'3TWC!VT:M6G4IO&PU*)6,YK-6NDU(L\R MZA,M?:)5.LZM7NL?J`O*Q?(\CK>E MX_**_O1-02&XB0@P,P`DG5__74/'@0I4*8DD`3(KCA5$`A@9KI__9Q'2PBW2#'N M4S%Z?:M_!.4!"!+-0<+J.4>Y1;6%2M#WTWD:FA-3\[(Y\7RAQ$Q$6MX()B/X M^R3VYK<&_8XU')`Z)$!4`'&LY7.ZX"56%&0@IM*7"6G#/8+_W'%<:SPJ\ M`!`H&@2%;5M]Q^T^*.JT(LWR'VRNFBBWFUG^ELS-9)/I=>];('I-I)]-.IKT5E'O8M-,*D:=Y(>%3CIT^+3?E MT`=E4OD+0@*5OVBS2]+U$@Y$NT;UYO."Z@N[#JV1#>,!OO MU4I`31\?_+R]X>NE0O+!MQ#J.6+?*U^>X,45O\8CMRYG7,VY+])$^CP$E^)C MY%]D8CHI273?7VC98-['Z'QI\(.N$IX(+.VI63QEGQ9"<5RLH]L_I+7R(G@A M\>)<1BR9Q:D&YP[XDT8\#60B@E?9D&0YBL8'MP)M=QML&UE:$V;PJT.^T/"- MX@J&G_WV_9D-E!`A>NJ^C*[+OQ<\"(J_;V60S,"KL.V7==2N"2WR-SSOY=9& MIWC'W?Q*4_>IZ3TU7>.U/.R=/,:G;:O+O(Q[O=WIIL\S)02;P[LSS02HWL#\ MI-AW^.LO:226`^C9UD/:J5FRG317KN37#O'D-*1SU106QK4FX;89,>X.?8RZ M(=5RB22G)>Q'P^3Z3`4Q^:B83))\`DSNCB37^`%=F(SY321,B1L1 MI2>QROW0B70S]"/9]T9H(#00&@@-A`9"0Q,YDD-7BXYU@G,MFH=4)8"@?K** MCV!!L"!8$"P(%FWRE[J]3JW;"\")G/#N0B/]9Q5JSA8JG=,(" M.0[D3Q(L"!8$"X(%P:(%T6?[W*5\1T1TS<37!6Z9T'3(.`V0!MCZ`>X]/&NJ MXET8@K:QV+6(0/.$9HLZ#^8RDCI!371S$NNG6F-PA_:P\X:6X-#UXROZ()7SO!II. M%?E)^P3^V*&Z.P2'I9]$1^L3'*I^TGA`CC,!HNR(U^\^'&K\I"YDF.H]IS3R MX\BLCC`E&'0ZT3*07$E:H[Y?P;!2!_?&]%%068 M^XTG!MT_89T`T6`\<0QE3PD0S<43CC7T:-43(6*)B('EN<>9L*<(D[Q]HAQ1 MCBCWK`CS@-7I=OU\G=7HP#[O7W%B=ZKB>1%PQQ$%VOMTFLY-I-W]^JH$B>8@ M86)M@@1!8@F)+-HF3!`F*I@P\7;W,;&=SSCZMHLV>IQ'=\C''QYS2YS#CUAI M0>B$RY1SGNT98+04':$5GT2&$@U$!J.4C74>$5=2**] MG_'H6N!>">A0*G"CQ$*)J5`*]T@DL?\GN^5*\2BAW-I>(Z3>J-_]\(@`T1P@ M^O:(`$&`J*1:>P0(`L2Q:8@Z/XJ6L!QL4IPH1Y0CRG6%<1)@@3 M%4QXENT>`29JG*4N3%54ZPKE:I1G14G2C,5A0^[?\O.3[YN^XPNP7QS8):*)"4(" MS4<0$F@:@J!P:K,/G0Z7>^`1!W$Z"<5^//`GMM?*X(5H1[0CVCTK;,XN.7RZ MMC=Y5&AZX[B@58LX,1O"&V;CO5K-6]/'!S]O;_AZ:0I]@;ORGV-N>N7+$[RX MXM?P278YXVK.?9$FTN>AMMC'R+_(S,.D)-']\+5E@WD?8SBO1<"N$IZ(.8XL MGK+W7,_83V%\J]L_(G=U1'@AC?,B(Y;,XE3S*`#VI!%/`YF(X%4V)%F.HO'! MK2#;W0;:1I369-F/PY`O-'RCN(+A9[]]?V8#)42(B1Y?1M?EWPL>!,7?MS)( M9N#.VO;+.FK7)(#R-T;NRZU]G>*=!UYIZOX!FJYQ&Q]V#Q\35K0U:EDF$+W= M2>F5_,KF\.9,,P$:*#`_*/8=_O9+&HEE]WNV]9"4-DNT[<.'(\3!JOHI%%I- M#GXS8MS=(<:U'>?@0""FW&.*?7"FU$AG%Y86+GTP=+:FQMFJGBP:73/N)_)& M)D6UR(<.XH!;F=O:)[NA!*QE),G*!Q_3KX#9OMM\$>J$TR4 M:);$3`D_CGP)T7M9]QGNXK6/9GV!^P<@OF&3.W:>8IY%1J]J+?R;CNA1,NSM M->S-E#*_PA.X7D\XHM6/YUA-SAQTWQ&`-J7`#JOF'4#UB`D39D=ZP^_4% M]V[RFU&('X2O!*A#/+$0SW=6TD_*DPJ56*3*G^'/H>03&*@:RP`HGK(_8@G?NX&F4R5('>[5<1P/NE]4 MD@#1&""\?O?AT%''L5XWII$?1V;6CALW,IUH&4BN)!TJL5?!&%F>0R$V`6)I M.OO68$ANXUY4X[(&P)1+A;VB0@"M$811;]1Y*2`X-%X^'/;N0399*D6C MGJQ,&FHM$FW*RQ4I1YI`/(T!=L*V7RJQX#)@XBO.'0J]+(3(_!1L.WPV@W!' M$'L<6GS4I^IG!(>CG#;9NW%O1D^^]?TXQ75$"WYG-@"AGN2^KU*Q8ME)3>Y1 M+LYIF27AH8H']PAJXM4IR$Z??]#M`\B(K&\SEM&-T+3-F"83 MVNU,?S0PS?;;R8@63[7%:7+&ECNBHX,)$U5'NF=YSA%@HJ.F_K+8B!1/<^MN MU";IQ7W*0']L]<9.]V6`,$%3K=NIQO8IPC6?D38C$?))(;8(%N=]R_-H6I62 MKI1T;0?E.AKPE!.M^=SJYIPF&?Q]K9X:6=Z05E`1)JIIH9'E#H^@MA29^U89 M+:+<*,:/-D+-LB%8[M6(-A MK_-B09!H#A+'>1P:)2(H$=$YRG4T7JK=X+4Q^B=;3[:>;/W!@B*G^YO]R-ZW MRFH1Y6CBX5!NAXR6M2B,"X)GQI@+\5P>\X M5*SG4"=F;E**%N,)FPAH+\(@#2>WA))Q0,IRCZ(Q/`K1($#0;":%:6T/-HAR MNPG3.F'H!1XY?$HF_M!UJ?LV+OSNO`XG(%#TV%XK MK7G+:5?!:G:)ATGC7__X+M6OKSE?O'D?HSG6(O@IFZ7DX<=H&JNY*>S]:7K) M\53^]_%\P:.[3U%X]T%J/XQUJL1G,.;OPMC_\X?__`_&_K'\H$X^37^.XT!? MQ2$6"H_0[/\NIM^??4B5^>X7!_YS;:/,Y9&,GOP7W#AN&V-Y@U'!/N..!/=B^)Q_$)*D!TV-H\\.*O.2>I)$7&]1OX5IF,I;=:\!4A/D: M_]_B1+#1Q5("<4!O,J4^*27NOF]Y3\ZK_?9VUN^/$?LG5_Z,(>4L%J>*+90$ M@5_PL'+P;'ELUAWC_"W7VBB4QNMQSF8`3/H\QS6;*?B0S>!L<1N&4OG*S5!%YD8<1BMS,)[)@(KO3R46B#9\]#N\`9 MH(60AE(P>A[\D6H\W.Q74-KPO8_XUH1'?[)/TZE`AOR.;YZ?_?KQW:??SUY9 M;!&F&CZ8(0K'/+@8V"^!_=GW0G@_PEXI$.&Z+1$(8-@4%1@M\EO@KF"J^+@QF M5NGD>(80O0OVSD`'D5\!3_D5=BO#$("1;5X&8\RN102]"4$WJD6.)P+]J/!.ZB&9!:B\HE5(O_/:'^L@E$> MV0(=6N1MK1(-')6R7,8RF7\E%LD:'LL6_U62GE\K(;`)"R4&MB:S(!`&OH%?9P6_A:, M2BTPG8&CP[G(IV508Q?8"C#\P3:PQDLV`YA,AD%Y8<2EC M_NK;!F9$$G6W>5HX'.%R9D@&>"/V-0X@P'BHGJ0 MT`3U.@\1.C"LO)]9,:F"-0\+=^O4TRH)T"T"#&H('92,00Q]X$R$!3#7AJ\E M?)ZK0D"VM=A51<++CZ_`?RXC.4_G9O."C&YBZ6,+!'JRR"""3*PNZ@1C(VV8(V_X0A"V7:K9Q89QDY""2NK8P" M^%,+X';&9F/5C(8N]/-J7SNVS`!V!N?H<[\ M;_13,AVX4/%,3B0,>45E%L,,@7$H1N*K#TH+J6AEVTC`S0:&8C?*GN*8C%#= M2I!1H)9A6X2D029,TOQ][(QYF`(=2!Y)6X6.F M(Q!Z$G@,(TUD^"T?J(1LZP3J[36H^6M$&42WJ%.HPJK9)+1/=KV0,?NL87&KY1 M7`&!LM^^/X,XUP?YT0N.1J'\>X%"FO]]*X-D]OV99[\\VY#TSY\8#5]NG=4J MWAEL?N6Y]^NR=!U8H_!3!7<(.V`#5>_\UK13@ZL#.S&_51M]N1V!2:=G,&J) M4'/E62-GU/E9C0[HRUI1Z)$H[%X41I8SJM$YW8#XILF0#3GI]<3U0@D(W(V# MW.3L1F\U>UYMYXD]>&0&WW'L;7M0$NG3%">'(&@S3_V>I0(P\:^O9A!=O.-: M!)=Y_J;A)+\SVE.6WW$OV!5NW'^->=+`Q$O%B-N;\?^WR++=T.%AWW*&=G;X M`$2U68@>I":F-('K3(FLR*R67[,?<:T>18!]>'KX[YYW1G;ECM> M;TE\%Q@445S#\/V6MBDHJ?((+/W[WD"D/.]WFE\ZH,O-5?/DV_..Z7GK.=LAAY MJ]./#[7TK#X]8O[/]I[>I<_Q#HCD]L?]]2YM:.@9'7J$?AV-W2?UYT>N,)NM M+X4JL`>0?[KMZ55[YI[]\'ITT?.6W:IM[LD]VFJ&_5Z/^A?]X:YZM)5UO-X#-ZM0LT/;]7NT!48[1J%%5;]:JS MCIY36<]1#&IY9R$4TSB^]CI]F8X1>==9V6.<0O-YZ*?95-TDGT1!9TQ&)IE_ M#EZ/?L7X#9>A223CU$3ET*I9'`9":7P5W;=;DU"#3_$;H?BU8%&*TZS5HZZP M79M(&AUD0',,T7(22RVH-=U8)\[`?;'J$6F_- MM35SIDD^_QW&MS@D;:;-35^`(&E2]F5B<()?VJ)7-:[ZXWIZQ#,C$#*_+',K MOIE^_,9,R=!^_$R)N[N9$FIZSTUO-\?PQ(3D<]*0C>8[5X6M$-^:;4GW.%!. MSWAUB/'!P(Q)1[3+&)*>UC"DE*"YER>$FIL6-=6"3P;C76QL M:'45#9`&V/H!;N=!M^`4/DRBFB7B2BQBE0@Z86(/:Y'.1Y8S'KQZ="_H.(F. M<]T;C8GK)\9UQ\53-8GMI\9VS[+=CK&]+EZBHV+HJ!BB'=&.:+'K8KWAQE6&AM!X M<+3[]VR5V[DYNB5.-?RN:R*(5NJDIH*41S;=<-CFNI8S]A[="8K5CX+[CC7N M]XGY)\I\$/V^0]P_4>Y;8Z=;>K^CX19..F;[),HM!KC`P9SW94XXHB",!D@# M;/T`GQF$[2?BBN!*YSN(WN-K2WJ^-0NLS$WV;GTW54=4T'&8WM?/Z`EY7P0! M@@!!@"!`$#B=2,QMQ%^Z6CGS"+VA]5WFY`81^DD!$@0(`@0!@@!!X,16CW:[ M]"U1CBA'E.L*Y6J49Y,1XP'7-!7G==&JIH-Y%+2JZ92Y3ZN:3IGYM*KIE+E_ M%*N:.AU$=GT[$]&.:$>TZQ;M'@XF:0MBV^+JXB`>SCY2>+2:U3+$@\ ML(8#VT(B%6MNI^:A:N%C)DUMWQF/KK.2N'X<:1D(51;3?3%V&?0TA#^S*KPI M!+CJ5LD$"R8O2P=G-8YC7.P;AG$RAR`XWR_*XGM#<)UB"-"O-$RR4LVF'B_V MGD>^J9O,(X9%:?$C/&0CS[4&#X^F?@1.[V*T.H9X.A4*&_4ADD;:W>^AE_7P M[TAD)7PA;^"Y"&+OA8I](0*]+(55E!_"H]*:^ MF:?V96-9]OM=<<=#N[&N?)`:^9IVMU:[5RG5OAP8BLA_7UVVMT#[>Z-'-/83 M15.N]YP%J9$3%!J]5N5T4YGM6Z$$UAR:QJ!6;O415]L>Y+6S:U*/^1.C_N.K M:P_V6NRY"RMH[@D4XPG[A4W3T@RTXH"$A7S#>#=@+"<@D`\`UA-IQZM\)\J)2+_CB6* M1SK,X@@>_)%F1H,$8(\",!@,CU'?=SLO2[NG#^2CUD9(IZ"/#NVANJ[E>B/2 M1&W31*>9;7;[N\O@Q*C9M#G4CR+,W8_5:6QGM"EF:XNRP--;WGIK=S,)YH@Y]C>7=IXI<[[;S2 M^/JH$52#N?'/,R5$GC4V-Q7[#N]O2"";;F](DS=+MI/FRM5:)K_*F?;QY%'2 MV;RW5A#M489V?T3;'FFKQK4PUS4QVV9,NKO#9!D8G9;XMYXI-C&E?4PA26DA M4PXO*0];RN*4A='F6&?YR*/.;3CDXS5C[L*4!>X)4N)&1*G0]]E)^<^R!T,"`@'!L>QQ M9X%0<8&RRT.?M#"E8/-_B)2_6_/$S%\DG=U?,,QI7S#'!<2/A4L#GP!89E MZ-'>4PW>:BV2K.A]*/D$V8XHR3MO\#%=C@FAA`>&I,K@!&LR:`1>/-UTPH$Y ML$2;(URF1@*RHP[@[2,^[,"Q[9=UZV`D>F8J"VYE)1C__I'4CYD6SYT.!*C MP1;8V);-X?R&P[DX]$BX>$W]-(;2#B)B__C!=[WT)Z*Y%A5!+NIQ(4A_)=D@ MWWX5!AC2?P<):)@$7/.?I0,.6]*]8(9;P(V-I?4;W(6$/4A?(/4N]2=QE)*7 M!.?%:P,`5P3PV-^&,$J_-5W,9OW89NS[*H3KYU@D[L-.YZ96:2YQQ+OJYV"" M,,$&3'`_;Z/N3D7!>$R8,,?0!$^2O5P!U5)JSG67>UJ=7J];?/X0_U<:_6-` MOJ7(P[IO,_JJKGM%G:?3@$T"AB."[@*_G^1>_"!JQ^'&QN2XS5[','N*2C[( M0>N5'X@`J`*0`U`%V790\ZR>[]?H7ER@X\L2IE#4D,A2$S!Z7MC/`T77>C%0 M5=&!"(`F`#$`39`=^E&ZV;?:UPX`YX!SP#E5.)>E/`\:-S`>\4XMW&4JT M2D^PXN,G7Q='UB7A=_,I--\WA!,,,,$63S#+6E.@>/.2D0%A3%YM)5J5/&+& ML`\!*7!,P"4%Y`%Y0!Z0;S?R68:-TF$HM9.=P#G@''!.%4`>D`?DP;UJ0\80>`>\`]ZIQ;N4$DW^+'=%`LK4O!DT%FKM7GY_ MN1%]YU-=[`G>"\9WU$^N4.!?^BE[#4^[ M!Z.DT[!X/Z2<#,Q2AYIE3Y81<_S MST7O4OF+<41']-_DK?D/IH;Y&6-Q.<-L#/'$\[M"S?0/>$7"UU*7"9P1CXSO M"%O(D*G+"P4TN%!@SPL%++A0H,U#9YC)V\WA/%Y38YRRY<4V6[Y-:50-%PHH M"!I<*-!V"8`+!0!P\39<*/!R996KA=SK1GRM\@O%OS!!F*!R5PA`L79]^26] M8YE&;AH@IZ@RYJKF%`%Y0!Z0;XN>SW*1E*X@4+OD$S@'G`/.J<*Y+.69)[[4 M."<9-E\PN)3"'$QM0!Z0;Q?RZNGY5^=DJ5[R";P#W@'OU.)=2HDF?Y8KTRZ_ M`USXZ&3":+JK(A_8;($V$>%676>#2:U?'./_4" M7]0$BVNB'FDTE#]U?GG10=C[&5-9*VS95L?F#`^'F"7%T>(A+QB/`W\ZV!`_ MB"=QNN(81W(D_F/B*V^Z':-K=)"HU'IC=S3-$.]Z.!R^0_\049DL(.ZC-Z9K MR6+K-Z[IBD?(TX3XH7ABA$4ANXD=%C:2].A%2PP/YPHGI5@JGQ6S*J#O"'V M[[D(43\I)E\[);"1F_.J]CB4M?J+(B*4KAQ"TW*A>8E0!ST21H2P\I440AU[ MVD1,F8+3;SAN_CIVW:BOI/N08V?8U-MMYSS.56-\MV;7"MX(7;.83:)L%J^E MUI$/3RL#LQ60G/?=G`-0`EHWK-?T27U0LWSN?6/S6<&"FJJV/N$1]CUIK=T1 M_N.^V%[Y)CDAC`;]#7MCK;+]^L)-KNM`L+&UZ(M@HYKH[VBI]#N%R M++L;;2I/+2%?U4H[=^X5E740@LJ$P#5=186@C,U7HPK\/(T`@MJK2>+?&AVC MJ_VNJ-2#((`@O,XTL]K5@<"Y"NLJF[=KIR(SQ.]#3`:*O]JP50/RL#>_BG(2 MX-VA]NAV$L-1MD/NJ1;D?O*2K?(`0@!*K:W4)7`.DKZO=,>NVQ/7.YK1551+`_IM1O_5[=&J)S"! M=Y7LT\F?LSX,[_^(P^-[C"=_?N%>[?^$4WM&0V\4B)/AX0W?GS^-`N_'QU]_ M0>C][-'_LB`,+UDPH)'H=2!V\2LR^'!T%C-YU=RMSO\3N:/;F^#6N34U^>(( MQ3Y-'OS._]"-(]0G'AWC$5^JQ^;11[UG\[DO*$H-DW-\J]#XQSVWHO&G\]?3 MX^L[Q^^:9E4$6(4(,+I6;S\"SGTO&).O_-,O+!B?SR,R#K\%OB">!:,1_^JYR'V2L%*).M8=S7"6 MIG1`RFMF44&A=QVWUQ(.%5N6Q[IA.RT3HKPLJ4KM/=,M4-%%1&=,%5;II&C40777AZKP&LSDNU;5C5$,U7Q>>D0=(G MXA.QUS^%]$^?CCX<12PF1^6D^H_JAMQ7)BL<:7^%F8X2=^G[_#Q^VGKQRN4F,YEF:NBF0!F@X^K_SZ0;/7U-H!)W9% M/$*3GE@5PF-WU^ROG>-73'%>/\%Q],I)/HN)T(]722NX2\P$,J?3-GH5LMM: MVU)R$'*P2>05?B?\[O<)NR*3F'E#_L')/2.D5P"G.!Q6"HRQ'EC9 M.GB%I.;DM>7LLGZV4QIA_YX*VT&R?!$>G4='\Q#[<2GVN]1JU#U8JU'Q95G" M_RV("++?+6+$B]DA+*?703Z)I@T\-U3][V[EZ1QL)FOTBJSNEAZI'&,ROB,L M];&>G&M(FICB<-JV-(2FI?]9-"VUG/Q-2ZWZ>I;"T#!T!4-GI'RWIW;S5`$T MILB@@B-KPCXXU)FUAK8F!9Q6<-J\L]:.%:SC^H^>RM2Q?#4]7>IAQIZY89)^ M#X]%D*AV>0'LEK$[\;QX',NXT0I:+*+_2N\&,&L89@O':`FRA4\'B#4,,="0 MZF('&E(]S)JO(3/L5A5.1EZRH!][$1I1CIF\2DB6C[?B1&3]%?:.J^HI.$"_ M[/AO7=M4M?$MH%]V?->T`?N68L_UONX"YJW"_*WCN*#MVXI^S]84Q3[#K6FN M$],7EYP&$U$,U2(WIH1D52OE1D?OP<5MK1>#XRK8`<+P.H0!=`*(0>+R.":` MWT[P84,`85C1!&J*088SI'9;&;4;F`'G@'/`.>`<<`XXM[-U5J&BC+WW:25L MP+JCX&;'A>O.6XL^U#NT&7VSHYDZH-]:]`U7!\Q;A3E4/+09?:/CZ!#F:X@3 MIWH'9.`=\`YX![P#W@'OC M?DQ0%*!H2*8=C:A__XI[&CG:;T=IZRIE1,/+W,-+-^AK;''+L#'-TN]F9 MQT-IC`/4[/.GTPIC^7IZ^'1^8G(QR53-\=U\G@?D+H!7%+Q4I7CZ[88`F+'B M53A+/&=XL?9"KZ\RO^X@S/*Q$S6#,2`%9<=?K;A34PZV6T%#(GCUXSS81>SF)>37KZQ/L9TY"*1B?R0LWIZ2DX,?7B2[,+^AFD84Z( M;8*:?C$UO;=!W23%G6I1!9J[UK7Z5G?MWY5?K2`0<,AIJY)4.NVM=NTR<*[" MJN\,&\3>;538^6R0[8_O[RK6:&&(+\OP7/Y.[LTQ-F8\+,6)_:,VTDBL=C-9 M[@Y6C`,M-2S4!W^U98*"\+\Z4T+UJ@C@W8M7E!C[5&+L4XB1J\ZCXB`#22ZN M0RRYB5(4J00QFP<>5KL&HT<NSN?(9#5+-&2$H#$??Q@BPJV7_H8+OSKR MQJ\WW*N>?S>D3_M\\QVZX0\_2AN,](_Q`V'XGJ`)833H3`,GK! M961E[/4[PLSO_XC#XWN,)W\N;L$[D8<'SVCHC8(P9N2&B\VG4>#]^/CK+PB] MW_2%;R3Z_.2-8A%W^6\0]!_I:,3%VQ=2=T4&'XY.PMN+P:UNW)KZK3BO<81B MGR8??>=_Z,81ZA./CO&(3^[8//IH.+JI:=IF&K.&K(1(Y];4!(WZ3AI-S=3+ MTT@8"?EC2?0S3Q/,J=O-08LAJWESV+4>!P;AH:A7SI7EM<8+F,"-RWK)3%CP0/JU"P,`LPS,95*&(5_/VF"0^WB$A3.3?A=+!/$($&P8 M@G/7$Y!I&#*@]!H*#"@]U1%LCM++L"Y5R`%]H3X-AZ2/[H.@WXK#XW47OG%_ MR#34JN$!T,N.KW<<"S!O%^:FT>DY`'K+0-<[NJU673.`7G;\X^)S!^251E[! MY9[AJ#3/+;G"CTB<.A2/M<(K:4QI&NBRUHN`X:A5&@_0`_0`/2A^$`%8_0!] M.Z#/\&)42+?,\U6(D9"P!P*^S0L*^5N]8YOF[TH).L`/%@Z(`&@`@+\*^%W+ M`?!;"CZH_]:+@'KK/\O/4;J'KMI-Y8%SP#G@''`..`>Y MB_W*6QX7,4.#I;8,B,[+!B=)RQ*TZ%."9LU)-O<\[?`?$(V-B;A;3YQ$7[W) M;T0>@L$H>!(]0V6#U'LR]BCG!/47%^%UT..0>L-IA]1I3QOY]`C'OB>H[<=, M$/=7/'I.KK9;MY@D/NENNIL;YFYHK?N-1.6Z57,ONY[P9BLCEVRU_1JA^>UP0I24ZSCM'4@:HKUG>[:AV5.3G)LIR@Y MX;E_1NZB$[__-V8_B-1JGW_&-'J^)AY?IA$E(?_PE+`(4_^&8:%63C8UE%>L M=[7Y#J4XT>"6U4+7TP6E6]I62ZT[O8J4:]KI=9M)EVIQ?^+KO5TS?Y]J:\O- MF6N!@]EWZNM=#$/#T!4,G3)DMV2>"\8CUY1+7>'.9O>C.PW"2+Z8-@Z\PR$- MM^T^U;(14-H+I>\^(_RW_TU:=P$@O9QL9&GM3>-X5<]7,P09@@3!`F6/JYC'VC>;O$Z=144F!#*#7/ MNHO!K&['M(WB#(!:0*7AAR/;@#P@WR[D0>4#_`!_6^%75>]G>"TJ1+O^#GSR M+'[X!XG0(/;;<054"1FK_*R+8UN*BCS(0>NU'H@`B`"(`.P&(`<@!R`'L"6H ME,$)QF/"//X0FN`)8>#WO*!D6YU>SU54ND$,6J_@0`0J;,C^.PA!VX5`;`== M$(.VBP%L!ZT7`94U08;;HT(*Z#1@DX#AB*"[P.^'LJ&#'T0$,D$O&O/I= MKJCD@QQ4U\T61*#M(O#6M<`G:KT4\`W!,'L@!VV7`W"*6B\"2JN"#*^H>3[0 M]VMT'SP0YHNCLRB<-\@"%^@%Q=SN:!H4_K9>#&##:[T(O#7``6J]$(A0L*I& M#X@!;`<@`J`),MV?I3'%[RIU-8C:MS,"YX!SP#G@''`..)<]_:P-.T\51^-Z M-94R=>H^#JX;W8ZI;$40X%\:?T"^I\`\Q><\S'_9G*5;SB]1C)\Q9=(.MIO1VGC+&6$39_HZODOC73KNTCP@$-G MV++;;=8\_DUCW*=E,9L);E/N]_G"5ZE\,;W91RY8.8V[^80.R$9`2?W+Z3*6 ML1KGD=O7F*GVT(L\=I^7!@BWJ8RYZ+RC$N+[626U*R]HIE!_P>CTP)Q*T@WH M5WM^7B7L%374X-!D`X0]J8U72=H!_$K/R:D$?9:B4SI)JG:I*W"NPB+A+?LS ME`17J?0RF9#QU[2<1"7]",)1WO;OPI8(N6!%-T75>9<2YN3/Y^>\&8I-QBA!E!$T8Y*?S7$8XB1N_B).4=!<@; M8O^>/T5]_B\BC(01$H'$\!WZAW"41!@1W9$1)0]$)/HCA/UGQ,@84Y_Z]QEE M`8Q,^*\(WQS[*(B&`GT^R'%$QB)&R9X1'4\P9=)]O\,A_V;`'XP9(B+;B",J M7@X0?L!T),DD#[1/?$^6#/`/_HI]LH##U#K(T'3]7:$B@@,64]P,"0KX_D)] M/$)>$$8R*LOYRZ$0!1$<("98L"B,$),3?-B&9"@N3`Q8-!2@!(_%9MWBTHEN M?:43!QQZ/\<`DO*'3,J?\B4N7TS3\5RUT?JS\8#2,DJ?9_HW#=5"!=>.5Y9A MKD!0_HSO7MR$"'R"G@EF:%H:N&%S`M^SRD-K;L?0(1;?.M#UKJX4Z/O9*`W0 M8WB0D46;"9!_0AT2KM4*=-2;+9.I&IFM'*/9I\M%W_H=N'*$^\>@8C_BR/3://MI=Q[`X)Q83 M2/UTGC&=6U,30^H[AW0TTS)R#\DY=1UQ/@R#$47`^@";*?@6^%X%1'`:C(U$+,98IN,;B4YQ.+QD@4B>]S\]?P])_]S_ M0GWLB\SKB1?1A_6U?18SF8"_U6\3*;F]">:D[A89LV?J^A*M^]-Q$/KU-/V[ M6:WKMMNU#SF!9+LX&`#'MJ;W]J$_@XZ#T)\3@&.KU]6M0T[@8D($A0<#0'9P+GLHCE:Q!6S&1',YQ5&A=CY2;#*D:&Z[AK MBZT$%04!TPW;.0`S\I+AZKTUS;F1"G$V]1(_"Q.Y$EO%T+JK`K$^1!$:]R:IJ*+5[.Z!*"JJ=#7-T@_+I+PD.8YAYZ1(5.16PN^RJ90Q2C(H?'9+F%B$BYEU7QPUDG)'.4$M3DB<04(X?O82+` M=3%8>#W3<,1Y&,;\'2**'T/T%-(_?3KZ1D5M7^)6#7>$06H<$7X-Y>9%3(0:MG]O0L)NY#R(X9G/L1 M]N\I_V:RL*O<`HV5W6;GX%72FI/'CF963:L\!7+N_Q50/_H?_S!FI$KN6KWL ME;6+ANH)S\MJ]P!DU:&KI#1WX&V'%.^@E9$)IOVIO(U9!8@Y=VS5[92D,/$+ZX1<6C,^HC*X)^;T8;%A9A]RO M7":?8LK;O' M'';1M'E>5US=)9O&Q>!Z&+!H+RAR!T=68GQ[45`UT;DC`WH51$\(BYXO1]@7 M)0XB`3T17_M&2FZM77=U9]T\4BF:]F=8UUWCUYXD727=SB\Q?_J&83_$G@`N MJ\`C#\(?EPI;E@XPNP<[P"R^+(_"B3@VTJUWBV*9Z3311,P31:F)3GNY;SA" MM_MHLG.PZ9QL.3PNSWF<$8^,[PA+?:S+C_E#?*.?$&E^CIX[Z)&@(>XCS-_V M"'V09Z#Y;[\Q-$?^TAO7<9-#^=?X7AAVUQ&C?>Y;?_UZRK\]I-X0T1"1)_&; MG(U1P+\^D$>[8VG/3%@PH-%Q.,1,'+*?K=#_=W=MS6DC6?BO:/VR215F#09? MJO:%D&36.YG8-9G=U#Y--5(;.A&25BTYYM_O^8TATML4BD1(%H]#K7%SV!8E^9W`Y`&RKD$@(,-\D*@P7?!$`^9:>@JMN M37&`WT1W]%J<+G@X-8]SW"L0Y)K4+]!I&TF5IFA%X!`EA<"7&-::^^):`4TO M!@^BOPRG%Q@K_0[H->`VN`!D,K-7S,Q<3`@VPM70GV_PY[P[YUM"QB.="O$! M3VN:YM.&6RDHS\_G.>D(C@ZA+X*7Q$*8#I_PQ\Q,[VQ&+Y1`@G`S9;T)CA]E MJ68=H_\A:#0Z4]57B;>X::'[ M@$I6IFX#`]:V?%:KU)^1>7RO2AY(9`]MO5LR]I#]8O.]4"#,SRL9D=19D M`_[-_3>>6(*^:,.YR>2[AGR#M-;YDA3L#_!=U55ZK8AH_7EW".\F`>^NP,7> M81U\4"G:[]B1[Q8:38MLRH]X>7%_NF MTX8PG?;[PXUYI\.0Y.X738ZB"DF=1\'<1'#KV`7<@Q=T,>PWK?9Z(.P.[.V$ M<'`Z'+XHV-N6)P;#@R#WIOHU.#][.M@(5MZA4=LXGN-W:=&VR^3@>?Z9T6[QBM6UDAS?D&NF\20]"*GIBJ2T%QOD.HX:M&)QC>1]UZ'ZH>2 M^R1=9N:&]'2N?)UG)!:A[=!4?K=#0,GO1Y[+5QU!C56T.'K;]6Y2@V]CRJL"ZQ]QB!-_WCCNEK`4 M7P*$`Q//A_G#N/I58%3^UF)0G3T=IK@[O58TNDR*8@\!"(.D[Z4=:>!IY<\D M/X8[1.,\LQE-"NIQZLQ*%J_Y-M*0)]U>_WQX67M*>((JHCRV)9WW:^58U]^A M82!`OI'^J0=N#*Y9_S-2^/E#66#H$>XRFV"G`OCX M2$)SY5!R?RRG-IW;9]+LZ_`1,[)Y77I0C M*0_NWL9QQG=S\0/8DU%#SD2$PURT1[KM$K4B?(5$>ZIY+PPC45_K)!'!428OM_Z1" M\8\(BW8^L28PI%5H-CZBI]"7-14K2!^<9^5-5(BM(>Y.\5I)2NPMU\IT:"B, M5<[<^77:\@KCC"4+IOBM1>2$YW\EHS^+R1PXJ-^,9SJ:!OG;EB?IC6N^S2>: MD5W3HU^_D.%DZ%84('-;E#&UM`B8:UHV`FYP7EKP3D&@L@4[0<4N$`V'EQ(Y M>BF:)07'BOSL>8I)BZ77>)2E<;C*SCFS21"WP*D1!$9/%D_IS*[0"/&8"[!> MJ*:'JV`?2XI<139+J% M;)T#;G5C0VC7@K7L@^]`-C+XE$O<6"M4U,1`UI3B MDH'F6XP:OU*V&X;,,IW-K9&2N462Y)@&G]>!7P%:;>R)7L30I;5&+6\N$!HT MN1'-T/;XZR#B[Q0YG%&1?$.FI8`P7B#`BM0^T'YJ(^VW7[HX@ M\?B6!]/RK57$ZWH?&R_0FN9+E:P29TGE((`HA@`F",*8Q/;NP!`X-XCM)B,-XNI!UYK^YHD4G#;'F(Q1FL2_(49=^ M>A#KHGCA$$7Z(BS^+V\+P1KJ;A3AA&`&.81W45T_XM;#IH6X=7&HY=]55-=( M$DYLG.1M0A7Q.?IS<]$_:AX7TDL/^5F:08&L> M8`>H*5:Z-O8 M&:T[#:WXZ@`KU^/2>*F`GI":C&-7&>IPKK`>"<_(1&8SD1G2`9A"D#[.LS". MOY=!D9!+ZR+ND<4]H.C7[90C.#-06J>L;R3*G?HU/9GV9Q%K36?)]9-VU>YX M8A7S%E)(+B%?H_.P":DI\<-FI,-*46D1`9=.^?5R'<".1K$/KJC%\D2!]`]1 M+%%PEYJH>^,6%H64W-@9LD,'9JM+7_,S(5*55KR;-([HLZ\/W.>\BKS?U,)M MEP0SIN2M0,(X3\U6IO!IZ@DFB&Y-3N9:82/@O'(:&T,A%LMDJR2\(CBQQ/WC M"3[`$W*O0T:B.*K%,7PTJ>/2;+0Z2:,\K_V$.!^UYG3B8O(&6F?JK=/5RKF` MOP1T="I[EIW-38W];IVH.[@"N,T052>EHF5E!%:B69`I26B]+$REI*7G)I\+ MF(&Q/*VM%:]&@9@2I.G$@C;(1QK#E04V]>6N2XOY/F&_FW=*:"4YT6%29`2! M=&--K-YS/KR71_'$ZE3V*KOW62>)Y_/$+42U<#W@A&E2)-LP1'4[5X+S`^+\ M18&SK1%H?E=&(XU5J'G/V`I0V`2S\59!G&12A*E3^I\J(N=@41%1TCU]8<[2 M-67UMWE87EY4HU@(`^9GQ=UCE9`=:@:/=!<;GW^BO*F>JC0HG/!VSG258[Q" M@\MTBDAA%6A(7CIV^8''O&VPA968?J2`RF48650:6Y,KL1!_I*8GB.*U"GBU M<7F05>M[$3MIP]`HSG^8*(]SVYRKBI-DW7P8>#(6%B4)^"B37'Q0?QY=G%2?-DZ\\:8>ZX,2M'=&/SK8KP/YT0_SYI5"`,0S5]:T!'\%Z+W;"KW!8'?,^\2Y)K8^U2')U\'#E:"_-+);?/Q*B74AM[T%T M'P+^`#!>B[.'A_&>U?7_">%#XC`_84=Y-HM3KH`\O_8N(?KS%;8-]0NBN!8S MEU`\O>R=GIT,^\^&X9[51W6S(T#+ M!R9[S8-*&X*R!SS6.N"VC,=@<&!XK'7X:;F76*^5\GIY1-8Z`K=T*K_?N]R_ M9"V]A;W\_@OHQVI`=H[#7G7CF7#8KUX\+R/VI!./(?&7X^./[B0#SE$`FN-C M^NGO?[N?I"%]^!]02P,$%`````@`E8D)/U<)=S8)"@``J9,``!4`'`!S9VYT M+3(P,3$P-C,P7V-A;"YX;6Q55`D``\JB04[*HD%.=7@+``$$)0X```0Y`0`` M[5U;<^(X%G[?JOT/7N:9<$MW)ZEDI@A)=V4KW:$@/3-O4XHM0#O&8B4Y"?OK M]\@88@=?)"Z-9/JITW".K.]\GR6=8\E<_O8Z]9UGS#BAP56M==*L.3APJ4>" M\54MY'7$74)JO_WZSW]<_JM>__-Z<.]XU`VG.!".RS`2V'->B)@X/48Y'Q&& MG:>Y,R#/6#A#.A(O"#Z)VW=.3UHG[5;[I.E,A)A=-!HO+R\G3-KRV/3$I=-Z M/;[:->+0.OA%EVV?M%;?].(KT^#".6N<-]K-5LLYOVB=7C1/G>[7E=U7`#(B M988^"?Y^@FLY$(N`7]42G7M]8OX)96-P;'8:2\/:PO+BE9.4]4MG:=MJ_/GU M?NA.\!352<`%"MPW+]E,EE_K_/R\$7T+IIQ<\,C_GKI(1.R4]LO)M9#_JR_- MZO*C>JM=[[1.7KE7@Q@XSB6C/A[@D1-UX$+,9_BJQLETYLN.1Y]-&![!9^-` MU&4G_RU``&5(1/1IX.`#2X`].?>))DJZ1+]$/)QAHKCGR,M\'=RDT M0S0&[_X$L2F2"FA(HX96LXW]@EA]RQ]&#S/,(D9VB":O_1\(JX?XY+-/7_:$ M*M%\#,I%OAOZ$=)[@!`#D@0$X/G53%_+E?4M9FJ`85W1SCA!_BNY0&&;'",VBP:F!?<&7 MGT14UINM^$;])?[XKR[G"5P^>L)^-%BGOFP::-*C7VS1X.%T&K56)T#RTG_$ MZ'0]?/'%J$['*?,P@UFTYH0<^D-G\EK(KSDOF(PG(OIFQ@AE1,RO:NW#<"1O MQ&[@R7]N_QN29^3+&[0K>HBQ.4S[OR,_Q#G<*?F:RFD1<^ML;P[5"A7!<&V%,==MHJN^"9^@_9?-O.(_:I$DUJ"Q%%%/7 M,9JZ/L,S1+S;UYEU2!Z4Z`Q_Z=&\S_`7##BPF"TS:RM MV4HU=+$+T+%&/ABMD>&$,O&(V50.>5Q$Z5:.$+),J\&V,K*8TH]&4]IU71H" M@@%V,>CUR<CJ98CDIA_Q6)"O?(;.,?:5(*S:-2! M8,GR6J!@3$"/"]"@RMM7UP]E"?T+I=X+\?W<97>Y:RHP;1F8EK'<;HS'DL4X MG6$FYGT?!0(6%%+),RG>_+RJR,4F8K5Q5&)U_8T&;N&DJ]Z`361OBS569>`%7$9<6M"^OXMD5M1>01@4QI$ M<2H\4_'.K$)4*T&S8@0?8(%(@+U;Q`*8D'A"Q#=X1%R2OT6@S+%"?&\(UHYA MW_/(HE]]1+R[H(=F1"`_(?&\D;[4L4(*V!#LAC7*R\:[,Z1[/UB:=TXWR4KN M"=.VZ@G3MZLX#R,G<9U#%(ZP>)N4\TI&:9O#[,)<7E^>X()H"A*$,`:]!>\: MCRB+%QBPKL#\]E4P!,HC`20<=Q#PJ&``GJ`#Z-_X+A"889Y_9FIO5S1O0,A4 M07KKYX^-AA4KP!B\A%)R!V58FB>"'\UQ1H5/,4Q6J..+?&/*XG%0CBH2%N:I M096+=1;+8%G!WA#YF`_P,PY"+/>V\_Q=X%FFYO%9QDI&54<5EQ6$]B@7#Z,( MQQ!6OKG9>LJJ"C2J0"I-TNLF4+@:DN+3P*6S[=(NA;DC,3>M'5W5P-E!Z`!S M#%&3AQ!N8)SQ:73H)`:66W$I\#&8Z$*ZLFHMNC"M&(6'.%H7?L$!A,4'<%UO M2@+"A0S2,RZF7LVY.AK8`J\55==TPJ%W5%;)MSI2V!QN:?5URYD@9Z-9;X*" M,:2*GQ%AT<.!AY'ZWC-E9_,(/EP2O8/(::X:.H=[X=%"\8L@%K_WZ)WE3\5D M#2YJ8;+B0_%2XIW53U5DJ:(\1*4/=HQ(,U8QBJ%1!2+ M]FI(-DT8#_N,+O'66:5'=)W-'M')RSB+ZQCS1L\^!C)@]2??TLWQ#5[\FU?6 MTFKB(!O8L9"]ZS/Z3("YZ_EWX`36,3"8!:[<(^A"RE-TCEJ]`?/NY$T83NUZ MWPZ[%96#/IK+^_%A](8JWIYXQWDHW]@L"YUYZE#T-D\:6U*[KI5M(E$J%".F M>XB5B[$7+9R6F&"J*-W)4^IW#.K8*`965)NRH25/'FCI(NEXM,(H#8(5*6,V MMG3=!`;)Q0=8_O"`]BA2UMC1*FBCP%CQ^K$DW@&>+:9=R%E6[S)5'')R?8], M,WIQL.(U93GQ6M3CMDAZ,AHP3RQ[2GI4L5NQ9GD?A[L@_?:^_!)6H9MY8MB2 MS,S:EWX(+,EOXF'PD79=N'%D#7A1J;T+_DU)('Z'+T.65PI2]#X"B6P3"3OV MUZPAA.!YH8P3+OR-J5*_8U2'4@SV_;1]]TO3&Q)%2"K]8:0WDNBU<@R:V4%$ M[,AM,H;.U*O!-2:?E-\QB&2C&)3F,V8,+.^Q=9\1\>7+>#Y3)O>3#[$;LJ*, M1J.%8]2*9C1*WUUEA&IRPK;:*[=I&IS1@'F:V5,:K(K=B@+M#9XQ[)(HE#D2 M2)J81_*6)*VS7@K7BF>Z7>\_X6+C&0QGW2EE@OROB.1<^R-@7`^[I=6M=V^G MEEO>U]YEK%SS4FGL"(2SP\!8,5GDXWW[:3%M#;VY'K5B2L*@N1WT8/O'W\/; MX->2]1HY2M%H!T0SQS5&/LL?(]:9G!(^1RF.,OR:F:LQ6HA_K_@FWM60^;O% MRB)1:>PHU;-Q8$K?^VR$K+1?RG0$(BC'&W-[9O3J5/XR`+Y&T9F&J51M4;Z; M;7P$9&L`CUD_-YKU(SSIO(]98+LCT*VFXJC_P9C%Q")!Y]\#`##`LY"Y$_BB M.V88ETA&MZ7C$-!.HK*4T[YJJS]/U.]'![L[(-]2K*NNEH]9IR0O&[)G3Z`W M^,__`5!+`P04````"`"5B0D_68CV1/L'```@90``%0`<`'-G;G0M,C`Q,3`V M,S!?9&5F+GAM;%54"0`#RJ)!3LJB04YU>`L``00E#@``!#D!``#M7=]SXC80 M?N],_P>7>VD?P)!?EV22WG`D[60FN3`A;>_M1M@"-&=;5)83Z%_?E3'$@&7+ M)CA[,WD*,;O2?OHD[6K742X^S7S/>J(B9#RX;'1:[89%`X>[+!A?-J*P24*' ML<:GWW_^Z>*79O/KYX=;R^5.Y--`6HZ@1%+7>F9R8O4$#\,1$]0:SJT']D2E M->`C^4S@2=*^==3JM`XZ!ZVV-9%R>F[;S\_/+:%DPT2TY7"_V4QZ^TQ":!WT MXFX/6IW5-[VD9QZ<6Z?VF7W0[G2LL_/.T7G[R.K>K>3N`,B(%0EZ+/@^A+XL M&(L@O&RDC)L-A=?B8@R*[4-[*=A82)[/0K8F_7RXE.W87^]N!\Z$^J3)@E"2 MP'G14LUDZ77.SL[L^-N5*'3ORI5LVIIC>_$EB(;L/(R[NN4.D3&1A1`LK83Z MK;D4:ZI'S=R/J67C9#Y4T]AC)]-!!W! MLW$@FVK(VR>';:7_82"!-S5Y>CQP:0#\PH>0>\Q5?'XFGAJHP83"C&A8JIN_ M'F[6T`S(&+3[$R)\HB:+K83L4LW:-8+HPYP.Y(1*YA!O3X@V^DC@$>&8(M1, MA>4,4W/@.`8^@2:$$PUITV5@FUK3#2OI*`UKU0H+I`VB=B)C9S:P1X-7O31= M[A-6TMIM[7I,I2,2>;*RK4OU?1H;CT?3I_Z0BI*&KJONT4CB>>5,BQ42@V`4 M6<#49GH+72<&**G7WHW2<.E,4M!P5T^95!V".VFWK::U:A<^KYJVTFU;2>-6 MTGJ,!=!XW%GKR%..@HO,@8V'9T3"83Q&$`*,"9G&CM.FG@R73^(ML=GN))[A M0_+XV\K(1S)\HQK[86G?]^4SI9^#:;I8' M`PTQGTL3H]&HE9B#W8G1P,!`S'(C@/".WL#'0K>?$MP3#7'\:;A_;9F=Z>.3 M*&!CO!>!\KG#`PD1Y[47BT*P3SFA8H$RGRLC MS5HI^UB5,B,HV)@SX>@MV3BM[%IPCWM1^/B%!TXN*64:J)6QLWU%U&E$V.CL M"SZE0L[['@DDF*[,GJI84Q\JY*O4>[!M5]_S\D!@8TE9)^=W5$ZX6WSJT4K7 MRTWEK(/6?FRTW`22!&,&T?\"%,R=ZYGC1>HELC\Y=Y^92FQJXFT3U7H)JYQ2 M,`.#C;U4E%/HM#2R]?)3.96@L1X;(0L+\>H(@,1?;&-\R,F0>4X+"1M951!]YR6R05@%#J6$7TO*PO1YQVV\PJR=JQH@(^A5\Q.1@0@2$ M*=E4%(MCV.:J$%&,#-OZ28Q-@2W<[W3R&&H,.VYY.FA[7SSK+[;\0X0@VR?1 M7$D,Q87*2T8'"MMJN>7!6!4/K^BPH!R7*8FAUK#+"LD$A8VC+UQ2L]@M4Q)# M<6$7CC)!8>/(V-V\N9_1%!QV6D5[=3"O3M!+;L/\%)NE@Z'J\$JT9<%#QV!J MKRY,Q.F$D9UB]5-1YZ4P)^;B_&$FNKQTJ48!V='5C*D\0-C82IE9O/^A.\$: MKIPT`FP$/%)_R@41"/"N9A M#E6;:+`15KIN@:92H:N*[[+.?J2218_[/@]BBW/_BF)+#,."*D?+-@9L9'1= MERWZ[Q/FW@0],F62>"G#=;E5`T4,<5[)M*H!*G04.D[D1W$=)8Y1P=BIH!/U MQ\%/]"9PN$]O>:C>R+@?/9*9/E=>KA4,06/IG'DYB-B8?J`2QH:ZUT0$X)K# M%*`K(,%A^AO!TB.?<]_0<97[AJQ?USK[[?W^(1-#W^\?>K]_ MZ/W^H?<+;8IAH"'F_4(;?,2\7VB#_T*;C?PR1$OW(L;FQJFQ/A7J]4-=U&*L MC6%5F1%K#`G;@6G#\-C*L!O)"5CYWTM$G<_@MA:.A%(%YK:A_!",W4=27DB>$%73/ZC.`@9L_0P^5J8'A5MS1;^#W;EK'%7BU?!<,+NQ5Y*NG- M,C*S%ZO_D0&__`]02P,$%`````@`E8D)/\X83L#O(@``N`$"`!4`'`!S9VYT M+3(P,3$P-C,P7VQA8BYX;6Q55`D``\JB04[*HD%.=7@+``$$)0X```0Y`0`` MW5U[;]PXDO__@/L.O.P!EP#M5Y+);H*97;3M>.#=)#9LS^X>!HN!6F+;G%%+ M/9+:L??3'Q]ZMOCLEE3,#3!(N[NJ5#^JJD@6B^3W?WE:Q>@19SE)DQ]>G!P> MOT`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`OLW3EI%BI1NK`]$N\B+<1=>!D.$\W68A=WF,5/OF3=FUG MH1F-)Y2316J<'/QT^^+/%2L*DHC&<<:,2,.-?J[X_W7X_1%_YK#8.F]H:$R4 M%PEFU.+>QF'C&"4(#F`9Y`N.@G9V]T&PYEW$$8Z+O/J&N]#!\4D9+O]0?OW+ M+7V%F&EV%RR:\%.B5A%-ZQYZ59DOR"E&,7R9<>@>W[.$F@C]S,G^Y<&[IZ$= M7]*/N0E8BQ#8!GHJ2^V@IH*SA2T5=/;`2!&GW=LHWJ>/1Q$FPA[HAVTS MH%_5(>V.BMU"TO]YVE>N4H^]Z.W?)GN]\@>KPSVCF>I=SND3(_;4BSBXE^B] M]?OT;U.J8/4Z.S].^CXE3^Z]T)H&,:*IO?,:9R2E8X[HG,8*C45NT<'YJU3A M;!K%0XH)^M]U7&VCA;$&I^+8]]`A! M;$*AA=HN!$-E'IP%QC;^%P>9G66T**'MHJ>TW"IJ,D";V-+!:!&,?EI[$!/+ M&WQ/V&0T*;X$*UEW(2>;WA)TZE9F(*.9U`;4"O0,H)S7-[2($4_[\L^H`69! M?)E$^.EO^%D)J$<']?H5"G??_Q81@`%(-5!90$F,.#6BY%/9P-DFRSKQ2CUF M5)-.;PDFM2MC4-%-:@]Z)7HF49)W.H6IQY#"+"](C+,S^MC[-%,'ABTJJ+`@ M5;8;%#HD`"%!\GQ50."DJ**=N$=(5ZLTN2W2\+?;AX`VP]6F8&MY;'54'>ZT M3&!]A064K8Y#PP'1BQC5478IG!-QUAD2S*C%[4$6^6IY09(@"0F=/J4YT:S$ MN;$"9YHM8$ESSQH^N&RT4:E^_Y7204S":ACHISR-2<2+%DZ#F)4#4$O$N-A[ M@C.`]9W%09Y?+;F#S)^(<2FC3P]L9RH`4N/:)H:S*+DF?3-B9"A=B@B&?F:D M@$M?;:W/TU5`MA>Q=80PAJ)6N6TA?:K)34.E@M$F!#'D@BC.",[GUU0DIJ/V MB.OU&:\6.%.Y@8X#**"8071"BII\^J!BTJ6_>LHYT!S5/)4Q"39P8SIU-B8% M!Z0Q:4'TC4E*#F1,&EU4QG3JH3'-\YP.LPS#Z6TB&).1J]JVDB[%Y(8A>WQ_ MP9<3H8IJE$*S`FJ/U"@3+\?D'UKL,Q04J)*`N(A17&5= MK=3KW&40A"'[@+<08OH#':<*+48$2&=560$#<8'O29*PMS@N4&/0&P7B.%!: ME?*@+C=#O&@?K@^XP;2+(F&!HWUZ`V;!\D60M)@@LV M^@\?@NP>+X+PMYQW96GQ@#,4X6@3L@5#(*D>A88![.!T78X'?WD#FA6IE\KO\&(M0`JF5#)!=R1[H,D*Y&L*5>O MQ&\:]QWC18![^'6&UP&)/CZM61D2G:)?L>&(6/70.[H5)XR_.X!JN[T%V^3> M;ZU3S_9*3E2R\K$F9T:"&S@8[`\,"];V*#HLR\$#Z:K=-&%B@C<&'C5LXH,7 MD<#H\[#>;6,57GBKC:+<)KUPP:&T]6>)YPLU=:VWN0CP8SBVNJ<[\#"JJU)JEL]6Y(ST+U-#7#*,[ MYE73`PQV3JFFV\?)15Q!K"U"F>/^/B(8W,R^]*:IA( M;5"^':05I)/'9ZT>_;V5G!H)#?E&PI$$O1K2N@'EIK?9/W5@RD7M`JJ M)%G$6$QQJ!-^?`KC#>L0?DS3Z"N)U8L/-JQ0"V#VL+H+8V8^@`4S6Z4D1E>Q MUAD?RHU>UORH$O`*:I5M"&Q!B0VL-]P#QC%Z/7MW\@8N!+2RB<:D@((6QLFU MBK>]6DHXN1MKM.@913=)._9$W63=0VBN&-H-`N`19XM4'V?<(4`G\(2RVGPD M;`YVYIM>2>W=S?%>H;78I^A=;UY-N>;9]FL/&])_!^>;NB72$Q??'L= M/+.20+NRVVUBV();N>JR4MLN)5B1K4P-=;UF20V]I+B3[FM!#5LDNU]S@Z?- MSC?X+G6LZ5,R@%7T&2!LU?,IJ"&J^;2J2$O(BM2_2KZ=4/A1Q3?H"]C#FQ67 M+]'`D6VH2"8B9':1*GUY^Q<@3=IU2C-BB$-6? MJA(^AU1?LD1QFMSC[-7$]T6YOZJ2`PD65/+`1-(](72M`G2PS_1I35&,XWT5 M/=B07P]@:]0O)X88^.LT4=I-9RX)/?S?"4$K:H%-`@9K^N$'#]T#N?Y!.Z>@ MOR*NI008,NB5KD<+F?LL,)!ON%CAP(M`Y*5HFGO M'K!-I]2\V/,604[RB?MEIY;9/@NN(@?HC'?4N_.*(!/#=!#&-NV?XX5AJ[N4 M$BC=JU:ZD]GMDTV?Q%7IT,_74DIQ)@*CK6,]^AP4FVS$CLO4X]HC..M/&.(: M5$3987K>(5\!>!+N2UI@NQRYE!+&7S5*M_U50C:YORIUZ!D+I_0D*>ZJ-6@Z M?-\F!O=!ZVFK/_-5NXFJ!S-4Z_G1=%-28_]BJW)W[YAF1@IBRDW%C'TQ@(P' MW,#50!2VWF>`-'N5-M+1"N*CE98I??!C*F&L,501PT\H]%6&<8M#V!Q_<\+I(:3A2-(6.`;!D6`NA5SH"[ MU@"*3N[8JD592PSB40?FVG`*Q M$SK>]ZWU@6V:CGJDEP,\%';>]^3?3B>WO4T>[69RWK]T*]F>A%Y&>$E"4KP" MS'.V[@O77J/6(P.Z,4VA;N=RM"V:Z>]!DRH@N?>Z?>%Z>-('NT'AO>W!?Q\?'I_PRGKVB?WW)U8E+^KD9NCD^'AV+/[G M1*_?S+Y[\W[VQW?O4;`I'M*,_+LLS'_]Q]F?OOMN]MW;M^+/V?%W;V=OW_T1 MI9LB+P+QOH,"_7638/3F>(98M.&DYSCD-YNB-R?\6_H;;9XU#@ORB&.@_2]# MF`7TZ;-11%A=4A!?!R2Z3,Z"-:$*M9`IL-LP`I6A6T/JU*,;N:8O3+=4J5\F M73,BQLE.72IYZ?"S98QPW/BPB( M?3[N^LFVH%12R@/E.W*0$(1>,E&OQ)ECZ1)1>8#!%A:X5Z$8NBE\"=2#MT-Y M:42G'0@7!+:U#/9-@U]T7`0DP=''(&/FEK>0G(MTD:+A;!BA3KVWA=0][=[$ M!7#*O9U*DF/?!2.J.-'+MH66S.,<:&G5U8R-S*>^9'RLGG06.P-MHRISU#"= MP?BORKM%'.L5!W\6;>P6:SQ8I+%:G"F/[)X71486FZ(ZD.0Z&*T,T2I"CX'& MIZ@\#CY/(K$U.+%J+CO,L%DM!+H1?4P(_IP=JD!O9@,O-=7"<3DCU+NS0U/.O7!L[:J;&@$OLIHU*?#+;YR=HTS=KJ3JL#` MFMN+,^5&WY@AQJRAWUBR= M>^-D7/U\7B_6V[5#G\L+IU*!T3C3-@NT$\GUL7`>P8@:3B\@K9>TV+U2.W,0/J^4V[FLHSQ_E$ MZ#\1/WA-J(V3T'(LIV#UPH&TL#1.).6#=B2-4A;.U.)&#;L7#N4"K.=4<0O7 M6HD+I.+:<8YDQ0E>E^TR-[)@@ZS>=IPP=$N[/)P/[0W-GXE0"XKE)$C+`>XU M-I,?#3FDEUC.$KK>XE#,LQP]BR<^89C=Z.CAO<(\"9"YQ6ST M*8WK7J#!T/BTY#@.OFF6'"TND-P=GH?345&PQPQFR^Q<\S+]ES=+5$5^+6%$H`6&_#[HVYP8\X MV6!VRS&K(U4M>$M)@6IN-&IWJFXD=-/7W2B5Z-=R\&M\2MH9O]E;W/<-5*9A MKSFK&,X$)5`]Q@"M#%[^=I;FQ=62*W2;QNJ9VQ85U,A4JFQW,-HA`1A_2IXO MB=8Y+W?G=(@10DV^7+3E5WY![1?>K5F!;Q`?H'VG"P4_9FF>BUO`%'`Z%#`A M0*)DV_U;/T_N^KUG]UXTIR@O?H-Q>%L=UR/J:/+U_72<\&C;Z@["CT]K-O3. M#5,B#3W0P;8F`)US;57$TQ]KJ]>D?YYJ?5*"VE%D`Z>XFTS``;"0S:B/9TB)XRF-5:BY4LD'M,7)'0J-K MM`D+%#4,4-N+AG\-X'.J6QQ3F?<_XH0&GIA"FTLD1JPXIT^5.*C5G]8+9CJA%^S<(KL"8&/#,.CN6^B"C@"@Q,M$[PP\D#2; M[2^H%XI*G,^X>$BCR^01YP5/[&K3QT9>R'2\);!^4T`[[D?)M M)(M:TP3';Q.5*3A.98O`F;6I7QY@6L%V&NQ-&L$J?0"?-C"F"RI"H'MC+/45 MFQ;37I+#`PMNG-2$L4T);,5]I:5VW)#!6?*V#AI;[H1VH*NH$A>+J(@LI)=2L0*ET=P[0(P,8\2MTD(RI*LK2!P&K*URT MIL(H;7D0'9\D\W/JH`:U^S6W!S-YT9[ZW%^/"LH/IKK7B4 M))S+_-E)VW($-[;3F:.%CUJ;0\4NEK%'@,CODX*[_?&[-\?S%D1"LI+W.ZB9B$LH=>K2= MFAVD7`JJQ$P=OP<&V7Z=2F.8.!GZ_P>B)FGH!4BH9:.S-*$3V`T-%$WY_RE> MIEEYEO-=\(3SCT]%%J191)(@>[XL\(I?4TPY:=/&?/HK^DNK;.S`3_1AB6J4 M1E0O;`WZ..#EL!&PV"Q<-(]M;7M!"_[@*AO&'SU#G83LA!)J\EJ+G]+CAVA]\-S7%UP8%X*V:&"<5*IH MVS4[!),[I.3ITDUQWHR6%B@4G]=EA0T4X>(?2*].M@JIL9@`]%*3"9DMH/G]Q27N>5)2FX7W;TL+*;DL,/W]2K/ZJJKOZYC09M6T$W2G24X;=-*T>53@*\M6;= M&*F2@4HA2$AA%MT_/!UT@#H$6L"!*]3+\K4?+;MYVY-(G:5X%7%,8"UBCDJ$ M+U%'K]^^I@PZ_!X&,>BP'/*E@4>@^I3)J^59D#]A:H>U7-,+HW MK*KI`>Y:-2FSVYFA3!CBTD!7$)D:?(TVPM'I\T]4ZAM=T,^5-O^" MB6_PC?"@#RCF^+&+#' MDFK2CX(M$AC+WD=C<#.O:AQP=):N6.6LSL95Q$#I"JWJG42%E'+Z%(5&C?XY M?8SX8!&(]$1##G20HI/J;!]8J7HXNNK&TQ*':'5P/Z7#QPQ3M M64US_E,2X>P&KVG#/=`?YO<9QH:#$=TE@>T:V17TUHX25S$0NTUVTU&V%X)+ M0"\K6:_8N+\2AS9,'FH$HD8BV$:5@:!7$AA>MK! MTZF4LG6WBA\U`@`/&-X57(TBJREG+.OG2\`8'`AD6&"GJR7T:41Y*JV!QY=` M(`&BCP`M!@]-K<^W&/WQ=1LT(ZF]NU][H+3%'O(1[,;'5`"=VP0D.B\/ MXBFWP,^3Z(J=0S?GPRW[R9>5,%\"F0MT0T[`0I('H<]>3>O,@)!8GYS`QN5< M&!+2_`F4>V"O0%:G@S?'-")VIAP[+S48`>T>.9!O%JM[6)[>ICT,XN<;S`XW MNL$QZ5@\#[/A=9'+/G]GA?B^:8 M*\=*<+`S\_9':JS1]LX+Q4TS`^P^TPKRRBLM(%MXIT:*+UYJ5-'56VN!/NW; M&`S\]KXT4J/UP7]I+\^+IN[2>?C[AF28`HXV3#&L71JPX(/Q3FM`;6Y8:]=.[)1_;WE-RHH85.&F_*ZBJXHGGK",">"VR_PA,`Y)1#0M\4M"?(=W4 MI9XL$%M/K+;9?$EJR.'HTQ=='@\2%3*%;.>G#2\?4OB3X;8"]?)BPX\G>84R M3(-`(N[((4E(UC0Z+`)*'/(#W5H5RN'@,'=/L'R#(-V3*@.:)WA`[(7[ZFJ3 MR^2O[$[WOXLKW6T["Q6W)V,]/3CMB$_."C_NT^EEU4FW;JM%7`0J97@S"G2" MV-QARPO'-^S:GN9XGE\YP$/-&,$=:KF?,V?.29I.U9.LR_BO3C'U&`2OQ45,T[U!V,D4 MU9BPE7>G9'F?SY-@J0)DFCIUF.`#HUPCV^E2R>I;LMP65+61G6==>((69>SD M7(^F0\/B\'&U>^]51?]7M_=;U?9X-7NX56RO:D[6KY:5N>QHKKK-Q5SD\EG2>1^`+3'_DW3LUE%N933+&%;HXS)DF>Q!X[-1TLO!:( M.#_?*-7(%%_Z%*4&:8!VY%K7#<`/T>0'3)$D!FIVTQ>>*?/8T<7%'P^N=RKIC:WE5=U^NG:XEYP=6RR4TD(JY4X,^8 M@OHE`3,WZ*J8+3C)VIB)%6J%S$XOU3H9,\`F;\:Z.]'QU9YX)C/*B=?+]H<8 M5;U:DS63>MNDRV??&BS+@H@I#!)\[F&?UMT[+^S_^L1^ZQ(>KT<,MP[AU:JA M&U*^:KAN(?5KY8$!I'&&_?/Q]PUY#&*6W+S&&4FC[7T@BF9R$P'CC;O`;/NC M"__D'NFNG'QYC'47_$-+R@P).4BRNP?&*P=`R_R25'A((GR4H>@,#1/7:4Q"BWM--0Q`-ZH9(72N5%-23W^GFD&5_C5(F]4JR)[9_=>WY#XA M2Q(&="S6R$&5(,";RQK%^OCN\%-Q&JOS/[;,0#>;.4'KW'1FQ3G]S6<.:O6- M46^!Z&S=DSR,TWR3857D=^#SP:@U@-3V+6'RQ-25FEE9?51S=X(]M`NX M@VIY`SJ7@YJV!QL!&.3),/4&(N/E>1)*J/-?E$IWCWSID0&<\J+00;?#W0MS MN$Q8A0J=9'\.LM]PP2KWV%2[>&YVJ+$9.,Z*@"1W6<".-A$[5\P=R_B/`S?, M49I/8=V#/@O2148`8CI)@CV0IWV:1R+QS-:F4?22I\7$B7X MUH2-6NRFJ>=&;XO.3,D!%SL,(+;=7T$.XL%:75SN.0,U&YL.2\WBC>$8.PX5 MO0^F8Q-R.(M_@7='),!>T-UW_`47'Y_">,-Z@Q_3-/I*8O.]VBXBH+S$'6;7 M:^SY`;S(53F)+6YM\)^A+[`7R78AN<1H"TX_C-`Z8AO9P$W.)>IM69IO<7PP M8,`N)`;[GW'QP!;%FSQ$$K6/\#+E?9REP+C6CF#;;N8H8G*7VTD_S8P-72;H M;[?7WAFH?:AW$>"565H&?GMN7XS1/EJ6218A`;6S,EYU!WOC],C?^I=@E3?T MF;&:]LXU^\B^LS30,K==P4MJ MX%Q%017([::G^IY!P_UZ?G4.@[>!/^[,E@ZLT^DJ8AAGU*O>]C4YY>2NI%.C M?ZVPY#@$*+,P17$EM0^&H8W""E)@TS!%$+Z8Z56$=-W=[,R/:-A+(CST,EDP#B`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`C!4/X[5)-T?7I?J0!^/HS*$E\H M!2,A`Y5"$)."ZJ>AVX(.M<"+QG9M!'-O-H#D;\U%#/W>WF*_(2 MT9+-;[N3N(]G7>?XK;-+#"D_?Z(JT[_I7_0#6_RC?_P?4$L#!!0````(`)6) M"3\JNZ!9OA0``()4`0`5`!P`&UL550)``/* MHD%.RJ)!3G5X"P`!!"4.```$.0$``.U=6W/;NA%^[TS_`^N^M#.5;<7.Q9FD M'=FRS[C'B3R63R]/9V`*DM!#`2I(VE9_?0&2DDB)(`!>`I#RY"&R!"RQN]\" MB\5R\>5OKPO/>8;41P1_/>H?GQXY$+MD@O#LZU'H]X#O(G3TM[_^_G=?_M#K M_>ORX`'LFX2^ M68\K9^TO38)8M>+WG:)?`9==8O>NR[X_[F MEZODR01_=CZ=7)R\.^WWG8O/_?//I^?.X-NFW3?&R!3)&GH(__;$GN4P66#_ MZU%J<*]/U#LF=,8ZGIZ=K!L>Q2T_O_HHT_KE;-VV?_*O;W=C=PX7H(>P'P#L M;GMQ,GG]^A<7%R?1KZRICS[[4?\[XH(@THYT7(ZP!?^KMV[6XU_U^N]Z9_WC M5W]RQ&3@.%\H\>`#G#K1`#X'JR7\>N2CQ=+C`X^^FU,X9=_-<-#CFG!L70*/*VT\APR=.J/7(OLCF;AG]H6# M.0R0"[R&.-IY1L/L;7[U1]/1$M((&34J2T3_![)U!?SYC4=>&N(J1;XR4T/D MNQ[Q0PK'X6(!Z&HT':,99A.P"Y@1NRX)F17CV3T;B(N@%D?ZM&MDYP'R!0R. M`^+^-EYZ*"@W\APR-0[R%C]#/XC46FYX&0(U#PP'A);6>(9`K0-CR_(,/7EP MX/ML[OH.2RHVEU`CJKW%/_O+JNI-B-0X0&9_-(23.P2>$,-U:4WGT:EQF$/X M5%+#<<\:AW(#$/T'\$+X#0+^=P6[%9"J<;!79+&D<,X6$N:JW[+=P0+>,6>_ MW'"%Q&H<\#6@F"T&_CVD8S806&ZD^U3J7"+Y*A!M<+A`F#3TO60IK9J70!Q" MYHDGGX9P$KK:[I8BP5H'[G&?A_FEP>J1`B:;:J,64:O7W!8H7HB9>)CGQAT; MMBDO/:T6$JQUX(FW&>\".!@!7HVPM[I!F.T1$/"VOF=95K0>D3#')AR??1&9 MQ1WC)>&(TZYM.YH6''P-(!OG9/,M"OB33D]/+TZ=GK,FE/[(B#HQ52=--AH_ MX\`C;N8)'@\*$"K3#?_FUZ)Q#Y[\@#(0KPEYX`EZ,27%?B=:0TR$'04G?.@> MS\CSR02B*"[#/T3#[YWVD]#$']E7FW$\,K([X]S]^=TV<<]9&2C*4F+DV4$PIX[1]Y&UU-*%EH"3$9! M%+DA=`+IUZ/^D1/Z;(QDR:EM]]I-*F+`!C;A@[OQP"Q'$YG?VZ\*.3N)+MX9 MT,6:(>:<(,)XF@S9K%=@'9EV[=>-.EN)CLX,ZNB&+5_`BX=ZP[[S"_2TU[8[ MNE)C+='7N7%]_1L"JJ:M3&K!3X#]%B@W]W@R`98Q:Z`7^^IM=^"9?_[H9Y&BZ":7= M$Q\51(GTNI:WPAJ8>@1/WN["EM_(&ILKHQAN=AIL"6-)2[9'H\QPH]B&4<5= M><#W1]-H[AB\HMW-F+2]O>H4JZ5`ETKL*:BU;T:MZ>$/R0(@+-#G?D-[%:FD MDWV=*K+80+RW@EE"GH4QN&#)A7\'K68NXQO&4?I2OJIJ%UZJRVE!;SU<#13GFE MQ6EE$B\\V\A>917+?5]A"GP5S*>)P=[%LA+R$3$1\/3,J&7:4,\-N4K`G_-L M#?;?]7]#]`R\*'\CN`*4KMB^.4KY$GE/*GVM0XB"HG.\J-*L-@J:,S.@>8!, M>,@-X*0*?#2I=`-(=3!=L.RW%E+C.:'!(Z2+3'YXOLN0T[0;X%#F3)AMT&($ M)&]7^`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`MG]@L+V;=:U M'E/"[;NAXOJ0R817B1^R%<8C40'PA`]A7FU!'^OTJ*>7J<]O%8X(Q]#Q> MWQEB)DV/R6(P62",N"0#]`R+`:/6N7/(JID=`X9:AS6=5!@4VFC#>=;XY"A8-O2.AR4 M<3(E[#3P"H>I6R'C&2[FM_ARR)V6;=:S*CL-Q.T-7;D"F3XD6XZ=5NW6KYR5 MJE'WW.6[ENJU5W.`9_`6WP!$HV/'T52]H*URYS;JMP8.JY8BK$'M3;CZ5P2S M=2MD2]?V].,23@E-WFI^!*_0OWYE$F4"0!C0572DQ8LXL9Z,)2]:]6*S4=H@ MU/K$-H+1E%CJNCO0N/.1B".9I"_9%EX+X&/7$6E1VVMT[B6 M&N4H$#/9Q?*WN]P/D1<&PDQ!0>NN0Z*(S2Y6KOHG1+,Y8WCPS-SA&?P>\I?V M1M.]U#C)FJ%+QCH8::PEM?`JO@/49A04K2!:-*S3?RU*+8^5PUJ)!%))YE[5 M?&5-*@<..2VQ_)B5SG3&\Q7PYS<>>5%->#XKE_#,'^/$SS%;N&C#KWK!HIPN MA@(3?"3WE#PCIIG+U2],YK=X4%9[.:1TAGC=+X>\I9I:!*_ZTEB;J2CST99U>2/BY.8G>3$- M10+6(;*QT$5%F33J_QG:6>R+9."Z_/))GYD_1,\%5Q6H=+4.6Q4AH((I12E4 M#>]*5D5K]A/<.\#L:>)+G@O['"*"9.Q7C8;:^;9MSJZ'PB5`_"*QB*DD-WR` MX_OJ!KX/=7:C"L0.$6REY=+-=[[W!30,(=_Q/,#H5KM[0+GG<15?]ZZ,OB(B MAX@Z;7E4C66T!6UK[R&)^/`J'JY+0S;D[?UHV@Y9$;%#1%]IN31:U]901$U] MNU4YS<_(:*0R642*AF,6AA)Q]OV#!R9=BEPV1BY] M97AX.L*@)I.#YA M"F"4N!!.HD/8(8KDRR4PFNH!38_*`0&N!L%T,>UBSQ`'SP!Y?/-\0R@O&#^& M;DB+=HD:%`X(;A6%TG!JA46+*,`SQ$,U6O[];K\#!I:2**IF4M@))W4A5PXX M'`[`*LJDIGM^\@-<=@52;Q`&V*TAP%5`R#K^'3+AL;W-'\$P#5?D= M#Q-2&K+H8D&C?%%D+*]8#;Z1@MC,F*'CKM2\FDTE=4J+*9NH-2"7:K? MH2-,)HH.Q[M&TZU0<6QA:[GP2_0D@0A9[P,"5@6!=#/&I2[JRIO$PX%919G4 M]2*134$)+@]F:_P__L[>,_#X_N<>LG%-=L]M!4C3(6$=UG0#$969;2!URQ[< M#)A]4;IBIA2]IJ<%F)V^'46*"I4Y[)QBH\-FW4#_"9/S/:O(V7WO:6&HG]OMNWWX24$]%R8F)U M5'+8&Z+`\&2-:RDKL4=_*P*1#2GWL\9\U,2^J?=0FK?66DU.<1J)O9SMVTN: MB-$K,F4K66Y+L[=Z^K>8G\PP-^P;H+_!@.=8Q45LMBE6W$>#-``(/U(0%0./ M4F7D!MOTXZRQJY8:="@F1N.,^?&]9$#!D:?_QJ.RB%.4+8 MP]1D"%)JROTIV[H$OQW&+3 MWEYN_K._5#3K#T6N-_OH_#R^-V'1@J*+S&]*OY,B<\ZUJ1BY/B]_D.KFK4[` M.BLOJ>;,17O5N&^MO8MKI4A,_N.^R2>TG#0Q,V'D'9:2,CGR:+*LGY&:]PJE M5]2MO"0UZTQ>6]C=S]\10H[Y1%CDR%H`+X;SK8# ME+G+Q5U,V&#>B&266-C'.GM445/:*O6Y:ZUM\EM**)Q#[*-GN'^Y7K%U]D_W MK3-#T(DI.G_B-/]LPD)S^/L.@]'T$;Q*#%6IIY$,J9R!D4"Z>,JZ66>U&JK+ M9$>5X;.U]GL-*$9XQC-*HZN'%`TW)_MI3F8XAB112R98I,55:RTORC817J(FL;^<[*6(7B\BZ&0H MFMB6;086O:ZU&4M27SEZN2;2[1,?[KHXB&S?69&HD?VIZI@OTV.6[F.K4;5N M=J@'+IE]<0,2:NU,P]/;<,@#N5$7! MN&49E-)NM>52"IZDD56I3L$:P]553R;3LB*_+3;#S>4"JT<*V(RD98,Y258) M12X\3/<9(' M.?Q)SN913NI91JPI&>5F0+=X2ICDN)1'TST1:'-D550)``/*HD%.RJ)!3G5X"P`!!"4. M```$.0$``.U;WV_;-A!^'[#_@?-3!U26Y:19;3@M$J<9@B:-$6=;WPI:HFRB M$NF25!+_]SM2DB5;,FVES5!@>FEH\N[C';_C3UU'[Y_B"#T0(2EGIQVOV^L@ MPGP>4#8_[232P=*GM//^W:^_C'YSG,_G=]O]M#"Z660]=]?'SL"BTK,]&NSV/' MR7H[QQ+00<]TV^]ZZY9QUC-G0_36';C]GN>AP=`['O:.T=G-6NX&'`GI/D'I M+TB,$8P$DZ>=DFF/1UTNYJ#4\]S/-]=3(]=)!8=/,Q'1#7%=DRLHE_.:WKEDN*0MY M]A,J]"@.!8_(/1B!=.&ONRO[B&@A=PJXQL8Q9P%A$*90D#RB@0[+TD` MX9:],^6E(!+`S>!=0T6FG8G8-'T<^4GT#,7"LMUZ66U.V$OSN&Z5M^'MD@CC MU4&$[M"T,]L_E-D"'=V&J,!O.?X^CL=8+BXC_MB8XD+1SO#1\QC6\,C@MPS7 M,7R1'4CROVGK%K4$UWBJO7V1(R*J!1 MCMWR:N?UCNA['IDJ[G^=+B.JMBFL"MC9ZE?9RB"0P4`&I*7%3LL5>R!2F@DRYI6`?!0JS.9U%Y$Q*V+0_ MD@],+N*73 M!]@H0()<8E2:O5Z5I`PBE2.B5QFHO_GNH^H`%@PNUG!`Q!2&RS5&E MW4Y.S64^1T``@0Q&R\F>QQA]D38?6G5@0U277TOW2=GYJ;F^&YSLNVX9J65I M_],*2\@9"[+2!0D2O_0YZC!1.U\U=_P,PCQMY^4"KV5M'VN1?BZ>8*%6]P)# MK.^B;(>J61:M+RC`,(8Z*+ZE5&ILHVXFM>7(H/AVE M^"CK`.D>T+J+TJ?>_P';^A^=Y'1'0F12F(8Z^^>T(VF\C'3JDZE;"!)"W9PI M1^E^@[^Y3'.4B&M^23&7B9-/R/D(SYHZ#RHD>D&O MKS7^"[D+,[.INUN3^86<'A>]U+H^ M<]\`653T+R?7RYJ=440_$0`^$=_(\+@9ID#,RU\?:P^R( MA-C0:FQ$B.7,("72F6.\/)B-6D671$KF-;NXR3)>S0E%+PE?;`E*9S.I!!SK M.\;V(JEICRR-8&G4DUF)!$([79-,$O,09.#,>07G$+UG@Y,)J%&5:(0_!4^6 MN2`%D0["&6@.E;;!$D)Y<&]@@T1D[PB['(3-(R1"Z#PZ[G_]!PNXJ^@S6NK2 MSE:+$S%G1&&Q.MB-JMGI&J+RIEF:YG/:\<$2GUN6"J2V?`S*SN5S)Y=B.2IO`SQ6*EA>3.J?VB_Y<[F4?V2:"AU3I-U$P M8)P(?2?)W;*+_)QSKA)?Q>WKGCRI\PCJ=\9BO6RMH^E_7QBJ7.Z'S+5GA.(> M]QII_;>.CMQTTX3BOU!+`0(>`Q0````(`)6)"3]V`\UEI%<``,6I!@`1`!@` M``````$```"D@0````!S9VYT+3(P,3$P-C,P+GAM;%54!0`#RJ)!3G5X"P`! M!"4.```$.0$``%!+`0(>`Q0````(`)6)"3]7"7]7``!S9VYT+3(P,3$P-C,P7V-A;"YX;6Q55`4``\JB04YU>`L` M`00E#@``!#D!``!02P$"'@,4````"`"5B0D_68CV1/L'```@90``%0`8```` M```!````I(%'8@``&UL550%``/*HD%.=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`E8D)/\X83L#O(@``N`$"`!4`&``` M`````0```*2!D6H``'-G;G0M,C`Q,3`V,S!?;&%B+GAM;%54!0`#RJ)!3G5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`)6)"3\JNZ!9OA0``()4`0`5`!@` M``````$```"D@<^-``!S9VYT+3(P,3$P-C,P7W!R92YX;6Q55`4``\JB04YU M>`L``00E#@``!#D!``!02P$"'@,4````"`"5B0D_@3SP^+0&``!O-```$0`8 M```````!````I('`L` A`00E#@``!#D!``!02P4&``````8`!@`:`@``VZD````` ` end